IMPAACT P1093  
 
 
Phase I/II, Multi -Center, Open -Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity 
of Dolutegravir , a Novel Integrase Inhibitor, in Combination Regimens in  
HIV -1 Infected Infants, Children and Adolescents  
 
 
A Multicenter, Domestic & International Trial of the  
International Maternal Pediatric Adolescent AIDS  
Clinical Trials Group (IMPAACT)  
 
Sponsored by:  
The National Institute of Allergy and Infectious Diseases (NIAID) ,  
The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) , and 
the National Institute of Mental Health (NIMH)  
 
 
Pharmaceutical Support Provided by : GlaxoSmithKline  
 
 
IND# 110,847    Held by  NIAID  
DAIDS ES# 11773  
EudraCT# 2010 -020988 -20 
 
 
The IMPAACT HIV Treatment  
Scientific Committee Chair:   Elaine Abrams, MD  
 
Protocol Co -Chair s: Andrew Wiznia, MD  
Theodore Ruel, MD 
 
NIAID Medical Officer:  Ellen Townley , MSN, FNP  
 
NICHD Medical Officer:  Rohan Hazra, MD  
 
Clinical Trials Specialist s: Kathl een George, M PH 
Nicole Monta ñez, MSW   
 
 
Final Version 5.0  
12 July 2018   
  
 
 
 
IMPAACT P1093, Version 5.0  Page 2 of 135 12 July 2018   TABLE OF CONTENTS  
 
PROTOCOL SIGNATURE PAGE  ................................ ................................ ................................ ...........  5 
PROTOCOL TEAM ROSTER  ................................ ................................ ................................ .................  6 
STUDY MANAGEMENT  ................................ ................................ ................................ ..........................  8 
LIST OF COMMONLY USED ABBREVIATIONS AND DEFINITIONS  ................................ ..........  9 
SCHEMA  ................................ ................................ ................................ ................................ ...................  11 
1.0 INTRODUCTION ................................ ................................ ................................ ........................  13 
1.1 Background  ................................ ................................ ................................ ................................ .... 13 
1.2 Clinical Efficacy  ................................ ................................ ................................ ............................  14 
1.3 Clinical Pharmacokinetics in Adults  ................................ ................................ ..............................  15 
1.4 Clinical Pharmacokinetics in P1093  ................................ ................................ ..............................  22 
1.5 Summary of Safety in Clinical Trials  ................................ ................................ ............................  22 
1.6 Rationale  ................................ ................................ ................................ ................................ ........  26 
1.7 Hypothesis  ................................ ................................ ................................ ................................ ..... 31 
 
2.0 STUDY OBJECTIVES  ................................ ................................ ................................ ................  31 
2.1 Primary Objectives ................................ ................................ ................................ .........................  31 
2.2 Secondary Objectives ................................ ................................ ................................ .....................  32 
 
3.0 STUDY DESIGN  ................................ ................................ ................................ ..........................  32 
3.1 Stage I Study Design  ................................ ................................ ................................ ......................  33 
3.2 Stage II Study Design  ................................ ................................ ................................ ....................  36 
3.3 Protocol Version 4.0 – Addition of Dispersible Tablets  ................................ ................................  36 
3.4 Protocol Version 5.0 – Addition of Evaluation by Weight Band or other Factors  ........................  37 
 
4.0 SELECTION AND ENROLLMENT OF PARTICIPANTS  ................................ ...................  37 
4.1 Inclusion Criteria  ................................ ................................ ................................ ...........................  37 
4.2 Exclusion Criteria  ................................ ................................ ................................ ..........................  40 
4.3 Concomitant Medication Guidelines  ................................ ................................ .............................  41 
4.4 Protocol Registration and Enrollment Procedures  ................................ ................................ .........  43 
4.5 Co-enrollment Procedures  ................................ ................................ ................................ .............  44 
 
5.0 STUDY TREATMENT  ................................ ................................ ................................ ...............  44 
5.1 Drug Regimens  ................................ ................................ ................................ ..............................  44 
5.2 Study Product Formulations and Administration  ................................ ................................ ...........  48 
5.3 Study Product Supply, Acquisition and Accountability  ................................ ................................  49 
 
6.0 PARTICIPANT MANAGEMENT  ................................ ................................ .............................  50 
6.1 Toxicity Management  ................................ ................................ ................................ ....................  50 
6.2 Screening  ................................ ................................ ................................ ................................ ....... 55 
6.3 Initiation of Dolutegravir and Management of Background ART  ................................ .................  55 
6.4 Dose Adjustments  ................................ ................................ ................................ ..........................  58 
6.5 Virologic Failure for Participant Management  ................................ ................................ ..............  58 
6.6 Long Term Safety Follow -up ................................ ................................ ................................ .........  60 
6.7 Pregnancy  ................................ ................................ ................................ ................................ ....... 60 
6.8 Criteria for Study Discontinuation  ................................ ................................ ................................ . 61 
6.9 Criteria for Treatment Discontinuation  ................................ ................................ ..........................  61 
 
7.0 EXPEDITED ADVERSE EVENT REPORTING  ................................ ................................ .... 62 
7.1 Adverse Event Reporting to DAIDS  ................................ ................................ ..............................  62 
 
 
 
IMPAACT P1093, Version 5.0  Page 3 of 135 12 July 2018   7.2 Reporting Requirements for this Study  ................................ ................................ ..........................  62 
7.3 Grading Severity of Events  ................................ ................................ ................................ ............  63 
7.4 Expedited AE Reporting Period  ................................ ................................ ................................ ..... 63 
 
8.0 STATISTICAL CONSIDERATIONS  ................................ ................................ .......................  64 
8.1 General Design Issues  ................................ ................................ ................................ ....................  64 
8.2 Endpoints and Outcome Measures  ................................ ................................ ................................ . 66 
8.3 Randomization and Stratification  ................................ ................................ ................................ .. 67 
8.4 Sample Size and Accrual  ................................ ................................ ................................ ...............  67 
8.5 Safety Guidelines for the Evaluation of Stage I Starting Doses  ................................ ....................  68 
8.6 Analyses  ................................ ................................ ................................ ................................ .........  72 
8.7 Monitoring  ................................ ................................ ................................ ................................ ..... 77 
 
9.0 CLINICAL PHARMACOLOGY PLAN  ................................ ................................ ...................  78 
9.1 Pharmacology Objectives  ................................ ................................ ................................ ..............  78 
9.2 Primary and Secondary Data  ................................ ................................ ................................ .........  78 
9.3 Evaluation of PK Exposures for Cohorts and Weight Bands  ................................ ........................  81 
9.4 Evaluation of PK Exposures for Individual Dose Modification  ................................ ....................  81 
 
10.0  HUMAN SUBJECTS PROTECTIONS  ................................ ................................ .....................  81 
10.1  Institutional Review Board/Ethics Committee Review and Approval  ................................ ..........  82 
10.2  Vulnerable Participan ts ................................ ................................ ................................ ..................  82 
10.3  Informed Consent  ................................ ................................ ................................ ..........................  82 
10.4  Essential and Source Documents and Access to Source Data  ................................ .......................  83 
10.5  Participant Confidentiality  ................................ ................................ ................................ .............  84 
10.6  Study Discontinuation  ................................ ................................ ................................ ....................  84 
10.7  Access to Dolutegravir at the Close of the Study  ................................ ................................ ..........  84 
10.8  Reimbursement/Compens ation  ................................ ................................ ................................ ...... 85 
10.9  Management of New Information Pertinent to Study Participation  ................................ ...............  85 
 
11.0  PUBLICATION OF RESEARCH FINDINGS  ................................ ................................ .........  85 
12.0  BIOHAZARD CONTAINMENT  ................................ ................................ ...............................  85 
13.0  REFERENCES  ................................ ................................ ................................ .............................  85 
 
Appendix IA  Schedule of Evaluations   Cohorts I, IIA, IIB, III and III -DT – Stage I  ..............................  89 
Appendix IB Schedule of Evaluations    Cohorts I, IIA, III and III -DT – Stage II  ................................ ..... 93 
Appendix IC Schedule of Evaluations   Cohorts IV, IV -DT, and V -DT– Stage I  ................................ ..... 96 
Appendix ID  Schedule of Evaluations   Cohorts IV, IV -DT, and V -DT – Stage II  ................................  100 
Appendix IE  Schedule of Evaluations   Long -term Safety Follow -up for Participants who Continue to 
Receive Dolutegravir  ................................ ................................ ................................ ...................  103 
Appendix IF  Schedule of Evaluations  Participants who Prematurely Discontinue Dolutegravir  ..........  105 
Appendix IG   Schedule of Evaluations Participants who Start Rifampin as Part of Treatment for Active 
Tuberculosis  ................................ ................................ ................................ ................................ . 106 
Appendix II Sample Consent Form for Participants Enrolling in Stage I  ................................ ...............  109 
Appe ndix III Sample Consent Form for Participants Enrolling in Stage II  ................................ ............  121 
Appendix IV  Sample Informed Consent Form for Specimen Storage and Future Use  ...........................  133 
  
  
 
 
 
IMPAACT P1093, Version 5.0  Page 4 of 135 12 July 2018   LIST OF FIGURES  
 
Figure 1: DTG  Day 11 Log10VL Change  ................................ ................................ ................................ .. 14 
Figure 2: Algorithm for STAGE I Enrollment and Analysis  ................................ ................................ ...... 35 
 
LIST OF TABLE S 
 
Table 1: Summary of DTG PK Parameters and Mean HIV -1 RNA Reduction from Baseline by Dose  .... 15 
Table 2: Summary of Week 2 DTG PK Parameters from ING112276  ................................ ......................  16 
Table 3: Treatment Comparison of DTG PK Parameters (Study ING114556)  ................................ ..........  17 
Table 4: Treatment comparison of plasma DTG PK parameters  ................................ ................................  18 
Table 5: Effect of concomita nt medications on DTG pharmacokinetics  ................................ ....................  19 
Table 6: Effect of DTG on the Pharmacokinetics of Concomitant Medications  ................................ ........  21 
Table 7: Pharmacokinetic Data Available from P1093 ................................ ................................ ...............  22 
Table 8: Statistic Summary of DTG PK Exposure from Combined Data in ING111521 and ING112276  28 
Table 9: IMPAACT P1093 C 24 and  AUC 0-24 Parameters  ................................ ................................ ............  29 
Table 10: Target Accrual at the Accepted Dose in Stages I and II  ................................ .............................  36 
Table 11: Summary of Disallowed ARV Medi cations  ................................ ................................ ...............  43 
Table 12. Stage I Timing and Management of DTG and Background ART  ................................ ..............  57 
Table 13: Supplemental Table for Grading of Psychiatric Events  ................................ ..............................  63 
Table 14: Power Estimation  based on Proposed Sample Size of 10 Per Cohort for Stage I  .......................  68 
Table 15: Probability of Failing Dose Escalation Guidelines under Potential Rates of True Toxicity  ...... 70 
Table 16: Probability of Failing Dose Escalation Guidelines Under Potential Rates of True Toxicity with 
n=10 participants  ................................ ................................ ................................ ................................ .........  71 
Table 17: Percent of Participants Experiencing Grade 3+ Adverse Events (or Grade 3+ Adverse Ev ents 
Attributed to the Study Medication) With Exact 95% Confidence Intervals  ................................ ..............  74 
Table 18: Percent of Participants Meeting Criterio n for Virologic Success with Exact 95% Confidence 
Intervals  ................................ ................................ ................................ ................................ ......................  76 
 
  
 
 
IMPAACT P1093  
 
Phase I/II, Multi -Center, Open -Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity 
of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in  
HIV -1 Infected Infants, Children and Adolescents  
 
IND#110,847 Held by NIAID  
DAIDS St udy ID #11773   
 
Version 5 .0 
 
PROTOCOL SIGNATURE PAGE  
 
I will conduct th is study in accordance with the provisions of this protocol and all applicable protocol -
related documents. I agree to conduct this study in compliance with United States (U .S.) Health a nd 
Human Service regulations (4 5 CFR 46 ); applicable U .S. Food and Drug Administration regulations ; 
standard s of the International Conference on Harmonization Guideline for Good Clinical Practice (E6);  
Institutional Review Board/Ethics Committee determinations ; all applicable in-country, state, and local 
laws and regulations ; and other applicable requirements (e.g., U.S. National Institutes of Health,  Division 
of AIDS ) and institutional policies.  
 
 
             
Signature of Investigator of Record     Date  
 
 
        
Name of Investigator of Record    
(printed)  
 
  
 
 
 
IMPAACT P1093, Version 5.0  Page 6 of 135 12 July 2018   PROTOCOL TEAM ROSTER  
 
Protocol Co -Chairs  
Andrew Wiznia, MD  
Jacobi Medical Center  
1400 Pelham Parkway South  
Bldg 1, Room 1W5  
Bronx, NY  10461  
Phone: 718 -918-4664  
Email: awiznia@aecom.yu.edu   
 
Theodore Ruel MD  
University of California, San Francisco  
550 16th Street, Box 0434  
San Francisco, CA 94158 -0434  
Phone: 415 476 -9197   
E-mail: theodore.ruel@ucsf.edu  
 
NIAID Medical Officer  
Ellen Townley MSN, FNP  
Maternal Adolescent Pediatric Branch  
Division of AIDS NIAID/NIH  
5601 Fishers Lane , RM8B39  
Rockville, Maryland 20892  
Mailstop 9831  
Phone: 240 - 292-4784  
E-mail: townleyem@niaid.nih.gov  
  
NICHD Medical Officer  
Rohan Hazra, MD  
Pediatric, Adolescent  and Maternal AIDS 
Branch  
Eunice Kennedy Shriver  National Institute of 
Child Health and Human Development 
(NICHD)  
National Institutes of Health  
6710B Rockledge Drive, Rm 2113  
Bethesda, MD 208 17 
Phone: 301-435-6868 
Email: hazrar@mail.nih.gov  
 
Clinical Trials Specialist s 
Kathleen George, MPH  
IMPAACT Operations - FHI 360  
359 Blackwell Street, Suite 200  
Durham, NC 27701  
Phone: 919 -544-7040 x11150  
Email: kgeorge@fhi360.org  
 Nicole Monta ñez, MSW   
IMPAACT Operations - FHI 360  
359 Blackwell Street, Suite 200  
Durham, NC 27701  
Phone: 919 -544-7040 x11844  
Email: nmontanez@fhi360.org  
 
Protocol Statisticians  
Terence Fenton, Ed.D.  
Statistical & Data Analysis Center  
Harvard School of Public Health  
651 Huntington A venue  
Boston, MA  02115  
Phone: 617 -632-2009  
Email: fenton@sdac.harvard.edu  
 
Carmelita Alvero, MS  
Statistical & Data Analysis Center  
Harvard School of Public Health  
FXB Building  
900 Commonwealth Avenue  
Boston, MA  02215  
Phone: 617 -582-7265  
Email: calvero@sdac.harvard.edu  
 
Protocol Data Managers  
Stephanie Popson, PhD  
Frontier Science and Technology Research 
Foundation (FSTRF), Inc.  
4033 Maple Road  
Amherst, NY 14226  
Phone: 716 -834-0900 x 7356  
Email: popson@fstrf.org   
 
Protocol Pharmacist  
Thucuma Sise, Pharm  D 
Pharmaceutical Affairs Branch (PAB),  
DAIDS, NIAID  
5601 Fishers Lane  
Room 9A27 MSC# 9829  
Rockville, MD 208 52 
Phone: 240 - 292-4848  
Email: sisetk@niaid.nih.gov   
 
 
  
 
 
 
IMPAACT P1093, Version 5.0  Page 7 of 135 12 July 2018   Protocol Virologist  
Paul Palumbo, M D 
Dartmouth -Hitchcock Medical Center  
Division of Infectio us Diseases and International  
Health  One Medical Center Drive  
Lebanon, NH 03756  
Phone: 603 -650-8840  
Email: paul.palumbo@dartmouth.edu  
 
Protocol Pharmacologist  
Edward P. Acosta, Pharm  D 
University of Alabama at Birmingham  
School of Medicine  
Shelby Interdisciplinary Biomedical Research 
Building  
1670 Univ . Boulevard,  Volker Hall,  Room 258  
Birmingham, AL 35294 -0019  
Phone: 205 -934-2655  
Email: eacosta@uab.edu   
 
Laboratory Technologist  
Patricia Anthony, C LS, MT(ASCP)  
University of Southern California  
Maternal, Child, and Adolescent Virology 
Research Laboratory  
1801 E. Marengo Street  
Los Angeles, CA 90033  
Phone: 323 -226-4162  
E-mail: patricia.anthony@usc.edu  
 
Laboratory Data Coordinator  
Katelynn Hergott, MPH, MSW  
Frontier Science  and Technology Research 
Foundation (FSTRF), Inc.  
4033 Maple Rd  
Amherst, NY  14226  
Phone: 716 -834-0900 ext: 7 212 
Fax: 716 -834-8432  
E-mail: hergott @fstrf.org  
 
Laboratory Center Representative  
Dale W. Dayton, RN, BS, CCRA  
IMPAACT Laboratory Center  
Children’s Hospital Los Angeles  
Phone: 301 -742-9077  
Email: ddayton@impaactlabcenter.org   
Westat Clinical Research Associate  
Kathryn Myers, BA  
Westat 1441 West Montgomery Avenue  
Rockville, MD 20850  
Phone: 301 -610-8803  
Email: Kathr ynMyers@westat.com    
  
Pharmaceutical Company Representatives  
Annie Buchanan, MD, MPH  
Physician Project Lead, Dolutegravir Pediatric 
Program  
Infectious Disease R&D  
ViiV Healthcare  
Five Moore Drive  
PO Box 13398, RTP, NC 27709 -3398, USA  
Mailstop 5.3200 
Phone: 919-906-4969  
Email:  ann.m.buchanan@viivhealthcare.com   
 
Cindy Brothers  
Clinical Matrix Team Lead, DTG Pediatric 
Program  
ViiV Healthcare  
5 Moore Drive; 5.3200  
Research Triangle Park, NC 27709  
Phone: 919 -414-1184  
Email: cindy.h.brothers@viivhealthcare.com  
 
Cindy Vavro  
Clinical Virology  
Infectious Disease, R&D  
ViiV Healthcare  
5 Moore Drive  
Research Triangle Park, NC 27709 -3398  
Phone: 919 - 483-9184  
Email: cindy.l.vavro@viivhealthcare.com  
 
Rajendra Singh  
RD Projects Clinic al Platforms & Sciences  
GlaxoSmithKline  
709 Swedeland Road,  
King of Prussia, PA,  19406  
Phone: 610 -270-6863  
Email: rajendra.8.singh@gsk.com  
  
 
 
 
IMPAACT P1093, Version 5.0  Page 8 of 135 12 July 2018   STUDY MANAGEMENT  
 
 
• All questions concerning this protocol including questions regarding screening, clinical 
management of study participant s should be sent via e -mail to impaact.teamp1093@fstrf.org . 
Remember to include the participant ’s PID when applicable. The appropriate t eam member will 
respond to questions via e -mail. A response should generally be received within 24 hours 
(Monday - Friday).  
 
• For computer and screen problems email user.support@fstrf.org  or call the DMC at (716) 834 -
0900 x7302.  
 
• For questions or problems regarding study drug supplies, records, and returns, contact the DAIDS 
Protocol Pharmacist at sisetk@niaid.nih.gov  or call ( 240) 292-4848 . 
 
• For Expedited Adverse Event (EAE) questions con tact the DAIDS RSC Safety Office via email 
(RSCSafetyOffice@tech -res.com ) or phone (1 -800-537-9979 or +1 -301-537-1709) or fax (1 -800-
275-7619 or +1 -301-897-1710) . For questions about the DAIDS Adverse Experience Reporting 
System (DAERS), email DAIDS -ESSupp ort@niaid.nih.gov . Questions may also be sent within 
the DAERS application.  
 
• Email the Computer Support Group at the Data Management Center (DMC) 
(user.support@fstrf.org ) to have relevant site personnel added to the protocol email group 
(impaact.protp1093@ fstrf.org ). Inclusion in the protocol email group will ensure that sites 
receive important information about the study during its implementation and conduct.  
 
 
 
 
 
IMPAACT P1093, Version 5.0  Page 9 of 135 12 July 2018   LIST OF COMMONLY USED ABBREVIATIONS AND DEFINITIONS  
 
3TC Lamivudine  
ABC  Abacavir  
AE Adverse Eve nt 
AIDS  Acquired Immunodeficiency Syndrome  
ALT  Alanine transaminase  
ART  Antiretroviral therapy  
ARV  Antiretroviral  
AST  Aspartate aminotransferase  
ATV  Atazanavir  
AUC 0-24 Area under the drug plasma concentration profile over time of dosing interval   
BSA   Body Surface Area  
C0 Drug plasma concentration immediately prior to dosing  
Cmax Maximal observed drug concentration during a dosing interval  
Cmin Minimal observed drug concentration during a dosing interval  
C24h Drug plasma concentration at the end of the 24 hour dosing interval  
CAP  College of American Pathologists  
CDC  Center for Disease Control and Prevention  
cDNA  complementary DNA  
CL/F  Apparent clearance  
CLIA  Clinical Laboratory Improvement Amendments  
CPK  Creatin ine phosphokinase  
CRPMC  Clinical Research P roducts Management Center  
DAERS  DAIDS Adverse Experience Reporting System  
DAIDS  Division of AIDS (United States)  
DMC  Data Management Center  
DNA  Deoxyribonucleic acid  
DRV  Darunavir  
DSMB  Data Safety and Monitoring Board  
DTG  Dolutegravir  
EAE  Expedited Adverse  Event  
EC Ethics Committee  
ECG  Electrocardiogram  
EFV  Efavirenz  
EIA Enzyme Immunoassay  
EMEA  European Medicines Agency  
ETR  Etravirine  
EU European Union  
EVG  Elvitegravir  
FDA  US Food and Drug Administration  
FPV Fosamprenavir  
FTC Emtricitabine  
GI Gastrointestinal  
GM Geometric mean  
GMR  Geometric mean ratio  
GSK  GlaxoSmithKline  
HAART  Highly Active Antiretroviral Therapy  
HIV Human Immunodeficiency Virus  
HHS  Department of Health & Human Services  
IB Investigator’s Brochure  
 
 
 
IMPAACT P1093, Version 5.0  Page 10 of 135 12 July 2018   IC50  Half Maximal Inhibitory Co ncentration  
IMPAACT  International Maternal Pediatric Adolescent AIDS Clinical Trials Network  
IgM Immunoglobulin M  
ICF Informed Consent Form  
IQ Inhibitory Quotient  
INR International Normalized Ratio  
IRB Institutional Review Board  
IUD Intrauterine device  
LAR  Legally Authori zed Representative  
LDH  Lactate dehydrogenase  
LMC  low mineral content  
LPV  Lopinavir  
MSDF  Missing, Switch or Discontinuation = Failure  
NIAID  National Institute of Allergy and Infectious Diseases  
NICHD  National Institute of Child Health and Human Development  
NIH National Institutes of Health  
NRTI  Nucleoside/Nucleotide Reverse Transcriptase Inhibitors  
NVP  Nevirapine  
OBT  Optimized Background Ther apy 
OHRP  Office for Human Research Protections  
PCR  Polymerase Chain Reaction  
PI Protease Inhibitor  
PID Patient Identifier  
PK Pharmacokinetic  
PRO  Protocol Registration Office  
QD Once daily  
RAL  Raltegravir  
RNA  Ribonucleic acid  
RSC  Regulatory Support Center  
RTV Ritonavir  
SAE  Serious Adverse Event  
SDMC  Statistical and Data Management Center  
SMC  Study Monitoring Committee  
SUSAR  Suspected, Unexpected Serious Adverse Reaction  
tmax time Cmax occurs  
tmin time Cmin occurs  
t1/2 half-life 
TB Tuberculosis  
TDF  Tenof ovir 
TPV  Tipranavir  
UAB  University of Alabama in Birmingham  
UGT  UDP -glucuronosyltransferases  
ULN  Upper Limit of Normal  
US United States  
WB Western Blot  
 
 
IMPAACT P1093, Version 5.0  Page 11 of 135 12 July 2018   SCHEMA  
 
Phase I/II Multi -Center, Open -Label Pharmacokinetic, Safety, Tolerability and Antivira l Activity 
of Dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in  
HIV -1 Infected Infants, Children and Adolescents  
 
DESIGN:  Phase I/II, multi -center, open -label, non -comparative intensive PK and 
safety study  
 
Two formulations of  dolutegravir (DTG ), film -coated tablets and 
dispersible tablets (DT) will be evaluated  under protocol Version 5.0.  
Evaluation of the f ilm-coated tablet began under protocol Version 1.0 ; 
and evaluation of the DT formulation began under protocol Version 4.0 . 
Evaluation of the granules for suspension formulation began under 
protocol Version 3.0 ; however, this formulation is no longer being 
developed for licensure .   
 
DTG is evaluated in each age -based cohort, with the exception of IIB, in 
two seque ntial stages: Stage I and Stage II. Stage I examines the 
pharmacokinetic (PK) parameters from intensive PK sampling, the short -
term tolerability and safety of DTG to determine a dose that is then 
studied with additional participants  as Stage II.  In versio n 5.0, doses will 
also be examined by weight band  group .   
 
POPULATION AND  
SAMPLE SIZE:  Up to 300 HIV-infected infants, children and adolescents aged ≥ 4 weeks 
to < 18 years of age enrolled in the age -specific cohorts specified below.   
 
Cohort I:  Adolescents ≥ 12 to <18 years of age  
 (film -coated tablets)  
 
Cohort IIA:  Children ≥ 6 to <12 years of age  
(film -coated tablets)  
 
Cohort IIB:  Children ≥ 6 to <12 years of age   
(granules for suspension  or dispersible tablets ) 
 
Cohorts III:   Children ≥ 2 to < 6 years of age   
 (granules for suspension) - Closed to Enrollment  
 
Cohort IV :  Children ≥ 6 months to < 2 years of age  
(granules for suspension) - Closed to Enrollment  
 
Cohort III -DT: Children ≥ 2 to < 6 years of age   
(dispersible tablets)  
 
Cohort IV -DT: Children ≥ 6 months to < 2 years of age  
(dispersible tablets)  
 
Cohort V -DT:  Infants > 4 weeks to < 6 months   
(dispersible tablets)  
 
IMPAACT P1093, Version 5.0  Page 12 of 135 12 July 2018   Stage I enrollment into Cohorts III -DT, IV -DT, and V -DT continue s 
until a minimum of 10 participants in each cohort AND a minimum of 8 
participants  in each of the  weight  band  groups below, are enrolled : 
 
a) 3 to < 6 kg  
b) 6 to < 10 kg  
c) 10 to < 14 kg  
d) 14 to < 20 kg  
 
When the PK parameters  and safety are determine d acceptable  among 
participants enrolled in Stage I , additional participants will be enrolled to 
Stage II (if necessary) to achieve  a minimum of 22 participants per 
cohort receiv ing the acceptable dose for long -term safety evaluation.  
 
REGIMEN:    Oral once daily dose of DTG  film-coated tablets or dispersible tablets , or 
twice daily dosing, i f indicated.   
 
TREATMENT DURATION:  Stages I and II: 48 Weeks  
 
Long Term Safety Follow -up: All participant s who successfully 
complete 48 weeks of DTG treatmen t will continue to receive DTG for 
up to, an additional, three years as part of long-term safety follow -up.  
 
HYPOTHESIS:  DTG will be generally well tolerated and demonstrate an acceptable 
safety profile, adequate PK and antiviral activity when used concu rrently 
with an optimized background therapy (OBT) in HIV -1 infected infants, 
children and adolescents.  
 
PRIMARY OBJECTIVES : 
 
1. To select a dose for each formulation of DTG for chronic dosing in infants, children and adolescents 
that achieves similar exposure to the DTG 50 mg once daily dose in adults.  
2. To determine the safety and tolerability of DTG in HIV -1 infected infants, chil dren and adolescents at 
24 and 48 weeks.  
3. To evaluate the steady -state pharmacokinetics of DTG in combination with OBT in treatment -
experienced and treatment -naïve HIV -1 infected infants, children and adolescents and to determine 
the dose of DTG that achiev es the targeted C 24h and AUC 0-24 PK parameters in this population.   
 
SECONDARY OBJECTIVES:  
 
1. To evaluate the antiviral activity of DTG in combination with an OBT by measuring virologic 
response in infants, children and adolescents at 24 and 48 weeks.  
2. To ev aluate the effect on immunologic response from baseline to 24 and 48 weeks.  
3. To assess changes in HIV -1 genotype and phenotype to DTG and other components of the OBT in 
participant s experiencing virologic failure.  
4. To determine DTG exposure, its variability and clinical covariates that impact DTG disposition (e.g. 
age, weight) using intensive and sparse sampling and population pharmacokinetic analysis.  
5. To determine the extended long term (> 48 weeks) safety , tolerability and efficacy of  DTG in HIV -1 
infected infants, children and adolescents.  
6. To explore the relationship between DTG exposure and the antiviral activity.  
7. To evaluate pharmacokinetic, safety  and tolerability  profile of DTG when dosed by weight bands.  
 
IMPAACT P1093, Version 5.0  Page 13 of 135 12 July 2018   1.0 INTRODUCTION  
 
1.1 Background  
 
Triple combination antiretroviral therapy including a protease inhibitor (PI)  or a non -nucleoside reverse 
transcriptase inhibitor ( NNRTI) has become the standard treatment of HIV -infected adults and children. 
In resource -advantaged countries, triple therapy with an integrase strand transfer inhibitor (INSTI) is now 
considered a preferred regimen in adults, adolescents and children  (1). The  World Health Organization 
(WHO) Treatment Guidelines still recommend triple therapy with a PI or NNRTI as preferred regimens; 
raltegravir is recommended as an alternative option in some children  (2). Effective antiretroviral therapy 
results in a reduction in viral load with a concomitant increase in the CD4 cell count that has been 
associated with declining morbidity and mortality in HIV -1 infected adults and  children  (3, 4) . However, 
very few third  agents have approved dosing for children of all ages from birth to adulthood.   Additionally,  
adherence , short and long-term toxicities and dosing intervals further complicate HIV management and 
may contribute to the development of drug resistance mutations  further limiting treatment options in 
children .  The establishment of dosing recommendation s for new antiretrovirals in children  is critically 
important , especially  for children and adolescents who have failed or are unable to tolerate currently 
available antiretrovirals. In addition, newer agents with novel resistance patterns not overlapping w ith 
established classes of therapies are also needed.   
 
Integrase, a viral enzyme essential for HIV -1 replication, mediates the integration of the viral DNA into 
the host genome. The primary role of the integrase enzyme is to catalyze the insertion of the viral cDNA 
into the chromosome of infected cells. This process requires two metal dependent consecutive steps in the 
viral replication cycle, 3’ -processing and strand transfer . After the integration of the viral cDNA into the 
cell’s chromosome, viral genom e is transcribed and viral proteins are produced  (6). Two metal integrase 
inhibitors preferentially block the strand transfer step.  
 
Currently, four INSTI are approved and available for use.  Raltegravir (MK -0518, Isentress, Merck) was 
the first approved HIV integrase strand transfer inhibitor and has demonstrated safety and efficacy in both 
treatment -naïve and highly antiretroviral (ARV) experienced adult  participants . Elvitegravir (GS -9137, 
Gilead) also show ed potent antiviral activity in adults  (7) and adolescents  (7). However, r altegravir needs 
to be administered tw ice a day  in children  and elvitegravir (EVG) , though  administered only once a day , 
requires a pharmacokinetic  (PK)  booster.  Bictegravir ( currently co-formulated with emtricitabine and 
tenofovir alafenamide  [Biktarvy®], Gilead ) was approved in 2018 for use in adults.  
 
Clinical resistance to both raltegravir and elvitegravir has been reported in both treatment naïve  and 
treatment experienced participant s. Two mutation pathways emerged among participant s experiencing 
virologic failure while on raltegravir.  One pathway characterized by the N155H mutation lowered the 
susceptibility to raltegravir by 10 -fold. The Q148H/R/K mutation pathway lowered the susceptibility to 
raltegravir by 25 -fold. Additional mutations have decreased raltegravir susceptibility; the most common 
being the Q148H and G140S conferring >100 fold decrease susceptibility to raltegravir  (8). Participant s 
experiencing virologic failure while on elvitegravir have shown similar mutation pathways as seen with 
raltegravir  (10). As the barrier to the above described resistance is low, there is a need for the 
development of ne w integrase inhibitors with different resistance profiles . Preliminary data suggests that 
elvitegravir exhibits similar resistance characteristics  to raltegravir . 
 
Dolutegravir  (DTG)  was the third approved INSTI and is a potent inhibitor of the HIV -1 integ rase. When 
tested against a panel of 18 integrase resistant viruses from participant s failing raltegravir or elvitegravir, 
DTG showed antiviral activity comparable to that seen against wild type viruses in 17 of 18 mutant 
viruses  (7);(10). Regulatory  approvals of DTG are based on studies showing clinical efficacy in 
treatment -naïve, treatment -experienced, and INSTI -resistant participant s. 
 
IMPAACT P1093, Version 5.0  Page 14 of 135 12 July 2018   1.2 Clinical E fficacy  
 
DTG is approved for the treatment of HIV -1 infection in adults and children weighing at least 1 5 kg in 
many countries but with a minimum weight of 30 kg in the US.   The clinical development program for 
DTG was designed to support a broad patient population, from naïve to highly treatment experienced 
patients.  The program involves 40 Phase I, 4 Phas e II, and 15 Phase III/IIIb clinical trials as well as a 
Named Patient Program and an Expanded Access Program.  The clinical pharmacology studies describe 
the PK and PD relationship of DTG in both healthy volunteers and special populations.  
 
The supportive  Phase II package for DTG (Studies 111521, ING112276, and ING112961) include initial 
safety data in ART -naïve, -experienced, and INI -resistant participant s. In these supportive studies, 
participant s were treated with doses of DTG from 2 mg daily up to 100 mg daily.  These data informed the 
design and conduct of this study.  
 
ING111521  was a proof of concept Phase II A, dose -ranging, randomized, placebo -controlled study  
amon g 35 HIV infected adults. For ten  days, participant s received either DTG monotherapy at the doses 
of 2 mg, 10 mg, 50 mg or placebo. In the group receivi ng 50 mg of DTG monotherapy, the mean decline 
in HIV -1 was 2.5 log 10 copies/m L and seven  out of ten participant s had a VL < 50 copies/ mL during the 
study . DTG was well tolerated  with only mild adverse events described including diarrhea, fatigue, and 
headache. No integrase signature resistance mutations were observed during the 10 -day monotherapy 
study  (11). 
 
In this study , DTG  demonstrated low PK variability and a steady -state half/life (t ½) of 14 hours . At 50 
mg once daily, the steady -state PK parameters (%CV) were; AUC 0-24 43.4 (20%) µg h/m L, Cmax of 3.34 
(16%) µg/ mL and C 24h of 0.83 (26%) µg/ mL. The ratio of the 10 and 50 mg C 24h to the protein binding 
corrected IC90 (0.064 g/mL), also defined as inhibitory quotient (IQ), were 3 and 13, respectively. Since 
the doses in this study covered a wide range of 25 -fold (2 to 50 mg), a concentration -response relationship 
was observed between C 24h and change in HIV -1 RNA from baseline to day 11 using a maximum effect 
(Emax) model. The concentration required to produce 50% of the maximum effect (EC 50) was estimated 
to be 0.036 g/mL (or 36 ng/ mL) (12). These d ata provide a basis for an AUC 0-24-and C 24h-targeted 
trial in pediatric participant s (Figure 1). 
 
Figure 1: DTG Day 11 Log10VL Change  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  

 
IMPAACT P1093, Version 5.0  Page 15 of 135 12 July 2018   Table 1: Summary of DTG PK Parameters and Mean HIV -1 RNA Reduction from Baseline by Dose  
Dose  AUC 24 
µg.h/mL Cmax 
µg/mL C24 
µg/mL IQ Δ Log 10 
HIV -1 RNA  
2 mg QD  
N=9 2.56 
(29%)  0.22 
(25%)  0.04 
(50%)  0.6 -1.51 
10 mg QD  
N=7 10.1 
(20%)  0.80 
(23%)  0.19 
(25%)  3 -2.03 
50 mg QD  
N=10  43.4 
(20%)  3.34 
(16%)  0.83 
(26%)  13 -2.46 
Geometric mean (CV%); IQ=C 24/PA-IC90 = 0.064 µg/ mL 
 
Potent antiviral efficacy was demonstrated  in treatment -naive and integrase -inhibitor resistant participant s 
in Studies ING112276 (SPRING -1) and ING112961 (VIKING Pilot) . In ING112276, a Phase IIb dose-
ranging study in 205 treatment -naive, HIV -infected participant s, rapid and sustained antiviral responses 
across all DTG  doses (10 mg, 25 mg, and 50 mg) were obser ved; 93% of participants who received DTG 
achieved HIV -1 RNA <50c/mL by Week 16 and 91%, 88%, and 90% of participant s, respectively, 
sustained this viral response  to Week 48 (14). At Week 96, the proportion of participant s with plasma 
HIV-1 RNA <50 c/mL was 79%, 78%, and 88% in the DTG groups  compared with 72% for the EFV 
group  (15). Neither dose trends nor differences were noted across DTG  arms (10 mg, 25 mg, and 50 mg) 
for efficacy or safety . No clinically significant dose -related trends in A dverse Events (A Es) were 
observed, and fewer participant s who received DTG withdrew because of AEs (3%) compared with EFV 
(10%) (16). All three doses of DTG were generally well tolerated through 48 weeks, and the 50 mg dose 
was selected for phase III evaluation.  
 
Study ING112961  was a Phase IIb , open -label, single -arm, pilot study of HIV -infected participant s with 
viral resistance to raltegravir ( RAL ) at Baseline .  The primary endpoint was to assess  the short -term 
antiviral activity of DTG plus a failing background regimen . Participant s received DTG 50 mg once daily 
(Cohort I) or 50 mg BID (Cohort II) while continuing a failing regimen (without RAL) through Day 10 . 
After Day 10 , the background regimen was optimized, when feasible, for Cohort I, and at least one fully 
active drug was mandated for Cohort II. Cohort I enrolled 27 participant s and Cohort II enrolled 24 
participant s. A rapid antiviral response was observed. More participant s achieved the primary endpoint in 
Cohort II (96%), compared with Cohort I (78%) at Day 11. At Week 24, 41% and 75% of participant s had 
an HIV -1 RNA load of <50 c/mL in Cohorts I and II, respectively  (17). At Week 96, 26% of participant s 
in Cohort I had an HIV -1 RNA load of <50 c/mL. At Week 48, 71% of participant s in Cohort II had an 
HIV-1 RNA of <50 c/mL . Results from Study ING112961 concluded D TG 50 mg BID with an optimized 
background provided greater and more durable benefit than the once -daily regimen in patients with prior 
RAL treatment failure.  
 
The Phase III/II Ib clinical development program for DTG comprised studies in antiretroviral therapy 
naïve and experienced adult participant s in which DTG was c ompared to numerous therapies. DTG 
generally demonstrated non -inferior or superior efficacy in these studies  (17).  
 
1.3 Clinical Pharmacokinetics in Adults  
 
Absorption and Effect of Formulation  
 
Following oral administration, absorption is rapid with average t max at one to two  hours and subsequently 
the plasma drug concentration declines almost mono -exponentially with average terminal half-life 
estimated at ~14 hours, supporting once daily dosing . The oral bioav ailability of the tablet was less than 
that of a suspension with a mean  AUC (0 -) decreased by 30% following administration of the tablet 
compared to the suspension under fasted conditions. The rate of absorption of DTG from the tablet was 
 
IMPAACT P1093, Version 5.0  Page 16 of 135 12 July 2018   slower than from  the suspension; the median t max for the suspension was 0.75 hours.  DTG exhibited linear 
pharmacokinetics with dose proportional increases in plasma exposure at doses from 2 to 100 mg using 
the suspension formulation, with less than dose proportional PK be tween 100  mg and 250  mg. For the 
tablet formulation, PK was close to linear over the dosage range of 2 to 50  mg but less than dose 
proportional between 50  mg and 100  mg. 
 
PK data (Week 2) are available across DTG doses  from the Phase IIb SPRING -1 Study (ING112276)  
Table  2. At Week  2, serial samples were obtained in 46 participant s and sparse samples were obtained in 
90 participant s for determination of PK parameters . DTG was less than dose -proportional between 10 mg 
and 25 mg but lin ear between 25 mg and 50 mg. PK parameters were similar to those reported in 
ING111521, although hig her PK variability was observed around AUC and C max. The increased 
variability is expected given that these are outpatient HIV -infected participant s and the majority had 
sparse PK sampling.  
 
Table 2: Summary of Week 2 DTG PK Parameters from ING112276  
Dose  Tablet  Parameter  Cmax  
(µg/mL)  AUC  
(µg.h/mL)  C 
(µg/mL)  Cmin  
(µg/mL)  
10 mg  10 mg  N 
GeoMean  
CV%  15 
1.10 
37 15 
16.0 
40 47 
0.30 
71 15 
0.33 
64 
25 mg  25 mg  N 
GeoMean  
CV%  15 
1.71 
43 15 
23.1 
48 44 
0.54 
67 15 
0.44 
68 
50 mg  2 x 25 mg  N 
GeoMean  
CV%  15 
3.40 
27 15 
48.1 
40 44 
1.20 
62 15 
0.94 
74 
 
Pharmacokinetics of DTG  Granul e Formulation  
 
A granule formulation of DTG  was developed as an alternative to tablets for use in pediatric populations . 
In a single -center, randomized, open -label, 5 -way crossover study (ING114556) in healthy adults, 20 
participant s received a single dose of DTG 50 mg as the Phase III tablet and in 10  grams  of granule (0.5% 
drug load) administered 1) direct to mouth; 2) wit h purified water; 3) with mineral water containing high 
cation concentrations; or 4) with a milk -based infant formula. Study treatments were separated by 7 days. 
Study data demonstrate d that the plasma DTG exposures in all granule treatment arms exceeded t hose of 
the tablet formulation (Table 3). DTG PK exposure was similar when DTG was mixed with purified or 
cation -containing mineral water or given direct to mouth. Inter -participant  variability was modest with 
CV% for AUC of 31 -43%. DTG was well tolerated with no withdrawals due to AEs.  
 
The exposure of DTG following administration of the granule formulation alone, with different types of 
water and with formula exceeded that of the tablet, and DTG exposure from granule formulation was 
similar when given direct to mouth, or with different types of water, indicating DTG granule can be given 
without restriction on the type of liquid, or can be administe red directly to mouth (e.g., when water  that is 
safe to drink  is not available)  (Table 3).  
  
 
IMPAACT P1093, Version 5.0  Page 17 of 135 12 July 2018   Table 3: Treatment Comparison of DTG  PK Parameters (Study ING114556 ) 
Comparison to T ablet  Geometric  mean ratio (90%CI)  
AUC 0-∞ Cmax 
Granule direct to mouth  1.58 (1.46 -1.71)  1.62 (1.49 -1.77)  
Granule with purified water  1.57 (1.45 -1.70) 1.66 (1.52 -1.81)  
Granule with mineral water  1.55 (1.43 -1.67)  1.65 (1.51 -1.79)  
Granule with formula  1.83 (1.69 -1.98)  2.02 (1.86 -2.20)  
 
This adult relative bioavailability study utilized an early formulation in which the granules contained 
0.5% DTG and were constituted as a suspension containing 2.5  mg/mL. The pediatric granule formulation 
used in the pediatric study ha d slightly different  drug content with 0.4% of drug load (dosed as a 
1.6mg/ mL suspension) . 
 
However, based on input from the  WHO , specifically that a dispersible tablet formulation is preferred to 
other pediatric appropriate formulations for ease of widespread distribution, s tability and patient 
acceptability (e.g., liquids, granules for suspension), the manufacturer took the decision to develop a DTG 
dispersible tablet as the preferred formulation to make available globally.  
 
Pharmacokinetics of DTG  Dispersible Tablet Formulation  (18) 
 
A dispersible tablet formulation has been developed as an alternative to the pediatric granule formulation 
for administration in younger pediatric populations . In a single center, randomized, open -label, 5 -period, 
single dose, crossover, relative bioavailability study (ING200401) in healthy adults , the PK of DTG given 
as dispersible tablet formulation was compare d to a DTG pediatric granule formulation and effect of 
different types of water on the dispersible tablet in healthy adult participant s was evaluated . Fifteen 
healthy participant s were enrolled to provide data from at least 10 evaluable participant s. Eligible 
participant s were randomized to one of 5 treatment sequences. Participant s received 1) DTG 20 mg of the 
pediatric granule formulation reconstituted with purified water (Treatment A); 2) DTG 20 mg of the 
dispersible tablet formulation dispersed in low mineral content ( LMC ) water and taken by participant  
immediately (Treatment B); 3) DTG 20 mg of the dispersible tablet formulation dispersed in Contrex 
mineral water (5% Contrex  / 95% purified water) and taken by participant  immediately (Treatment C ); 4) 
DTG 20 mg of the dispersible tablet formulation dispersed in LMC water, held for 30 minutes, re -
dispersed, and then taken by participant  (Treatment D); 5) DTG 20 mg of the dispersible tablet 
formulation dispersed in Contrex mineral water, held for 30  minutes , re-dispersed, and then taken by 
participant  (Treatment E).  There were washout periods of at least 7 days between treatments . DTG PK 
parameters were determined from serial PK samples collected over a 48 -hour dosing interval and 
compared between tr eatments . Study results are shown in Table 4:  
 
• DTG PK exposure following a single dose oral administration of 20  mg dispersible tablets dispersed 
in low mineral content water is equivalent to that following a single dose oral administration of 2 0 mg  
granule formation reconstituted with purified water . 
• DTG PK exposure following a single dose oral administration of 20  mg dispersible tablets dispersed 
in Contrex mineral water is equivalent to that following a single dose oral administration of 2 0 mg  
dispersible tablets dispersed in low mineral content water . 
• DTG PK exposure following a single dose oral administration of 20  mg dispersible tablets dispersed 
in both low and high mineral content water held for 30 minutes before, re -dispersed, and then 
consumed is equivalent to that following a single dose oral administration of 2 0 mg  dispersible tablets 
re-dispersed in both low or high mineral content water and consumed immediately.  
 
 
 
IMPAACT P1093, Version 5.0  Page 18 of 135 12 July 2018   Table 4: Treatment comparison of plasma DTG PK parameters  
Treatment  GMR mean ratio (90%CI)  
 AUC 0-∞ Cmax  
Dispersible tablet in LMCa water  1.07 (1.01, 1.13)  1.13 ( 1.06, 1.20)   
Dispersible tablet in Contrex water  0.944 (0.893, 0.999)  0.918 (0.863, 0.976)    
Dispersible tablet in LMC, held for 30 minutes, then re -
dispersed  1.03 (0.971, 1.09)   0.987 (0.928, 1.05)    
Dispersible tablet in Contrex water, held for 30 minutes, then 
re-dispersed  1.05 ( 0.988, 1.11)   1.05 ( 0.986, 1.12)    
a. LMC= low mineral content  
 
In a 2 -part phase I, single -dose crossover relative bioavailability  (RBA)  study, the 10 mg conventional 
film coated tablets were compared to the adult 50 mg tablet  (Part 1) , and the DTG  5 mg dispersible tablets 
were compared to a 25 mg tablet  (Part 2)  (ING205893) . Part 2 of the study specifically evaluated the 
RBA of the disper sible tablet with 5 tablets administered as “dispense and immediately take” and 5 tablets 
taken direct to mouth against the DTG  25 mg film coated tablet taken direct to mouth. The geometric 
mean systemic exposure of DTG from the dispersible tablet was appr oximately 1.5 to 1.8 -fold higher than 
that observed following administration of a single 25 mg conventional tablet taken direct to mouth. 
Comparable bioavailability was observed following disperse and immediate administration and direct to 
mouth administra tion. These data demonstrate that the 5 mg dispersible tablet can also be taken direct to 
mouth.   
 
Effect of Food 
 
The Phase III  tablet formulation at a 5 0 mg  dose demonstrated that low, moderate, and high fat meals 
increased DTG AUC  (0-t) by 33%, 41%, and  65%, respectively . Such effect is not considered clinically 
significant based on accumulated toxicity data  and safety and tolerability data in humans receiving DTG 
to date . DTG is licensed to be taken without regard to food.  
 
Accumulation and Time -dependence  
 
Following once daily dose administration, steady state was achieved after approximately 5 days of dosing. 
DTG (suspension and tablet formulations) showed time -invariant pharmacokinetics . The PK variability of 
DTG is between low to moderate  with between -participant  CV% for AUC and C max of ~20 to 30% and 
for C of 30 to 50%.  
 
Metabolism and Excretion  
 
DTG is primarily metabolized via UGT1A1 with a minor CYP3A component. DTG is the predominant 
circulating compound in plasma and renal elimination of unchanged drug is low (< 1% of the dose). Fifty -
three percent of total oral dose is excreted unchanged in the feces , but unknown if all or part of this is due 
to unabsorbed drug or biliary excretion of the glucuronidate conjugate which can b e further degraded to 
form the parent compound . Protein binding in human serum is 99.3%.  
 
Drug Interaction Profile of DTG  
 
The drug interaction profile of DTG has been evaluated in a number of clinical studies in healthy 
volunteers (Table 5).  
 
 
IMPAACT P1093, Version 5.0  Page 19 of 135 12 July 2018   Table 5: Effect of concomitant medication s on DTG pharmacokinetics  
Concomitant Drug  N DTG Dose  GMR1 (90% CI)  Conclusion  C or C 24h AUC  Cmax 
TDF  300 mg QD  16 50 mg QD  0.920  
(0.816 -1.04)  1.01 
(0.908 -1.11)  0.969  
(0.867 -1.08)  No dose 
adjustment  
DRV/r  600/100 mg 
BID 15 30 mg QD  0.620  
(0.555 -0.694)  0.782  
(0.722 -0.848)  0.892  
(0.825 -0.965)  No dose 
adjustment  
LPV/r  400/100 mg 
BID 15 30 mg QD  0.944  
(0.848 -1.05)  0.973  
(0.911 -1.04)  1.00 
(0.937 -1.07)  No dose 
adjustment  
ETV 200 mg BID  16 50 mg QD  0.121  
(0.093 -0.157)  0.294  
(0.257 -).337)  0.484  
(0.433 -0.542)  No dose 
adjustment  
ETV 200 mg BID + 
LPV/r 400/100 mg 
BID 8 50 mg QD  1.28 
(1.13 -1.45)  1.10 
(1.02 -1.20)  1.07 
(1.02 -1.13)  No dose 
adjustment  
ETV 200 mg BID + 
DRV/r 600/100 mg 
BID 9 50 mg QD  0.63 
(0.52 -0.76)  0.75 
(0.69 -0.81)  0.88 
(0.78 -1.00)  No dose 
adjustment  
Multivitamin  16 50 mg 
single dose  0.679  
(0.560 -0.824)  0.668  
(0.553 -0.806)  0.646  
(0.540 -0.774)  No dose 
adjustment  
Maalox  16 50 mg 
single dose  0.256  
(0.211 -0.311)  0.264  
(0.218 -0.318)  0.276  
(0.231 -0.331)  DTG should be 
taken 2 hrs. before 
or 6 hours after 
antacid  Maalox 2 hrs. after 
dolutegravir  16 50 mg 
single dose  0.703  
(0.579 -0.853)  0.743  
(0.615 -0.897)  0.821  
(0.686 -0.984)  
Calcium carbonate 
(fasted)  12 50 mg 
single dose  0.61 
(0.47, 0.80)  0.61 
(0.47, 0.79)  0.63 
(0.50, 0.81)  DTG should be 
taken 2 hrs. before 
or 6 hours after 
supplement if taken 
without food or, 
alternatively, take 
with food  Calcium carbonate 
(fed)  11 50 mg 
single dose  1.08 
(0.81, 1.42)  1.09 
(0.84, 1.43)  1.07 
(0.83, 1.38)  
Calcium carbonate 2 
hrs. prior (fasted)  11 50 mg 
single dose  0.90 
(0.68, 1.19)  0.94 
(0.72, 1.23)  1.00 
(0.7, 1.29)  
Ferrous fumarate 
(fasted)  11 50 mg 
single dose  0.44 
(0.36, 0.54)  0.46 
(0.38, 0.56)  0.43 
(0.35, 0.52)  DTG should be 
taken 2 hrs. before 
or 6 hours after 
supplement if taken 
without food or, 
alternatively, take 
with food  Ferrous fumarate 
(fed)  11 50 mg 
single dose  0.99 
(0.80, 1.22)  0.87 
(0.80, 1.19)  1.03 
(0.85, 1.26)  
Ferrous fumarate 2 
hrs. prior (fasted)  10 50 mg 
single dose  0.92 
(0.74, 1.13)  0.95 
(0.78, 1.15)  0.99 
(0.81, 1.21)  
ATV/r 300/100 mg 
QD2 12 30 mg QD  2.21 
(1.97 -2.47)  1.62 
(1.50 -1.74)  1.33 
(1.25 -1.42)  No dose 
adjustment  
ATV 400 mg QD  12 30 mg QD  2.80 
(2.52 -3.11)  1.91 
(1.80 -2.02)  1.49 
(1.40 -1.59)  No dose 
adjustment  
Omeprazole 40 mg 
QD 12 50 mg 
single dose  0.954  
(0.752 -1.21)  1.00 
(0.808 -1.25)  0.915  
(0.754 -1.11)  No dose 
adjustment  
Tipranavir/RTV 
500/200  mg BID  13 50 mg QD  0.24 
(0.21 -0.27)  0.41 
(0.38 -0.44)  0.53 
(0.50 -0.57)  DTG 50 mg BID  
Efavirenz 600  mg 
QD 12 50 mg QD  0.25 
(0.18 -0.34)  0.43 
(0.35 -0.54)  0.61 
(0.51 -0.73)  DTG 50 mg BID  
 
IMPAACT P1093, Version 5.0  Page 20 of 135 12 July 2018   Table 5: Effect of concomitant medication s on DTG pharmacokinetics  
Concomitant Drug  N DTG Dose  GMR1 (90% CI)  Conclusion  C or C 24h AUC  Cmax 
FPV/RTV 
700/100  mg BID  12 50 mg QD  0.51 
(0.42 -0.63)  0.65 
(0.54 -0.78)  0.76 
(0.63 -0.92)  INI naïve: No dose 
adjustment  
INI-resistant: 
Alternative 
combination that 
do not include 
FPV/RTV should 
be used where 
possible  
Rifampin  11 50 mg BID  1.22 
(1.01, 1.48)  1.33 
(1.15, 1.53)  1.18 
(1.03, 1.37)  DTG 50 mg BID  
11 50 mg BID  0.28 
(0.23, 0.34)  0.46 
(0.38, 0.55)  0.57 
(0.49, 0.65)  
Rifabutin  9 50 mg QD  0.70 
(0.57, 0.87)  0.95 
(0.82, 1.10)  1.16 
(0.98, 1.37)  No dose 
adjustment  
Prednisone  12 50 mg QD  1.17 
(1.06, 1.28)  1.11 
(1.03, 1.20)  1.06 
(0.991, 1.14)  No dose 
adjustment  
Boceprevir  13 50 mg QD  1.08 
(0.911, 1.28)  1.07 
(0.948, 1.20)  1.05 
(0.960, 1.15)  No dose 
adjustment  
Telaprevir  15 50 mg QD  1.37 
(1.29, 1.45)  1.25 
(1.20, 1.31)  1.19 
(1.11, 1.26)  No dose 
adjustment  
Rilpivirine  16 50 mg QD  1.22 
(1.15, 1.30)  1.12 
(1.05, 1.19)  1.13 
(1.06, 1.21)  No dose 
adjustment  
Carbamazepine  14 50 mg QD  0.27 
(0.24, 0.31)  0.51 
(0.48, 0.55)  0.67 
(0.61, 0.73)  DTG 50 mg BID  
Daclatasvir  12 50 mg QD  1.45 
(1.25, 1.68)  1.33 
(1.11, 1.59)  1.29 
(1.07, 1.57)  No dose 
adjustment  
1GMR = geometric mean ratio  
 
DTG has a low propensity to cause drug interactions. In a metabolic probe substudy, DTG did not alter 
the pharmacokinetics of midazolam, demonstrating that DTG does not induce or inhibit CYP3A4. In vitro 
studies in liver microsomes against other CYP isozymes demonstrate  that DTG would not be expected to 
affect the exposure of concomitant medications that are metabolized by CYP450 enzymes. In addition, in 
vitro data demonstrate that DTG did not inhibit UGT2B7 and had only a 20% inhibition of UGT1A1, and 
this occurred at c oncentrations (IC 50 > 100 M) that are not clinically relevant. DTG also had no 
significant effect on tenofovir exposure ( Table 6).  
  
 
IMPAACT P1093, Version 5.0  Page 21 of 135 12 July 2018   Table 6: Effect of DTG on the Pharmacokinetics of Concomitant Medications  
Concomitant 
Drug  N DTG 
Dose  GMR1 (90% CI)  Conclusion  
C AUC  Cmax  
Midazolam 25 
mg 10 25 mg 
once 
daily  ND 0.953   
(0.790 -
1.15)  ND No effect on MDZ  
TDF  300 mg 
QD 16 50 mg 
once 
daily  1.19 
(1.04 -
1.35)  1.12 
(1.01 -
1.24)  1.09 
(0.974 -
1.23)  No TDF dose adjustment  
Methadone  11 50 mg 
twice 
daily     No methadone adjustment  
Oral 
contraceptive2 15 50 mg 
twice 
daily  1.02 
(0.93, 
1.11)  1.03 
(0.96, 
1.11)  0.99 
(0.91, 
1.08)  No OC adjustment  
Rilpivirine  16 50 mg 
once 
daily  1.21 
(1.07, 
1.38)  1.06 
(0.98, 
1.16)  1.10 
(0.99, 
1.22)  No RPV adjustment  
Metformin  14 50 mg 
once 
daily  NA 1.79 
(1.65, 
1.93)  1.66 
(1.53, 
1.81)  Consider metformin dose adjustment/reduction 
when starting or stopping co -administration 
with DTG to maintain glycemic control  Metformin  14 50 mg 
twice 
daily  NA 2.45 
(2.25, 
2.66)  2.11 
(1.91, 
2.33)  
Daclatasvir  12 50 mg 
once 
daily  1.06 
(0.88, 
1.29)  0.98 
(0.83, 
1.15)  1.03 
(0.84, 
1.25)  No DCV adjustment  
1GMR = geometric mean ratio  
2ethinyl estradiol 
 
With respect to DTG exposures, no clinically significant drug interactions requiring a dosage change have 
been observed with lopinavir/ritonavir, darunavir/ritonavir, atazanavir (ATV), atazanavir/ritonavir 
(ATV/ r), fosamprenavir/ritonavir (FPV/RTV), tenofovir, and omeprazole .  
 
It is recommended that the dose of DTG be increased to twice daily in participant s receiving EFV, FPV/r, 
or TPV/r concomitantly . The DTG unit dose in mg will stil l be based on weight banding per the 
IMPAACT P109 3 Dosing Table Appendix , which is available at 
http://impaactnetwork.org/studies/P1093.asp . 
 
As the key of the PK evaluation in the pediatric study is to evaluate the impact of development (organ 
maturation, age, or body size) on DTG in order to guide dose selection, it would be optimal to limit other 
confounding factors that introduce variability  as much as possible, especially during the intensive PK 
evaluation/dose determination in Stage 1 . Therefore, use of ATV , boosted (ritonavir or cobicistat)  ATV , 
FPV, TPV /r, FPV,  and EFV will be disallowed during the intensive PK assessment in Stage 1.   
 
DTG is recommended to be taken at least  two hours prior or 6 hours after antacids due to reduced 
absorption resulting from chelation with metal cations in antacids  (12). However , DTG can be taken with 
proton pump inhibitors and H 2 blockers without res triction. Concomitant administration with a 
multivitamin containing metal cations modestly decreased DTG AUC (0 -) by 33% and DTG may be 
administered concurrently with multivitamins. These dosing recommendations are supported by clinical 
data (19). Concomitant administration with an antacid, Maalox Maximum Strength, decreased the AUC 
(0-) of DTG by 74% . The reduction in exposure was decreased to 26% when DTG was administered 2 
hours before the antacid.  
 
IMPAACT P1093, Version 5.0  Page 22 of 135 12 July 2018   Effect of Rifampin on DTG   
 
Rifampin induces UGT1A1  and CYP3A4 which are involved in DTG metabolism. In an open -label, 
three -period, fixed -sequence drug interaction study, 11 healthy participant s received DTG 50 mg once 
daily for seven  days (period 1), then DTG 50 mg twice daily for  seven days (period 2), then DTG 50 mg 
twice daily together with rifampin 600 mg once daily (period 3) for 14 days . Twice daily DTG plus 
rifampin achieve d mean PK parameters that were 18 -33% higher than once daily dosing alone. Therefore, 
a dose  of DTG 50 mg twice daily is recommended when co -administered with rifampin.  
 
1.4 Clinical Pharmacokinetics in P1093  
  
Available data from P1093 as of 14  April 2018 are summarized below:  
 
Table 7: Pharmacokinetic Data Available from P1093  
Age Cohort  DTG Dose  
(once daily)  DTG PK Parameter Estimates  
Geometric Mean (CV%)  
AUC 0-24 μg.hr/mL  Cmax ng/mL  C24h ng/mL  
12 to 18 yrs1, (n= 10) 50 mg (n=9)  
35 mg (n=1)  46.0 (43) 3490 (38) 900 (59) 
6 to <  12 yrs1 (n=11)  50 mg (n=5)  
35 mg (n=2)  
25 mg (n=4)  50.5 (6 4) 3960.6 (50)  920 (89) 
2 to <  6 yrs2 (n=11) 20 mg (n=1)  
15 mg (n=9)  
10 mg (n=1)  43.5 (43)  4239 (41)  504 (61)  
6 mos to <  2 yrs2 (n=1 3) 15 mg (n= 5) 
10 mg (n=7)  
5 mg (n=1)  55.9 (61)  4691 (45)  807 (87)  
4 wks to <  6 mos2 (n=10) 10 mg ( n=4) 
5 mg (n= 6) 61.2 (44) 4459 (38) 1207 (55) 
1 DTG film coated tablets  
2 DTG dispersible tablets  
 
Dosing recommendations for DTG in adolescents and in children ≥15 kg have been approved in the EU  
based on these data , and ≥30 kg in the U.S . Assessment of DTG d osing in the youngest children is 
ongoing.  
 
1.5 Summary of Safety in Clinical Trials  
  
Summaries of findings from both clinical and non -clinical studies conducted with DTG can be found in 
the IB version 11 and product label s.  The following section outlines select summaries of safety for DTG . 
Where available, the approved country product label should be referenced.   
 
DTG has been administered to a total of 6004 participant s (4814 HIV -infected and 1190 healthy) 
cumulative to 1 6 July 2017 in ongoing and completed ViiV sponsored and clinical trials ranging from 
Phase I to IIIb and the DTG compassionate use program.  DTG exposure has occurred among a total of 
1190 healthy adults in Phase I clinical trials; 4814 HIV -infected adults  in Phase IIa -IIIb studies; 514 HIV -
infected adults via either the Named Patient Program or Expanded Access Program; and 121 HIV -
infected children and adolescents via the P1093 Study.  
 
 
IMPAACT P1093, Version 5.0  Page 23 of 135 12 July 2018   Meta -Analysis of 26 Completed Phase I/IIa Clinical Pharmacology Adult Studies  
 
Based on a safety meta -analysis of 26 clinical pharmacology Phase  I/IIa studies using DTG single entity, 
the most commonly reported adverse events (AEs) were headache (14%), nausea (6%), and diarrhea 
(4%). These AEs are comparable to those seen in  adult HIV clinical trials. Headache and nausea were the 
only AEs reported with greater frequency among participant s receiving DTG compared to placebo, 
among common AEs reported in at least 5% in any analysis group (headache 14% vs 3%, and nausea 6% 
vs 3%) .  Withdrawals due to AEs were infrequent (2%), and the majority of AEs were Grade 1. A total of 
two SAEs were reported and both were unrelated to DTG.  
 
In summary, the safety profile for DTG in healthy adult participant s participating in phase I/IIa clin ical 
pharmacology studies  was similar to that observed in HIV -infected adults in the Phase IIb/III clinical 
adult program.  
 
Phase IIb to IIIb Adult Clinical Studies and Compassionate Use Program  
 
The integrated safety output (ISO) for the ART -naïve adult population is derived from four randomized 
controlled trials ( ING112276 , ING113086, ING114467, and ING114915), comprising a total of 1222 
participant s who received DTG once daily. The ART -experienced population was comprised of 621 
participant s from four t rials (ING112961, ING112754, ING111762, and ING116529). For both ART -
naïve and ART -experienced (INI -naïve) patients, the ISO was similar to both RAL and DRV/RTV, and 
the most frequently observed AEs were diarrhea, nausea and headache, which tended to be Gr ade 1 or 2 
in severity and typically did not require discontinuation from study.  
 
There has  been a total of 13 deaths up to 16 July 2017 across the DTG pivotal and supporting clinical 
trials. One death was considered related to investigative product (IP) (a 40 -year-old male with renal 
failure, ING114467). Few participant s receiving DTG have developed AEs requiring permanent 
discontinuation of study drug and withdrawal from study. Please refer to the DTG Investigator Brochure 
v11 for a complete listing of S AEs and AEs leading to withdrawals.  
 
Pregnancy Outcome data from the Tsepamo Study in Botswana  
 
In May of 2018, a preliminary analysis of the Tsepamo Study, a large observational study of pregnant 
women in Botswana,  showed an increased rate of neural tube defects (NTDs) among infants born to 
women who started DTG at the time of conception.   
 
The Tsepamo birth outcomes surveillance study was designed to evaluate adverse birth outcomes by 
maternal HIV status and ART re gimen, and to determine whether there is an increased risk of neural tube 
defects (NTDs) among infants exposed to EFV from conception. Botswana’s HIV program moved to 
universal ART with DTG/FTC/TDF provided as the first -line regimen for patients starting A RT, 
including pregnant women, in May 2016 (women already on other regimens were not switched to a DTG -
containing regimen). The previous first -line regimen was EFV/FTC/TDF. Almost all women on DTG -
based and EFV -based ART took these drugs in combination with  FTC/TDF. More than 95% of women in 
Botswana deliver in -hospital, and obstetric records are available for more than 99% of women. The 
Tsepamo study is conducted at eight of the largest public maternity wards across Botswana, representing 
approximately 45% of all births in the country. Research assistants extract exposure data from maternity 
cards for all consecutive in -hospital deliveries. Trained nurse midwives perform systematic infant surface 
examinations of all newborns, whether stillborn or live born. Reports and photographs (when available) of 
major abnormalities are reviewed by an experienced medical geneticist who is blinded to exposure 
information  (20) (22) (22). 
 
 
IMPAACT P1093, Version 5.0  Page 24 of 135 12 July 2018   A preliminary unscheduled analysis of the Tsepamo study data collected between 15 August 2014 and 1 
May 2018 was recently performed at the request of colleagues who were preparing for a WHO meeting. 
This analysis identified four infants with NTDs born to 4 26 women who became pregnant while taking 
DTG (prevalence 0.94%, 95% CI 0.37%, 2.4%). In comparison, 14 infants with NTDs were born to 
11,300 women who became pregnant while taking a non -DTG -containing three -drug ART regimen 
(prevalence 0.12%, 95% CI 0.07% , 0.21%); approximately half of these women were taking an EFV -
containing regimen). No NTDs were identified among infants born to 2,812 women who started DTG -
containing ART during pregnancy (including 280 women who started DTG -containing ART during the 
first trimester). (23) 
 
At this time, only a small amount of additional data exists regarding birth outcomes among women taking 
DTG from conception, fro m multiple sources of varying data quality and completeness; from these 
sources, only one NTD was reported among infants born to approximately 323 women taking DTG from 
conception (24). Additional data will continue to be  collected — in Botswana and ideally in other settings 
— to try to determine whether this signal for NTDs with DTG exposure from conception persists, and 
whether it is found in different populations.  
 
The Tsepamo study had previously showed similar rates o f other adverse pregnancy outcomes (stillbirth, 
neonatal death, preterm or very preterm birth, small for gestational age or very small for gestational age) 
among 845 women initiating DTG/TDF/FTC (at median 19 weeks gestation) compared with 4593 women 
initiating EFV/TDF/FTC (at median 21 weeks gestation) in pregnancy. Among 512 women initiating 
ART in the first trimester of pregnancy (116 DTG/TDF/FTC, 396 EFV/TDF/FTC), one major congenital 
abnormality was identified (skeletal dysplasia in an EFV -exposed infa nt) (25). 
 
Although there is limited experience with the use of DTG in pregnancy, the data analyzed prior to May of 
2018 from all sources including the Antiretroviral Pregnancy Registry  (26), other clinical trials and post 
marketing use has not indicated a similar potential safety issue.  
 
Additional Pregnancy and Lactation Data  
 
Sixty -nine pregnancies were reported across ViiV Healthcare (sponsored clinical trials and compassiona te 
use program) up to 16 July 2017. Few cases resulted in an adverse pregnancy outcome, such as an ectopic 
pregnancy or spontaneous abortion. One congenital anomaly was reported for a participant  who was 
taking DTG + ABC + ATV + RTV during the first month of gestation. A diagnosis of double -outlet right 
ventricle with ventricular septal defect was made on routine ultrasound at 31 weeks gestation. Surgery 
was performed for the defect following delivery of the infant but the infant died at day of life 4 due t o 
post-operative complications. The investigator considered the congenital anomaly to be unrelated to  IP. 
With the exception of this case, no other congenital anomalies have been reported in clinical trials.  
 
Post-marketing data identified a total of 235 pregnancies relating to the use of DTG in pregnant women  
(17).  
 
It is expected that DTG will be secreted into human  milk based on animal data, though this has not yet 
been confirmed in humans  (27).  
 
DTG was tested in a complete package of reproductive toxicology studies including embryofetal 
development studies.  In reproductive toxicolo gy studies in animals, DTG was shown to cross the 
placenta. However, no adverse development outcomes, including NTDs, were identified from 
reproductive toxicology studies performed in animals.  
 
 
 
IMPAACT P1093, Version 5.0  Page 25 of 135 12 July 2018   Recognized Risks with Dolutegravir  
 
The following risks have been recognized for DTG and are summarized cumulatively  from the clinical 
development program.  
 
Hypersensitivity Reaction : in the latest integrated analyses performed for DTG single entity, there were 
17 adult  participant s with AE preferred terms of “drug hypersensitivity” or “hypersensitivity” or who had 
a syndrome of drug hypersensitivity in 1856 cases (0.91%) exposed to at least one dose of DTG in ViiV -
sponsored IIb -IIIb clinical trials. DTG as a contributing factor to the event could not be ruled out in all but 
5 cases (0.27%), these were all potentially confounded by other ARVs (ABC, ETV, and/or DRV for 
which HSR and rash are possible outcomes). Thus, the frequency of HSR with DTG in clinical trials 
remains low, and SAE reports are generally confo unded by concurrent ART.  
 
Rash : The overall rate for rash reported in the most recent ISO was 5% (91/1843) and was similar when 
taken once daily (5%) compared to twice daily (6%).  
 
Hepatobiliary Disorders:  for ART -naïve participant s, the incidence of grade 3 and 4 liver chemistry 
toxici ties in the most recent ISO was low (<2%) for all liver chemistries across all treatment groups in the 
Phase III and IIIb studies. For ART -experienced participant s, safety data suggests no excess risk of 
hepatic toxicity for DTG. In most cases where liver abnormalities have been present, one or more of the 
following have been present: history of hepatitis virus co -infection; medical history of alcohol abuse, or 
ART included drugs with well -described bilirubin or liver enzyme elevation. Please refer to the I B v11  
for further information on hepatobiliary disorders in HBV and HCV -co-infected participant s. 
 
Renal Function:  small increases in mean serum creatinine have been observed in participant s on DTG 
across the entire clinical development program, related to  a likely benign effect on creatinine secretion via 
blockade of the OCT2 receptor. Phase I studies on iohexol and para -aminohippurate clearance have 
confirmed, however, that there is no effect on GFR.  
 
Psychiatric Disorders including Suicidality:  Patients with HIV infection may occasionally experience 
symptoms of depression and/or suicidal ideation. In the most recent ISO, the psychiatric profile for DTG 
was favourable compared to EFV and similar to RAL and DRV/r. There was no excess ri sk of DTG 50 
mg BID compared to 50 mg QD.  The adverse drug reaction of depression, suicidal ideation, and suicidal 
behaviors were added to the Company  Global Data Sheet (GDS) and  Reference Safety Information (RSI) 
after a review of cumulative data on depr ession, suicide, and self -harm with DTG up to November 21, 
2014. It was determined that a causal association could not be ruled out, though it is not considered to 
sugges t a change in the positive risk benefit assessment for DTG as psychiatric events have already been 
recognized as potential risks and alternative backbone drugs for HIV treatment already have these adverse 
reactions in their labelling [ie – RAL, EVG, EFV]. Furthermore, the risk is primarily in those participant s 
with a pre -existing history o f depression or psychiatric illness. Thus, it is important to monitor 
participant s being treated with DTG for depression, suicidal ideation, and behaviour, before and during 
the clinical study.  Insomnia is listed as a common non -serious adverse reaction as sociated with DTG 
based on clinical trials and post -marketing experience. Additionally, it was observed at a greater 
frequency with the combination of DTG + ABC/3TC  vs Atripla in one study , SINGLE  (ING 114467), but 
the incidence has been lower and similar t o comparators in all other Phase  III studies to date, including 
ARIA (ING117172), which compared TRIUMEQ with ATV/r +TDF/FTC  (28). In the latest ISO, t he 
psychiatric profile for DTG, which includ es insomnia, was favourable compared with EFV, and similar to 
RAL and DRV/RTV. There was no e xcess risk of DTG 50 mg BID compared to 50 mg once daily.  
 
Clinical Laboratory Evaluations : No clinically significant trends in treatment emergent hematology 
abnormalities, electrolytes, or vital signs have been in any integrated safety analyses or across studies. 
 
IMPAACT P1093, Version 5.0  Page 26 of 135 12 July 2018   There was no evidence of a clinically significant impairment of the lipid profile by DTG treatment in the 
Phase III/IIIb studies. Lipase elevations have been noted among ART -naïve participant s in the Phase IIb 
and Phase III studies though most have been transient. There is no evidence to suggest a higher rate of 
clinical pancreatitis wi th DTG vs comparator ARVs.  
 
Immune Reconstitution Inflammatory Syndrome (IRIS):  Based on medical adjudication by the Phase III 
clinical trial Independent Data Monitoring Committee, despite the rapid decline in HIV -1 RNA observed 
on DTG, IRIS cases were gen erally infrequent on DTG, and the rates of IRIS on DTG were comparable 
to those observed on RAL, EFV, and DRV/RTV.    
 
Post-Marketing Data Sources (Spontaneous Reporting)  
 
DTG was approved by the US FDA in August 2013, by Health Canada in October 2013, and by the 
European Medicines Agency (EMA) in January 2014.  As of 16 July 2017, DTG has been approved in all 
EU member states, the US, and Japan, as well as 70 other countries.  The best estimates of post -marketing 
experience with the 50 mg once daily and BID  doses are 275,818 and 13,164 patient -years, respectively, 
as calculated from Intercontinental Medical Statistics (IMS) Health “Sales Data” available from licensure 
until 31 March 2017.  
 
No new safety concerns emerged from an analysis of psychiatric diagno ses in patients prescribed DTG in 
the OPERA observational database, which indicated that use of DTG was not associated with an 
increased risk of psychiatric symptoms compared to other ARVs. These findings are also discussed in a 
paper published by the Mark eting Authorization Holder (MAH)  (28). As a result of a subsequent MAH 
review of psychiatric events with DTG, t he term “anxiety” was added to the expected adverse reactions in 
the global datasheet for DTG -containing drugs, and has been reported with a frequency of “common”. 
These reactions were generally not severe, and were often seen in participant s with a histor y of anxiety. 
Anxiety has been added to the Investigator’s Brochure as a non -serious adverse drug reaction, and, as 
such, is not considered to impact the Clinical Trial Reference Safety Information  used for expectedness 
assessment of ‘suspe cted serious adv erse reactions’ .  ViiV Healthcare does not consider the addition of 
anxiety to the list of adverse drug reactions to change the overall benefit risk for participant s in ongoing 
clinical studies.  
 
Conclusion  
 
DTG based regimen have demonstrated good tolera bility as shown by the analyses of clinical trial data 
presented in the DTG IB  v 11. No other new significant safety concerns or new potential or identified 
risks were identified from Post -Marketing experience or the analyses of clinical safety data, for t he most 
recent Development Safety Update Report to Regulatory Agencies, with a Data Lock Point of 16 July 
2017. The safety data were consistent with the known safety profile of the DTG single entity and/or the 
treatment populations.  
 
1.6 Rationale  
  
The accelerated development of DTG dosing recommendations for the treatment of HIV -1 infection in 
children of all ages  is needed.  A limited number of ARV medications have approved dosing for children ; 
not all agents are available globally ; and t here remains an  unmet international medical need for novel and 
potent ARV therapy for children with drug resistance or toxicity, or who are failing their current ARV  
regimen. Potential participant s are often heavily pre -treated and have limited therapeutic options . In 
addition, younger children, who are infected despite exposure to ARVs in utero and after birth for 
prevention of perinatal t ransmission may have virus that is resistant to currently available medications. 
 
IMPAACT P1093, Version 5.0  Page 27 of 135 12 July 2018   Drugs with new mechanisms of action, such as the HIV integrase inhibitors, demonstrate activity even in 
participant s with resistance to currently available reverse transcriptase and protease inhibitors.   
 
The purpose of P1093 is to determine the appropriate dose for the pediatric DTG formulations and 
acquire short and long-term safety data, intensive and population PK data, and efficacy experience with 
DTG in HIV -1 infected children .  These data are needed to guide potential us e in children ages 4 weeks 
through adolescence .  Results from this trial are intended to support a regulatory filing for DTG use 
across the pediatric  age spectrum.   
P1093 participants  are enrolled  in two stages.  The objectives of Stage I are to examine PK parameters 
after intense sampling and to evaluate the short -term tolerability and safety of DTG in approximately 10 
participant s per cohort  allowing for the selection of a dose .  Longer term safety, tolerability, and  efficacy 
of that dose is then studied in additional participant s enrolled in Stage II.  The intensive PK evaluation of 
Stage I is performed on days 5 -10 to minimize the risk of sub -optimal doses (as identified by real -time 
PK evaluation) being used for prolonged periods of time.   A number of agents are prohibited during the 
intensive PK evaluation in Stage I , refer to  Concomitant Medication Guidelines  in Section 4.3 to 
minimize the impact of drug -drug interactions that might increase PK variability including  ritonavir or 
cobicistat boosted ATV , NVP, FPV or TPV, or  ATV, EFV and FPV.  However, concomitant introduction 
of NRTI agents or lopinavir/r is not expected to al ter steady state DTG levels.   
Two sets of PK exposure criteria are developed: the minimal and maximal exposure and the target 
population exposure. The minimal and maximal exposure is developed for patient management in case of 
extre me exposure which preve nts the participant to be considered as evaluable. The target population 
exposure (range) is developed for dose selection for the population.  
 
1.6.1 Rational e for Pharmacokinetic Exposure Targets  
 
The goal of P1093 is to determine the doses for children that approximate DTG exposure s (AUC 0-
24 and C 24h) observed in adults who received 50 mg once daily in the Phase I to III trials  of DTG .  
Steady state intensive PK data of weight -based dosing for children will be collected in P1093  
under fasting condition . Two sets of PK exposure criteria are used in this protocol . The geometric 
mean of participant C24h and AUC 0-24 are used to assess population exposures for dose 
determination.  In addition, range s of acceptable individual C24h and AUC 0-24 values have been 
separately designated to ensure the safe management of participants.   
 
Minimal and Maximal Exposure  
 
Since pediatric pharmacokinetics tend to be more variable than adults, a lower threshold range for 
both the A UC 0-24 and C 24h have been identified. Using maximum effect (E max) models, the 
estimated AUC 0-24 required to produce 95% of the maximum virologic response (EC 95) is 
25µg.h/mL, and the EC 95 for the C 24h is 0.5 µg/mL.   These are to be considered the lowest 
threshold exposures acceptable in this study. This lower threshold is in place to ensure minimum 
exposure criteria are met in case, for some reason, the targeted range cannot be met in an 
individual using the selected dose for the population. Similarly, the m aximal exposure (upper 
threshold) is also defined to ensure participants are not exposed to extremely high drug 
concentrations which may cause safety concerns. Based on accumulated data in adults (in Phase I 
and IIb) to date, DTG is generally well tolerated with no significant safety issues identified. A 
dose of DTG 50 mg BID was studied in ING112961 (VIKING) and ING112574 (VIKING3) in 
adult HIV -infected participants . The exposure (geometric mean, 80%  CI) at steady state 
following 50 mg BID exposure was 75.6 (48.8 -115) µg.h/mL. The minimum -maximum AUC0 -
24 range was 28.4 -214 µg.h/mL following 50mg BID dosing. Therefore, the maximal exposure 
 
IMPAACT P1093, Version 5.0  Page 28 of 135 12 July 2018   target is 213 µg.h/mL for AUC0 -24. Such upper threshold may be adjusted upon availability of 
further clinical data .   
  
An exception to the minimum exposure target may be allowed. When a participant has a low drug 
exposure, after consideration of the clinical, pharmacologic, immunologic and virologic data, and 
upon agreement of the site investigator, study co -chairs, pharmacologist and medical officers, a 
given participant may be allowed to continue w ith the study drug at the initial dosing that resulted 
in the exposures below the minimum target. Individual participants with extreme PK values (less 
than the minimal and greater than the maximal exposure as defined above) using the selected 
dose for the population are eligible for individual dosage adjustment.  
 
Target Population Exposure  
 
Steady state C24h and AUC 0-24 are the key PK parameters  utilized to compare drug exposures in 
P1093 to those obtained after 50 mg once daily dosing  in adults . The geometric mean (GM) of 
C24h and AUC 0-24 will be utilized to assess population exposure  in study cohorts , with C24h as the 
primary target and the AUC 0-24 as secondary target.  
 
DTG demonstrated good short -term safety/tolerability and antiviral activity a s monotherapy and 
combination therapy in Phase IIb and Phase III trials in adults and adolescents  (30). Based on 
Phase III trial data, a dose of 50 mg once daily dose is FDA approved for INI -naïve adult patients.  
The proof  of concept (POC) study (ING111521) used doses of 2, 10, and 50 mg once daily as 
monotherapy for 10 days in treatment naïve participant s. Spring -1 (ING112276) was a Phase IIb 
trial where treatment naïve participant s receiv ed 10, 25, or 50 mg once daily for  96 weeks . There 
was no difference among these regimens with participant s on all three doses achieving high rates 
of virologic suppression at 96 weeks. Table 8 summarizes the steady state pharmacokinetic 
parameters from 25 participant s at the 50  mg once daily dose (combining these two studies).  
  
Table 8: Statistic Summary of DTG PK Exposure from Combined Data in ING111521 and 
ING112276  
PK 
Parameter * Dose 
(mg)  N 
Obs Mean  Std 
Dev Median  10th  
Pctl 25th  
Pctl 75th  
Pctl 90th  
Pctl Geometr ic 
Mean  CVb (%)  
AUC 0-24 50.00  25 48.333  14.629  47.732  30.670  42.324  55.957  67.222  46.1385  32.8404  
C0 50.00  24 1090  597 1017  464 667 1318  1869  946.3 59.6907  
Cmax 50.00  25 3464  838 3464  2630  3042  3713  4069  3377 .9 22.7659  
C24 50.00  25 1084  560 957 604 803 1165  2260  955.5 56.9724  
*Units: ug.h/mL for AUC (=AUC 0 -24), and ng/mL for C 0, Cmax, and C 24 
 
The P1093  target population exposure (GM) for C 24h is 995 ng/mL, with an acceptable 
range of 697 – 2260 ng/mL.  The C 24h population exposure (GM) target is selected as 995 ng/mL 
based on PK data from phase III adult studies ING111762 (SAILING) and ING113086 
(SPRING -2) where  the PK of DTG was characterized without regard to food. The primary 
difference between phase III studies and P1093 study is the collection of the PK under fed/fasted 
conditions. In phase III studies, PK was characterized without regard to food whi le in P1093 
study, under fasting conditions. Notably, the PK of DTG varies with the ingestion of food in adult 
participants .  DTG C24h showed ~33% - ~73% increase with low to high fat meals, respectively 
(ING113674).  The acceptable range for GM C 24h targe t  is selected as  697-2260 ng/mL. The 
lower limit is the 70th percent of geometric mean and the upper limit is the upper 80th percentile of 
observed C24h concentrations from combined data in ING111521 and ING112276.   The lower 
 
IMPAACT P1093, Version 5.0  Page 29 of 135 12 July 2018   limit is still significantly above the in vivo  EC90 (300 ng/mL) from day 11 data in monotherapy 
(PoC) study, and there have been no toxicities observed at the upper limit.  This range for GM 
C24h also approximates values seen in adults receivin g 50 mg once daily and are based on Emax 
modeled data as well as data collected in P1093 thus far; the upper value is approximately the 
95th percentile of observed C 24h concentration in pediatric participants  in study P1093.   
 
The P1093 target population exposure (GM) for AUC 0-24 target is 46 µg.h/mL, with an 
acceptable range of 37-134 µg.h/mL.  The AUC 0-24 target of 46 µg.h/m is from combined data in 
ING111521 and ING112276 and was similar to  seen in adults following 50 mg once daily dosing.  
To accommodate variability around this target and the high mg/kg dosing required to meet the 
higher C 24h target, the acceptable range for AUC 0-24 is defined as follows. The lower limit for GM 
AUC 0-24 is selected as 80% of the target (37 µg.h/mL). The upper limit (134 µg.h/mL) is selected 
based on the upper 95th percentile of AUC obtained at steady state following 50 mg BID dosing. 
A DTG dose of 50 mg BID was studied in ING112961 (VIKING) and ING112574 (VIK ING3) in 
adult HIV -infected participants. In the VIKING study (ING112961), the 50 mg BID dose was 
tolerated as well as the 50 mg QD dose; the observed AUC24 (min, max) from the 50 mg BID 
dose was in the range of 28.4 -214 µg.h/mL. The AUC 0-24 (geometric mea n, 90% CI) at steady 
state following 50 mg BID exposure (from VIKING and VIKING 3) was 75.1 (40 -134) µg.h/mL  
 
P1093 is designed to characterize  the PK of DTG  in pediatric participant s compar ing it to the PK 
obtained in  adult participant s for dose selection for children .  In protocol versions 1 -4, AUC 0-24 
was considered the primary target parameter and C24h was the secondary  target parameter.  
Recently,  a regulatory agency suggested that C24h be elevated to a  primary target . Therefore, in 
protocol Version 5, C 24h is selected as a primary target parameter for PK comparison , with AUC 0-
24 secondary .   
 
Emerging  data from Cohort IIA through V -DT showed that C 24h (primary PK endpoint) was not 
comparable to the predefined target in pediatric participant s weighing <30kg . Higher  doses were 
selected  to achieve a predefined C 24h target based on modeling and simulation. Simulation s from 
the interim population PK model s howed that the proposed doses will provide trough 
concentrations in the target range. However, targeting a higher trough concentration may result in 
the expected  geometric mean  AUC 0-24 being approximately 1.33-2 fold  higher.   
 
Acceptable Individual Minimal and Maximal Exposure  
 
To ensure the safety and optimal management of participants, the P1093 protocol has specified 
ranges of acceptable C24h and AUC 0-24 values for individuals.  The acceptable ranges have 
changed with differe nt protocol versions based on evolution and accumulation of safety and 
efficacy data both in P1093 and outside  studies , refer to Table 9.  
 
Table 9: IMPAACT P1093  C24 and  AUC0-24 Parameters   
P1093  Protocol  
 Version 3  Version 4  Version 5  
C24    
Target for GM  960 ng/mL  750 ng/mL  995 ng/mL  
Range for GM 770-2260 ng/mL  500 – 2600 ng/mL  697 – 2260 ng/mL  
MIN -MAX for individual  MIN 500 ng/mL  MIN 400 ng/mL  MIN 500 ng/mL  
AUC 0-24    
Target for GM  46 µg.h/mL  46 µg.h/mL  46 µg.h/mL  
Range for GM  37 – 67 µg.h/mL  37 – 86 µg.h/mL  37 – 134 µg.h/mL  
MIN -MAX for individual  25 – 92 µg.h/mL  25 – 115 µg.h/mL  25 – 214 µg.h/mL  
 
IMPAACT P1093, Version 5.0  Page 30 of 135 12 July 2018    
Owing to difference in PK collection between the phase III studies and the pediatric study and 
relatively higher variability in the trough concentrations, these targets will be use d as guide for 
dose selection. The individual data from participants will also be considered in final dose 
determination for age group and weight bands . Doses for each weight band will be selected taking 
the entirety of the PK and safety data  into consider ation.  
 
1.6.2 Rationale for Selection of Initial  Dose(s)  
 
The initial starting dose(s)  for Cohort I and Cohort II A using the  film-coated  tablet formul ation is  
presented in the IMPAACT P1093 D osing Table Appendix posted on the study -specific web 
page: http://impaactnetwork.org/studies/P1093.asp  and labelled Table A.  Starting doses in 
subsequent cohorts are outlined in tables also on this study specific web  page.  
 
While this study is enrolled based on age cohorts  to meet regulatory standards , weight -based 
dosing is also being evaluated in Version 5 in accord with WHO consensus guidelines.  The 5 mg  
dispersible tab was formulated to facilitate storage and adm inistration globally .  
 
As the granule and the dispersible tablet  formulation s demonstrated higher exposure than the 
tablet formulation, the proposed initial doses using the granule formulation for Cohort IIB  and 
successive cohorts  was calculated by adjusting the tablet dose(s) by  a common factor with the 
goal to match target exposure s in adults. As DTG exposure from granule and dispersible tablet 
formulation s given direct to mouth or with different types of water were similar and demon strated 
55-58% higher exposure than the tablet formulation, initial doses for these formulation s were 
obtained by dividing  the tablet doses by a common factor of 1.55 for each weight band. Under 
protocol Version 3.0 , the PK targets for Cohort IIB Stage I a nd Cohort III Stage I were met, but 
required an increased dose of  ~0.8 mg/kg  (granule formulation) ; there were no safety concerns in 
either Cohort. Under protocol  Version 4 .0, Cohort  IV Stage I (≥ 6 months to < 2  years of age) 
opened with an initial dose of ~0.8 mg/kg (granule formulation ).  In order to achieve higher 
C24concentrations higher doses were evaluated in Version 4.0.  
 
1.6.3 Rationale for the Enrollment of  HIV-infected Children < 2 years of age  
 
There is a need  for new ARVs like DTG to treat HIV -infected children < 2 years of age . Access 
to ARVs for pregnant women has increased and rates of vertical transmission have decreased  
globally  (30). However, the expanded use of NNRTIs has also corresponded with rising rates of 
ARV resistance that limit the utility of NVP and other NNRTI for the treatment of infected 
infants  (32, 33) . LPV/r is recommended by the WHO as first line for treatment of children < 2 
years  (33), but there are persi stent concerns about the storage requirements and palatability  (35). 
 
The management of young HIV -infected children is distinguished by the clinical urgency with 
which treatment must be initiated . HIV-infected children < 2 years of age suffer extreme viremia , 
rapid disease progression and high mortality rates  (36). Current guidelines recommended 
treatment for all HIV -infected children, but initiation is considered “urgent” for children < 2 years 
of age by the WHO  (33) and U S Department of Health and Human Services Panel on 
Antiretroviral Therapy and Medical Management of HIV -Infected Child ren (36). Accordingly, 
national guidelines in limited resource countries often recommend initiation of ART on the bas is 
of a single positive HIV nucleic acid based test, rather than waiting for confirmatory results (37, 
38). 
 
 
IMPAACT P1093, Version 5.0  Page 31 of 135 12 July 2018   Version 4 .0 of P1093 expanded eligibility to include children < 2 years who were ART -naïve or 
for those who  recently started ART (< 4 weeks prior)  so that treatment initiation  be in  accord with 
current guidelines and standard of care . In P1093, c hildren < 2 years of age can enroll and  initiate 
an ART with only a single positive nucleic acid test if a confirmato ry test was pending ; these 
participants started  background regimens that were  empiric or based on national guidelines while 
the results of genotype testing drawn at screening were pending.  Background regimens are 
subsequently  optimized  based upon the results of the genotype.  
 
1.6.4 Rationale for  Including ARV Naïve Participants  
 
In Versions 1.0-3.0 of P1093 , only treatment -experienced children were eligible for 
enrollment.  In Version 4.0, the enrollment criteria were expanded to include treatment -naïve 
children < 2 years old . In Version 5.0, treatment -naïve children can enroll in any treatment group 
open for enrollment.  The inclusion of treatment -naïve children is based  on cumulative safety data, 
and the rationale that it is likely to be used and recommende d as first line therapy in children  
consistent with  DTG  now being recommended as first line therapy for adolescents and adults in 
U.S. Public Health guidelines (39). Cumulative safety and efficacy from P1093 cohorts I and IIA 
contributed to European Medicines Agency approval of DTG for children > 6 years of age (40)as 
well as FDA approval for children 30 kg  and above  (41). 
 
1.6.5 Ration ale for Adding Dose Analysis by Weig ht Band in Version 5.0  
 
The P1093 protocol is designed to enroll participant s and analyze data based on age cohorts.  
Since the study was first initiated, the W HO (42) and other guideline groups around the world 
have advocated moving away from age -based dosing to one based up on weight  band  dosing . 
Regulatory Agencies are increasingly expect ing to receive  and analyze  pediatric data by weight 
band to facilitate dosing recommendations in product labelling , based on this standard . Rather 
than completely modifying the P1093  study design from  age-based cohorts to weight -based 
enrollment , analysis of WHO -recommended weight bands is included as a key secondary 
consideration  in Version 5.0 .  Therefore, e nrollment into P1093  will be monitored to ensure that 
minimum numbers of participant s are accrued into both age based cohort s as well as  each 
relevant WHO weight band  to facilitate  gathering  robust weight -based data  to allow flexible 
treatment recommendations . The fundamental design of the study remains unchanged.  
 
1.7 Hypothesis  
 
DTG will b e generally well tolerated and demonstrate an acceptable safety profile, adequate PK and 
antiviral activity when used concurrently with an optimized background therapy (OBT) in HIV -1 infected 
infants, children and adolescents.  
 
 
2.0 STUDY OBJECTIVES  
 
2.1 Primary O bjectives  
 
1. To select a dose for each formulation of DTG  for chronic dosing in infants, children and 
adolescents that achieves similar exposure to the DTG  50 mg once daily adult dose .  
 
2. To determine the safety and tolerability of DTG in HIV -1 infected infants, children and 
adolescents at 24 and 48 weeks.  
 
 
IMPAACT P1093, Version 5.0  Page 32 of 135 12 July 2018   3. To evaluate the steady -state pharmacokinetics of DTG in combination with OBT in 
treatment -experienced and treatment -naïve HIV -1 infecte d infants, children and adolescents 
and to determine the dose of DTG that achieves the targeted C 24h and AUC 0-24 PK  parameters 
in this population.  
 
2.2 Secondary Objectives  
 
1. To evaluate the antiviral activity of DTG in combination with an OBT by measuring 
virologic response in infants, children and adolescents at 24 and 48 weeks . 
 
2. To evaluate the effect on immunologic response from baseline to  24 and 48 weeks . 
 
3. To assess changes in HIV -1 genotype and phenotype to DTG and other components of the 
OBT in participant s experiencing virologic failure . 
 
4. To determine DTG exposure, its variability and clinical covariates that impact DTG 
disposition (e.g. age, weight) using intensive and sparse sampling and population PK 
analysis .  
 
5. To determine the extended long term (≥48 weeks) safety , tolerability and efficacy of DTG in 
HIV-1 infected infants, children and adolescents . 
 
6. To explore the r elationship between DTG exposure and the antiviral activity . 
 
7. To evaluate pharmacokinetic, safety and tolerability profile of DTG when dosed by weight  
bands.  
 
3.0 STUDY DESIGN  
 
P1093 is a Phase I/II multi -center, open -label, non -comparative study of pharmacokinetic (PK) 
parameters, safety, tolerability, and efficacy of DTG in pediatric populations. Formulations will be 
evaluated in age -specific cohorts as shown below.  
 
Cohort I:  Adolescents ≥ 12 to <18 years of age (film -coated tablets)  
Cohort IIA:  Children ≥ 6 to <12 years of age (film -coated tablets)  
Cohort IIB:  Children ≥ 6 to <12 years of age (granules for suspension  or dispersible tablets )  
Cohorts III:  Children  ≥ 2 to < 6 years of age (granules for suspension)  – closed to enrollment  
Cohort III -DT:  Children ≥ 2 to < 6 years of age (dispersible tablets)   
Cohort IV :  Children ≥ 6 months to < 2 years (granules for suspension)  – closed to enrollment  
Cohort IV -DT: Children ≥ 6 months to < 2 years of age (dispersible tablets)  
Cohort V -DT:  Infants > 4 weeks to < 6 months (dispersible tablets)  
 
Participants receiving the film -coated tablet formulation  were initially enrolled sequentially into Cohorts I 
and IIA. Granu les for suspension were introduced in Protocol Version 3.0.  When it subsequently became 
clear that dispersible tablets (DT) would be the commercially available pediatric formulation, new cohorts 
for DT were opened in Protocol Version 4.0 ( Section 3.3).  Under protocol Version 5.0, two formulations 
of DTG (film -coated tablets and dispersible tablets) will be evaluated; the target enrollment in Stage I was 
increased to allow for additional examination of PK, safety, and tolerability by weight bands, including 
participants from all of Cohorts III -DT, IV -DT, and V -DT ( Section 3.4).  The approach for currently open 
cohorts III, IV and V is described below ( Section 3.1).  However, additional cohorts and weight -band 
 
IMPAACT P1093, Version 5.0  Page 33 of 135 12 July 2018   groups might be opened or reopened to investigate data gaps or new modifications to dosing, for example, 
regarding fasting requirements or background regimens.  
 
The fundamental procedure for evaluation of DTG doses has re mained unchanged through all protocol 
versions.  Each cohort is enrolled in  two sequential stages: Stage I and II . (The only exception is Cohort 
IIB which only enrolled through Stage I).   In Stage I, participants undergo intensive PK sampling and are 
moni tored for the safety and tolerability of DTG; to accept or reject a dose, the Protocol Team evaluates 
PK parameters exposures (Section 8.5) and 4 -week safety and tolerability data (Section 9.3).  Once a 
treatment dose has been accepted, enrollment to Stage II begins to complete the cohort. Parti cipants in 
Stage II will be followed for 48 -weeks and evaluated for PK parameters (using population PK methods), 
safety and tolerability. After study week 48 all Stage I and Stage II participants transition to long-term 
follow -up and remain on study for ap proximately three additional years (144 additional weeks of follow -
up, for a total of 192 on study).  Study drug is provided for the duration of the study. Thereafter, 
participants are transitioned into care outside of the study ( Section 10.6).   
 
3.1 Stage I Study Design  
 
The primary objective of S tage I enrollment is to enable selection of a treatment dose.  Participants 
enrolled during Stage I undergo intensive PK sampling and are monitored to determine the safety and 
tolerability of the study dose of DTG, as summarized in Figure 2. If the Protocol Team determines the PK 
parameters, safety or t olerability data to be unacceptable at any point, Stage I enrollment is stopped. A 
new mini -cohort might be opened to evaluate new dosing that might include changes in the weight band 
dosing tables available on the study -specific website at http://impaactn etwork.org/studies/P1093.asp or 
other modifications including the potential of an alteration in recommendations for food ingestion with 
study drug.  This cyclic process continues until the PK parameters, safety and tolerability are considered 
acceptable fo r all doses evaluated by cohort and weight band groups.  
 
Mini -Cohort Analysis  
The first analysis of participants enrolled in Stage  I includes the “mini -cohort” of the first 4 participants 
who have evaluable PK parameters and 4 -week safety and tolerability  data.  The purpose of this mini -
cohort analysis is to promptly identify concerning safety or PK signals.  If data from the mini -cohort  are 
acceptable, per the Protocol Team (as per Sections 8.5 and 9.3), Stage I enrollment continues in that 
cohort with participants receiving the same dose.  If data from the mini -cohort analysis are deemed 
unacceptable, Stage I enrollment to that cohort is s topped, and new dosing is selected for evaluation. In 
Version 5.0 up to a maximum of seven participants can enroll while waiting for the mini -cohort analysis 
of the week 4 PK and safety analyses of the first four participants with evaluable data. Allowing 
enrollment to continue prevents delays in this early safety analysis that can occur when participants with 
unevaluable data (i.e. inadequate PK collection, incomplete adherence) must  be replaced by new 
enrollees. The Protocol Team  is continuously monitorin g safety of all participants real tine.  
 
Interim Cohort Analysis  
The next analysis is an interim analysis that includes PK parameters and 4 -week safety and tolerability of 
a dose given to the first 10 participants in each cohort with evaluable data , according to criteria outlined 
in Sections 8.5 and 9.3.  If PK parameters safety and tolerability data in this interim analysis are 
considered unacceptable by the Protocol Team, Stage I enrollment to that cohort is stopped, and new 
dosing is selected for evaluation and the process restarts.  
 
Stage 1 Full Cohort and Weight -band Analysis  
The study aims to ensure that adequate numbers of participants are enrolled into each of the age -defined 
cohorts as well as each of the weight -band groups.  To this end, once 10 participants with evaluable data 
are enrolled into a cohort, additional enrollments into that cohort are only permitted if a participant will be 
 
IMPAACT P1093, Version 5.0  Page 34 of 135 12 July 2018   contributing to achieve the minimum enrollment of 8 evaluable in a weight -band group.  To ensure 
continuous enrollment into cohorts during Stage 1, enrollment does not close until it has been confirmed 
that 8 participants with evaluable data have been enrolled and completed PK and safety assessments into a 
weight band, up to a maximum of an additional 2 participants while waiting  for these results to become 
available . 
 
Stage I enrollment of all three Cohorts III -DT, IV -DT and V -DT will therefore be considered complete 
when two conditions are met simultaneously: at least 10 participants have enrolled in each of the three 
cohorts AND a minimum of 8 participants have enr olled in each of the four weight bands ( Section 3.4).  
At this point , the team will perform Stage I analyses of PK, safety, and tolerability of all  three age cohorts 
(III-DT, IV-DT and V -DT) and all 4 weight band groups together.  At this point, the Protocol Team could 
pass all groups together, could “fail” a dose applied to cohort or weight band and enroll additional 
participants to investigate addi tional dosing questions.   New cohorts or weight -band groups will be 
evaluated in the same manner (min imum  10 for age, and minimum 8 for weight, with mini -analysis after 
first 4).   
 
 
IMPAACT P1093, Version 5.0  Page 35 of 135 12 July 2018   Figure 2: Algorithm for STAGE I  Enrollment and Analysis  
 
 
 
 
 
 
 
 
 
 
 
 
          
 
 
  
 
            Open Stage I e nroll ment  of a cohort  to assess a selected DTG dose 
Mini -cohort Analysis:  
PK, safety and tolerability data from first 4 participants with evaluable data.  
Enrollment may continue u p to 7 before this analysis performed.  
 
Mini -cohort PK , safety and tolerability data  
ACCEPTABLE.  
Stage I enrollment continues.  
 
Interim  Cohort Analysis : 
Interim PK, safety  and tolerability  data from first 10 
participants with evaluable data.    
PK, safety and 
tolerability data  
NOT  ACCEPTABLE.   
New dosing selected 
for evaluation in a new 
mini-cohort.   
   
 
Stage I Full Cohort and Weight Band Analysis : 
Minimum of 10 in each cohort AND minimum 8 in 
each weight -band group across all of cohorts III -DT, 
IV-DT, V -DT with evaluable data.  
PK, safety  and tolerability studied by  cohort  AND by 
weight  band group.  
Stage I Cohort and weight band group PK, safety and 
tolerability data  
ACCEPTABLE.  
 
Open Stage II enrollment.  Interim PK, safety and tolerability data  
ACCEPTABLE.  
Stage I enrollment continues to complete weight band 
groups.  
Stage I PK, safety and tolerability 
data for weight band group   
 NOT  acceptable;  
new weight band group  enrolled 
to evaluate new dosing  
 
IMPAACT P1093, Version 5.0  Page 36 of 135 12 July 2018   3.2 Stage II Study Design  
 
Stage II enrollment opens once a dose has been accepted based on analysis of data from Stage I 
enrollments. The additional enrollments during Stage II are intended to complete a full cohort of 
participants receiving the accepted study dose who are followed  for long -term safety, tolerability and 
efficacy outcomes.  Enrollment during Stage II for each cohort will progress independently until the target 
of 22 per cohort is met; therefore, the number enrolled during Stage  II varies depending on the number 
enrol led during Stage I, as described in Table 10. 
 
Table 10: Target Accrual at the Accepted  Dose in Stages I and II  
Cohort  Cohort Description  Approximate Accrual  at the Accepted Dose  
Minimum Stage I  
Participants  Total  Stage I and II  
Participants3 
I Adolescents ≥ 12 to <18 years of age  
(Film -coated Tablet formulation)  10 22 
IIA Children ≥ 6 to <12 years of age  
(Film -coated Tablet formulation)  10 22 
IIB Children ≥ 6 to <12 years of age  
(Granules for Suspension  or Dispersible Tablets )1  10 10 
III Children ≥ 2 to < 6 years of age  
(Granules for Suspension - closed to enrollment ) 10 22 
III-DT Children ≥ 2 to < 6 years of age  
(Dispersible Tablets)  102 22 
IV Children ≥ 6 months to < 2 years  
(Granules for Suspension -closed to enrollment ) 10 22 
IV-DT Children ≥ 6 months to < 2 years  
(Dispersible Tablets)  102 22 
V-DT Infants > 4 weeks to < 6 months  
(Dispersible Tablets)  102 22 
Note: Enrollment of children into cohorts using the granules for suspension was stopped in protocol Version 
4.0; therefore , Cohorts III, and IV did not reach full enrollment targets .  
1 Dispersible tablets may also be evaluated in this cohort if requested by the regulatory authorities.  
2 Under Version 5.0 , accrual into Cohorts III -DT, IV -DT, and V -DT will be continued until a minimum of 10 
participants per cohort at the accepted dose and a minimum of  8 participants  per weight band  is achieved as 
per Section 3.4. 
3 Additional participant s might  be enrolled to a  cohort  for additional evaluation of weight band dosing and/or 
if requested by the regulatory authorities  and/or to fill a  data gap (Section 3.1).  
 
3.3 Protocol Version 4.0 – Addition of Dispersible Tablets  
  
In addition to the film-coated tablet and granules for suspension , dispersible tablets (DT) were introduced 
for study under Prot ocol Version 4.0 . The DT formulation is being p roposed as  the commercially 
available pediatric formulation . In a relative bioavailability study in adults, the dispersible tablets resu lted 
in PK exposure that was, on a ‘mg to mg ’ basis, equivalent to granules  and there were no observed 
adverse  events . Based on th is PK equivalency and safety data the mini-cohorts for the dispersible tablets 
could  enroll  simultaneous ly if the dose from the respective age-equivalent granules for suspension  mini-
cohort  was approved  under Version 4. 0. With varying timelines for IRB approvals and drug importation  
at U.S. and non -U.S. sites, it was anticipated that DTG dispersible tablets would not be available to all 
sites simultaneously . Therefore, enrollment into cohorts for granules for suspension  was continue d with 
approval from the Protocol Team  until all sites obtained the DT formulation. In January 2018,  all 
participants on granules were recommended to transition to DT formulations . Participant s who switch ed 
form granules for suspension  to dispersible tablets had additional evaluation s as follows:  
 
IMPAACT P1093, Version 5.0  Page 37 of 135 12 July 2018   • On the day of switch, the initial dose of dispersible tablets should be given in the study cl inic and 
observed by study staff.  
• Two weeks after switching to dispersible tablets, the participant  should have an additional ‘Switch 
Visit’ during which a palpability assessment and RNA PCR test will be done; if this visit falls within 
the window for another scheduled visit, a combined visit can be completed to avoid duplication of 
procedures.  
• For participants  who have completed 24 weeks of follow -up at the time of the ‘Switch Visit’ in 
addition to the procedures mentioned above, these participants  will have population PK specimens 
collected at the two -week post switch visit and at the next regularly scheduled visit.   
 
3.4 Protocol Version 5.0 – Addition of Evaluation by Weight Band or other Factors  
 
As described in Section 1.6.5  there is increased interest globally in dosing DTG by weight band  
(independent of age). To facilitate analysis of the PK, safety, efficacy, and tolerability data by weight 
band , target enrollment in Cohorts III -DT, IV -DT and V -DT is expanded in Version 5.0 to ensure that a  
minimum of 8  participants in each following weight band s will be enrolled  into Stage I : 
 
a) 3 to < 6 kg  
b) 6 to < 10 kg  
c) 10 to < 14 kg  
d) 14 to < 20 kg  
 
Note that individual participants within a given weight band  group are also included in an age -based 
cohort  for analysis .  Additional groups of participants based on weight band alone , also generally 
including a minimum of 8  might be enrolled if dosing within a specific weight band appears concerning 
during the full cohort analysis at the end of Stage 1 or  if requested by the regulatory authorities . Such 
weight band groups will be evaluated in a similar manner as the cohorts that are based on age, with 
analysis of PK parameters and 4 -week safety  and tolerability data from a minimum of 8 participants  have 
evaluable data .   
 
Instructions fo r intensive PK sampling are provided in Section 9.2.1 . Initially, PK sampling will be done 
in a fasting state . If, upon review of PK data, the Protocol Team determines that an additional evaluation 
of PK should be performed with and without fasting , the team will notify the sites to which cohorts or 
weight band groups this will apply and sites will follow new instructions for  non-fasting around  PK 
sampling . 
 
 
4.0 SELECTION AND ENROLLMENT OF PARTICIPANT S 
 
Participant s, who fail the study inclusion / exclusion criter ia for viral load or toxicities at screening, may 
be rescreened after 4 weeks . NOTE : Genotypes do not  need to be repeated at screening if they were 
acceptable at the previous screen.  
 
4.1 Inclusion Criteria  
 
4.1.1 Age: ≥ 4 weeks  to <18 years at study entry . 
 
 
IMPAACT P1093, Version 5.0  Page 38 of 135 12 July 2018   4.1.2 Confirmed HIV -1 infection  
 
• Documentation of HIV -1 infection defined as positive results from two samples 
collected at different  time points . All samples tested must be whole blood, serum or 
plasma . All test methods should be FDA -approved if available . If FDA -approved 
methods are not available, test methods should be verified according to GCLP and 
approved by the IMPAACT central laboratory .   
• Sample #1 may be tested by non -study public or PEPFAR programs . However, both 
the result and the assay date must be recorded in the participa nt’s chart . Source 
documentation (patient’s medical record/chart, in-country Ministry of Health  
registers, laboratory results, etc .) must be available if requested . 
• Sample #2 must be performed in a CAP/CLIA -approved laboratory (for US sites) or 
in a labora tory that operate according to GCLP guidelines and participate s’ in 
appropriate external quality assurance program (for non-US sites).  
 
4.1.2.1  Acceptable tests when participant s are ≤ 18 months of age : 
 
Sample #1 and Sample #2 may be tested using any of the following :  
 
• One HIV DNA PCR  
• One quantitative HIV RNA PCR (above the limit of detection  of the assay ) 
• One qualitative HIV RNA PCR  
• One total HIV nucleic acid  
 
Note: Participant s ≤ 18 months of age  can be enroll ed on the basis of one positive test 
result (from Sample #1 ) if the results from Sample #2 are pending . The HIV RNA test 
required at screening per the Schedule of Evaluations may serve as Sample #2 and may 
be pending at the time of enrollment . However, any participant  in whom in fection is not 
confirmed by the results of Sample #2 should discontinue study drug, per Section 6.9 and 
be followed per  Appendix IF   
 
4.1.2.2  Acceptable tests when participant s are > 18 months of age :  
 
Sample #1 may be tested using any of the following:  
  
• Two rapid antibody tests from different manufacturers or based on different 
principles and epitopes  
• One EIA OR Western Blot OR immunofluorescence OR chemiluminescence  
• One HIV DNA PCR  
•  One quantitative HIV RNA PCR (above the limit of detection  of the assay ) 
• One qualitative HIV RNA PCR  
• One total HIV nucleic acid   
 
Sample #2 may be tested using any of the following:  
 
• Rapid antibody test. If this option is used in combination with the two tests for 
Sample # 1, at least one of the three rapid antibody tests for Sample #1 must be FDA 
approved and the third rapid test must be from a third manufacturer or based on a 
third principle or epitope.  
• One EIA OR Western Blot OR immunofluorescence OR chemiluminescence  
 
IMPAACT P1093, Version 5.0  Page 39 of 135 12 July 2018   • One HIV DNA PCR  
• One quantitative HIV RNA PCR ( above the li mit of detection  of the assay ) 
• One qualitative HIV RNA PCR  
• One total HIV nucleic acid   
 
4.1.3 Participant s must belong to one of the ARV  exposure groups below :  
 
4.1.3.1  ARV -treatment  experienced (not including receipt of ARVs as prophylaxis or for 
prevention of perinatal transmission)  
 
⎯ Previously took AR Vs for treatment, but not c urrently taking ARV s: 
• Must have been off treatment ≥ 4 weeks  prior to screening.   
 
OR 
 
⎯ Currently taking ARVs  for treatment but failing : 
• Must be on an unchanged, failing therapeutic regimen within the 4 to 12  weeks  
prior to screening  (≤1 log drop in HIV -1 RNA within the 4 to 12 weeks prior to 
screening ).   
 
NOTE:  To meet this criterion, two HIV RNA levels are req uired: one from a date 
between 4 -12 weeks prior to study screening and a second one at study screening.  
The HIV RNA level at screening must be higher than, equal to or ≤ 1 log lower than 
the prior HIV RNA level.  
 
NOTE: Dose adjustments for growth or formu la substitutions (i.e. switching from 
single agent to fixed dose combination) during this  4 to 12-week  period , substitutions 
of one ARV within the same class for toxicity or tolerability management, or 
discontinuation of ARVs  are permitted between the HIV RNA measurements and 
screening or enrollment.  
 
OR 
 
⎯ For participant s < 2 years of age, in itiated ARV s for treatme nt < 4 weeks prior to 
screening .  
 
4.1.3.2  ARV treatment naïve (no exposure to ARVs for treatment; could have received ARVs for 
prophylaxis or prevention of perinatal transmission)  
 
4.1.4 If an infant has received NVP as prophylaxis  to prevent perinatal transmission , he or she 
must have not received NVP for at least 14 days prior to enrollment  into Stage I or II.  
 
4.1.5 HIV-1 RNA viral load greater than 1,000 copies/mL of plasma at screening  
 
NOTE: For participant s enrolling into cohorts IV , IV-DT, and V -DT, the HIV RNA test 
performed at screening may be pending at the time of enrollment . If the screening HIV 
RNA  is ≤ 1000 c/ mL, the participant  should discontinue study drug, per Section 6.9 and 
be followed per  Appendix IF   
  
 
IMPAACT P1093, Version 5.0  Page 40 of 135 12 July 2018   4.1.6 Demonstrated ability or willingness to swallow assigned study medications .  
 
NOTE: Film  coated t ablets MAY NOT be crush ed or dissolved.  Dispersible tablets MAY 
NOT be cut and must be used in f ive milligram intervals . 
 
4.1.7 Parent or legal guardian able and willing to provide signed informed consent.  
 
4.1.8 Female participant s of reproductive potential , defined as having reached menarche , and 
who are engaging in sexual activity that could lead to pregnanc y must agree to use two 
contraceptive methods while on study and for two weeks  after stopping study drug .  
 
4.1.9 Males engaging in sexual activity that could lead to HIV -1 transmission must use a 
condom.  
 
4.1.10  Optimized background therapy (OBT):  
 
• Participants who are both ≥ 2 years of age and ARV -treatment experienced (meet ing 
entry criterion 4.1.3.1 ) must have available at least one fully active drug for the OBT 
to enroll. If screening genotype testing is inconclusive, h istorical genotypes obtained 
within 1 year of screening will be considered by the Protocol Team for determination 
of fully active  drugs.  
• Participants who are ≥ 2 years of age and ARV -treatment naïve (meet ing entry 
criterion  4.1.3.2 ) can enroll if genotype testing has been obtained  with results 
pending.  
• Participants < 2 years of age (either ARV -treatment experienced or ARV treatment 
naïve) can enroll if genotype testing has been obtained with results pending.   
 
4.2 Exclusion Criteria  
 
4.2.1 Presence of any active AIDS defining opportunistic infection  
 
4.2.2 At enrollment, participant  < 3.0 kg  
 
4.2.3 Known Grade 3 of any of the following laboratory toxicities within 30 days prior to study 
entry : neutrophil count, hemoglobin, platelets, AST, ALT, lipase, serum creatinine  and 
total bilirubin . A single repeat  within the 30 days  is allowe d for eligibility determination .  
 
NOTE : Grade 3 total bilirubin is allowable, if the participant  is on ATV .  
 
4.2.4 ANY k nown Grade 4 laboratory toxicities within 30 days prior to study entry .  
 
NOTE : Grade 4 total bi lirubin is allowable, if the participant  is on ATV .  
 
4.2.5 The following liver toxicities within 30 days prior to study entry : ALT  > 3x ULN  AND  
direct bilirubin is >  2x ULN  
 
4.2.6 Any prior history of malignancy , with the exception of localized malignancies such as 
squamous cell or b asal cell carcinoma of the skin  
 
4.2.7 Clinical or symptomatic evidence of pancreatitis, as determined by the clinician  
 
 
IMPAACT P1093, Version 5.0  Page 41 of 135 12 July 2018   4.2.8 Use of any disallowed medicat ions at time of screening (see Section 4.3.2  for a complete 
list of disallowed medications)  
 
4.2.9 Known history of exposure to integrase inhibitor treatment by the participant  or 
participant ’s mother prior t o deliv ery/cessation of breast feeding   
 
4.2.10  Known resistance to an integrase inhibitor  
 
4.2.11  Women who are p regnan t or breastfeeding  
 
4.2.12  Participant  is currently participating in or has participated in a study with a compound or 
device that is not commercially availa ble within 30 days of signing informed consent, 
unless permission f rom both Protocol Team s is granted  
 
4.2.13  Participant  is unlikely to adhere to the study procedures, keep appointments, or is 
planning to relocate during the st udy to a non -IMPAACT study site  
 
4.2.14  Any clinically significant diseases (other than HIV infection) or clinically significant 
findings during the screeni ng medical history or physical examination that, in the 
investigator’s opinion, would compr omise the outcome of this study  
 
4.2.15  Participant  has used, or anticipates using, chronic systemic immunosuppressive agents or 
systemic interferon (e.g. , for treatment of  HCV infection) within 30 days prior to 
beginning DTG study drug. Systemic corticosteroids (e.g. , prednisone or equivalent up to 
2 mg/kg/day) for replacement therapy or short courses (≤30 days) are permitted. ( See 
disallowed medications Section 4.3.2 ) 
 
4.2.16  Any condition that would, in the opinion of the site investigator, place the participant  at 
an unacceptable risk of injury or render the participant  unable to meet the  requirements of 
the protocol . 
 
4.2.17  Active TB disease  and/or requirement for treatment that includes rifampin  at the time of 
the screening visit . However, participant s who need rifampin treatment while on DTG 
will be allowed to continue i n P1093 provided the DTG dose is adjusted according to 
Section 6.1.8 . 
 
4.3 Concomitant Medication Guidelines  
 
The concomitant use of other medications/therapies is allowed unless specifically prohibited in the 
Disallowed Medications section below .  
 
4.3.1 Precautionary Medications  
 
DTG should be administered two  hours before or  six hours after taking  any products  containing 
divalent cations . Examples include antacids containing aluminum , calcium,  magnesium  and 
supplements that contain zinc or iron .  Proton pump inhibitors and H 2-antagonists may be used in 
place of antacids with no scheduling restrictions . Concurrent administration with multi vitamins is 
acceptable.  
 
 
IMPAACT P1093, Version 5.0  Page 42 of 135 12 July 2018   It is the responsibility of the investigator to check on potential drug -drug interactions between 
background ARV  therapy and other concomitant therapies, before placing a participant  on a 
specific medication.  
 
4.3.2 Disallowed Medication s 
 
For clarity, the following information on disallowed ARV medications is summarized in Table 
11.  
 
Disallowed ARV Medications for Stage I Participant s BEFORE the Intensive PK Only  
The following medications are disallowed prior to the initial intensive PK evaluation for Stage I 
participant s only, since they could significantly increase or decrease the le vels of DTG  due to 
enzyme induction or inhibition and result in increased PK variability . However, these medications 
ARE allowed in Stage I participant s as part of OBT after the intensive PK evaluation has been 
completed:  
 
Atazanavir (ATV)  
Boosted (ritonav ir or cobicistat) Atazanavir  
Efavirenz (EFV)  
Boosted (ritonavir or cobicistat ) Fosamprenavir   
Fosamprenavir (FPV)  
Boosted (ritonavir or cobicistat ) Tipranavir  
 
Disallowed ARV Medications for Participant s on Stage I (BEF ORE and AFTER the Intensive 
PK) and Stage II participant s 
When constructing a participant ’s background ART regimen, the following medications are 
prohibited for Stage I and Stage II participant s because no PK data about co -administration are 
available and/or they could significantly decrease the levels of DTG  due to enzyme induction:  
 
• Nevirapine (NVP): Nevirapine has significant drug -drug interactions with DTG  resulting in 
lower ed DTG  exposure . The expectation that PK interaction data would become available, 
led protocol Version 3.0 to allow concurrent therapy with increased (BID) DTG  dosing. Data 
has not been become available and concomitant DTG  and nevirapine use is not permitted in 
protocol Version 4.0 .  Prior historical NVP treatment is permitted but NVP treatment must  be 
discontinued 14 days prior to initiation of DTG .  
• Etravirine (ETR) : Etravirine  UNLESS it is co -administered with lopinavir/ ritonavir or 
darunavir/ ritonavir; these boosted pro tease inhibitors  have been shown to counteract 
etravirine enzyme induction . Thus, DTG  may be co -administered with e travirine if the 
participant  is receiving concomit ant lopinavir/ ritonavir or darunavir/r itonavir . 
• Raltegravir (RAL)  
• Elvitegravir (EVG)  
• Bictegravir (BIC)    
• Other INSTI drugs , including long acting preparations  
 
Additionally, due to their enzyme induction potential, the following medications, or their 
equivalents, must NOT be administered concurrently with DTG : 
 
• Barbiturates  
• Oxcarbamazepine  
• Pioglitazone  
 
IMPAACT P1093, Version 5.0  Page 43 of 135 12 July 2018   • Troglitazone  
• Rifampin (NOTE : see Section 6.1.8  regarding  TB exclusion)  
• Rifabutin  
• Phenytoin  
• Phenobarbital  
• Carbamazepine  
• St. John’s wort  
 
Dolutegravir  may inhibit the renal tubular secretion of dofetilide resulting in increased dofetilide 
concentrations and potential for toxicity . 
 
• Dofetilide  
 
The following medications are also prohibited:  
 
• Medications for HCV therapy  
 
Table 11: Summary of Disallowed ARV Medications  
Medication  STAGE I   
STAGE II  Allowed Prior 
to Intensive PK  Allowed After 
Intensive PK (OBT)  
Efavirenz (EFV)  No Yes*  Yes*  
Atazanavir (ATV)  No Yes Yes 
Atazanavir /Ritonavir (ATV/r)  No Yes Yes 
Tipranavir / Ritonavir (TPV/r)  No Yes Yes 
Nevirapine (NVP)**  No No No 
Fosamprenavir / Ritonavir 
(FPV/r)  No Yes Yes 
Fosamprenavir (FPV)  No Yes Yes 
Etravirine (ETR)  No No No 
Etravirine with Lopinavir / 
Ritonavir (ETR/ LPV/r)  Yes Yes Yes 
Etravirine with Darunavir / 
Ritonavir (ETR/ DRV/r)  Yes Yes Yes 
Raltegravir (RAL)  No No No 
Elvitegravir (EVG)  No No No 
Bictegravir (BIC)  No No  No 
*May NOT be given as part of OBT if it is in combination with TPV/r  
**Prior historical NVP treatment i s permitted but NVP treatment must be discontinued 14 days prior 
to initiation of DTG.  
 
4.4 Protocol Registration and Enrollment Procedures  
 
Prior to implementation of this protocol, and any subsequent full version amendments, each site must 
have the protocol and the protocol informed consent form(s) approved, as appropriate, by their local 
institutional review board (IRB)/ethics committee (EC) and any other applicable regulatory entity .  
 
Upon receiving final approval, sites will submit all required protocol registration documents to the 
DAIDS Protocol Registration Office (DAIDS PRO) at the Regulatory Support  Center (R SC). The DAIDS 
 
IMPAACT P1093, Version 5.0  Page 44 of 135 12 July 2018   PRO will review the submitted protocol registration packet to ensure that all of the required documents 
have been received .  
 
Site-specific informed consent forms (ICFs) WILL be reviewed and approved by the DAIDS PRO and 
sites will receive an Initial Registration Notification  from the DAIDS PRO that indicates successful 
completion of the protocol registration process. A copy of the Initial Registration Notification should be 
retained in the site's regulatory files.  
 
Upon receiving final IRB/EC and any other applicable RE appro val(s) for an amendment, sites should 
implement the amendment immediately . Sites are required to submit an amendment registration packet to 
the DAIDS PRO at the R SC. The DAIDS PRO will review the submitted protocol registration packet to 
ensure that all th e required documents have been received. Site -specific ICF(s) WILL NOT  be reviewed 
and approved by the DAIDS PRO and sites will receive an Amendment Registration Notification when 
the DAIDS PRO receives a complete registration packet. A copy of the Amendme nt Registration 
Notification should be retained in the site's regulatory files.  
 
For additional information on the protocol registration process and specific documents required for initial 
and amendment registrations, refer to the current version of the DA IDS Protocol Registration Manual.  
 
Participant s meeting the study eligibility criteria will be enrolled through the Data Management Center 
(DMC) registration screens . Written informed consent for study participation must be obtained before any 
study related procedures are performed.  
 
Sites interested in screening potential participant s into MUST request and receive permission from the 
Protocol Team  in order to proceed with screening visits . Prior to emailing the team to get permission to 
screen a patient the sites must complete the PS2001 IMPAACT Screening Checklist within the 
Participant  Enrollment System to obtain a screening number, which should be included in the sc reening 
request . For all participant s from whom informed consent is obtained, but who are deemed ineligible or 
who do not enroll into the protocol for any reason, a Screening Failure Results form must be completed 
and keyed into the database .  
 
NOTE : If the participant  has a milestone birthday that will change cohort assignment, it is the site's 
responsibility to notify the DMC data manager to request a cohort assignment change .  
 
4.5 Co-enrollment Procedures   
 
Co-enrollment is permitted except for protocols t hat would violate the exclusion criteria and where 
permitted by local/country regulations . All co -enrollments in protocols require the assent of the protocol 
chairs of the main protocol and the co -enrollment protocols .  
 
5.0 STUDY TREATMENT  
 
Study treatment is defined as DTG  film-coated tablets, DTG  granules for suspension  (granules mixed 
with liquid) for oral administration or DTG  dispersible tablets . Refer to Section 6.3 for further 
instructions regarding the timing of initiation of DTG  and OBT.  
 
5.1 Drug Regimen s  
 
All dosing tables referenced below are available in the IMPAACT P1093 Dosing Table Appendix poste d 
on the study -specific web page: http://impaactnetwork.org/studies/P1093.asp . 
 
 
IMPAACT P1093, Version 5.0  Page 45 of 135 12 July 2018   Weight will be measured and  recorded at each visit to verify the participant  is receiving the appropriate 
dose based on the current dosing table. If a participant ’s weight change requires a dose adjustment, the 
dose adjustment should be made, the Protocol Team must be notified, although Protocol Team approval 
for a weight -based do se adjustment is not required.  Dose adjustments for weight decreases will only be 
made if the weight decrease persists for two consecutive study visits.   
 
Participant s enrolled into a given age cohort will remain in that cohort throughout their participat ion in 
the study . It is possible that the dose chosen for one age cohort (based upon a “mg/kg” target) may differ 
from the a ccepted  target dose for the next older  age cohort. In this case, the participant  will stay on their 
current dose and will “grow” int o any subsequent increase in dosing, as per the original dosing table; their 
dose should not be automatically decreased as they age. This approach is supported by acceptable safety 
and tolerance observed in adults treated with DTG  50 mg PO BID. The Protoco l Team will continue to 
monitor protocol safety and, if any signals are noticed that require a modification to this approach; the 
sites will be contacted as to any necessary changes for individual participant s or cohorts , see Section  6.4.  
 
Stage 1  
 
Participant s enrolled to Stage I of the study  will be stratified at screening into one of the age specific 
cohorts  as shown below . Participant s who add EFV, FPV/r, or TPV/r as par t of OBT after intensive PK 
will have the frequency of the dose of DTG  changed to twice daily. Beginning with protocol version 5, 
Stage I enrollment into Cohorts III -DT, IV -DT and V -DT will continue until a minimum of 10 
participants in each cohort and a minimum of 8 participants in each of the following weight band -groups 
are enrolled: 3 kg to <6 kg, 6 kg to < 10 kg, 10 kg to <14 kg and 14 kg to < 20 kg  
 
Cohort I : Adolescents ≥ 12 to <18 years of age  
• Dolutegravir  film-coated tablets  
• Participant s will tak e an initial starting dose orally of dolutegravir  tablet (s) at 
approximately 1 mg/kg once daily  per Table A in the IMPAACT P1093 Dosing 
Table Appendix posted on the study -specific web page: 
http://impaactnetwork.org/studies/P1093.asp.     
 
Cohort IIA: Children ≥ 6 to <12 years of age  
• Dolutegravir  film-coated tablets  
• Participant s will take an initial starting dose  orally of dolutegravir  tablet (s) at 
approximately 1 mg/kg once daily  per Table A in the IMPAACT P1093 Dosing 
Table Appendix poste d on the study -specific web page:   
http://impaactnetwork.org/studies/P1093.asp .  
    
Cohort IIB: Children ≥ 6 to <12 years of age  
• Dolutegravir  granules for suspension  (1.6 mg/mL) . Note: Dispersible tablets may 
also be evaluated in this cohort if requested by regulatory authorities.  
• Participants will take an oral starting dose* of dolutegravir granules for 
suspension or dispersible tablets once daily (or twice daily as indicated below) 
per the dose determined by review of all available data, as well as any relevant 
bioavailability studies.  
• Participants who add EFV, FPV/r, or TPV/r as part of OBT after intensive PK 
will have the frequency of the dose of DTG changed to twice daily.   
• The ini tial dose of dispersible tablets will be administered in the clinic and 
observed by study staff.  
 
 
IMPAACT P1093, Version 5.0  Page 46 of 135 12 July 2018    Cohort III: Children ≥ 2 to < 6 years of age  (Closed to Enrollment)  
• Dolutegravir  granules for suspension  (1.6 mg/mL)  
• Participants will take an oral starting  dose* of dolutegravir granules for 
suspension or dispersible tablets once daily (or twice daily as indicated below) 
per the dose determined by review of all available data, as well as any relevant 
bioavailability studies. Refer to the selected Dosing Tabl e.   
• Participants who add EFV, FPV/r, or TPV/r as part of OBT after intensive PK 
will have the frequency of the dose of DTG changed to twice daily.   
• The initial dose of dispersible tablets will be administered in the clinic and 
observed by study staff for tolerability .  
 
Cohort III -DT: Children ≥ 2 to < 6 years of age  
• Dolutegravir  dispersible tablet  
• Participants will take an oral starting dose* of dolutegravir dispersible tablets 
once daily (or twice daily as indicated below) per the dose determined by review 
of all available data, as well as any relevant bioavailability studies. Refer to the 
selected  Dosing Table.  
• Participants who add EFV, FPV/r, or TPV/r as part of OBT after intensive PK 
will have the frequency of the dose of DTG changed to twice daily.   
• The initial dose of dispersible tablets will be administered in the clinic and 
observed by stud y staff  for tolerability . 
 
Cohort IV: Children ≥ 6 months to < 2 years (Closed to Enrollment)  
• Dolutegravir granules for suspension (1.6 mg/mL).  
• Participants will take an oral starting dose* of dolutegravir granules for 
suspension or dispersible tablets on ce daily (or twice daily as indicated below) 
per the dose determined by review of all available data , as well as any relevant 
bioavailability studies. Refer to the selected Dosing Table.  
• Participants who add EFV, FPV/r, or TPV/r as part of OBT after intens ive PK 
will have the frequency of the dose of DTG changed to twice daily.   
 
Cohort IV -DT: Children ≥ 6 months to < 2 years  
• Dolutegravir dispersible tablet  
• Participants will take an oral starting dose* of dolutegravir dispersible tablets 
once daily (or tw ice daily as indicated below) per the dose determined by review 
of all available data, as well as any relevant bioavailability studies. Refer to the 
selected Dosing Table.  
• Participants who add EFV, FPV/r, or TPV/r as part of OBT after intensive PK 
will ha ve the frequency of the dose of DTG changed to twice daily.   
• The initial dose of dispersible tablets will be administered in the clinic and 
observed by study staff for tolerability.  
• Refer to Section 5.2.3  for additional administration procedures.  
 
Cohort V -DT: Infants ≥ 4 weeks to < 6 months  
• Dolutegravir dispersible tablet  
• Participants will ta ke an oral starting dose* of dolutegravir dispersible tablets 
once daily (or twice daily as indicated below) per the dose determined by review 
of all available data, as well as any relevant bioavailability studies. Refer to the 
selected Dosing Table.  
 
IMPAACT P1093, Version 5.0  Page 47 of 135 12 July 2018   • Participants who add EFV, FPV/r, or TPV/r as part of OBT after intensive PK 
will have the frequency of the dose of DTG changed to twice daily.   
• The initial dose of dispersible tablets will be administered in the clinic and 
observed by study staff  for tolerability.  
• Refer to Section 5.2.3  for additional administration procedures.  
 
*Note: The initial starting Cohort dose selected and any Cohort dose adjustments will be 
communicated to study sites by the Protocol Team. For individual participant  dose adjustments, 
sites will be notified by a PID specific e -mail from the Protocol Team, see Section 6.4.  
 
Stage II  
  
Beginning with protocol Version 5, upon the confirmation of an acceptable cohort dose in Stage 
I, additional participants will be enrolled to Stage II (if necessary) to achieve the targeted number 
of participants per cohort (refer to Section 3.2).  Participant s enrolling to Stage II of each of the 
following  cohorts will receive the Stage I accepted  DTG  dose to be administered o rally once 
daily  or if on EFV, FPV/r, or TPV/r as part of OB T, DTG  will be dosed twice daily , as shown 
below.     
 
Cohort I :  Adolescents ≥ 12 to <18 years of age – dolutegravir  film-coated tablets.  
Cohort IIA:  Children ≥ 6 to <12 years of age – dolutegravir  film-coated tablets   
Cohort III:   Children ≥ 2 to < 6 years of age – dolutegravir  granules for suspension    
Cohort III -DT:  Children ≥ 2 to < 6 years of age – dolutegravir  dispersible tablets  
Cohort IV :  Children ≥ 6 months to < 2 years  of age  – dolutegravir  granules for suspension  
Cohort IV -DT:  Children ≥ 6 months to < 2 years  of age  – dolutegravir  dispersible tablets    
Cohort V -DT:  Infants ≥  4 weeks to < 6 months  of age  – dolutegravir  dispersible tablets  
 
Changing Dolutegravir  Study Product  Formulation  
 
Provisions for changing study product formulations is outlined below.  
• Participant s entering Cohorts III -DT, IV-DT and V -DT and receiving dispersible tablets 
must continue to receive the dispersible tablets through Week 48. After W eek 4 8, those 
participant s who reach the appropriate age and weight may elect to change to film -coated 
tablets upon approval of the Protocol Team .   
• Participant s receiving granules  will switch to dispersible tablets , see Section 3.3.  
• The Protocol Team will retain the ability to modify participant s’ dose and formulation as per 
the protocol, based on PK data, age, weight, and/or other variables.  
 
5.1.1 Duration  of Study Product Regimen  
 
Stage I  and Stage II :  48 weeks  
 
Long term follow -up: Participant s who successfully complete 48 weeks of DTG  treatment will 
continue to receive DTG  as part of long term safety follow -up. For additional information please 
refer to Section  6.6. 
 
 
IMPAACT P1093, Version 5.0  Page 48 of 135 12 July 2018   Vomiting or Missed Doses   
 
If a participant spits out a dose of DTG or vomits within 4 hours after  taking DTG, the parti cipant  
should take a full replacement dose.  If vomiting occurs more than 4 hours after  taking study 
product , a replacement dose should not be taken (the next scheduled dose should be taken ).   
 
If a participant misses a dose of DTG the participant should take DTG as soon as possible, 
provided the next dose is not due within 4 hours. If the next dose is due within 4 hours , the 
participant should not take the missed dose and si mply resume the usual dosing schedule.  
 
5.2 Study Product  Formulation s and Administration  
 
5.2.1 Dolutegravir  Film-coated  Tablets   
 
Dolutegravir  film-coated tablets in  10 mg, 25 mg, and 50 mg per tablet . Store at 15C to 30C 
(59F to 86F). Dispense and store only in the original manufacturer’s container . If provided,  the 
desiccant should remain in the bottle.  
 
5.2.2 Dolutegravir  Granules for Oral Suspension  
 
Dolutegravir  granules for suspension 1.6 mg/1mL suspension . When the granules in the bottle are 
reconstituted with 73 mL of potable (drinkable) water as direc ted, each container contains 160  mg 
per 100 mL. Once reconstituted, the suspension is stable for 12 weeks in the manufacturer’s 
container . The reconstituted pro duct should be  stored at temperatures up to 30 ºC (86ºF). Storage 
in a refrigerator is fully acceptable and preferred, if available.  
 
Preparation of oral suspension by the site pharmacist  
 
In order for the product to be dosed as 1.6 mg/ mL suspension in glass bottles: The DTG  pediatric 
granules 0.4 % w/w are to be reconstituted into a suspension containing 1.6 mg/mL through the 
addition of water by the site pharmacist as follows:  
 
Using a graduated syringe, the dispensing pharmacist, will mea sure 73 mL of potable (drinkable) 
water (in two portions) to mix with the DTG  granules; the resulting concentration of the 
suspension after it is mixed is 1.6 mg/mL of DTG  if reconstituted as directed . Insert a bottle 
adapter into the neck of the bottle and replace the child resistant cap . The bottle must be shaken 
for about one minute to ensure homogeneity. After shaking, visually check to ensure that there is 
no non -dispersed material adhering to the bottom or sides of the bottle. If non -disperse d material  
is observed, additional shaking is required as above . The maximum in use period of the pediatric 
formulation after it has been reconstituted with water is 12 weeks and may be refrigerated or 
stored at room temperature up to 30ºC (86ºF). The susp ension should not be frozen. The DTG  
pediatric suspension reconstituted from granules should be dispensed in the same amber glass 
bottle in which the granules were mixed with water.   An oral dispenser will also be provide d with 
each bottle . The suspension must be retained within the bottle in which it is dispensed and not 
transferred to any other container except the dosing syringe used for administration . The 
reconstituted suspension should be used within 12 weeks of the initial reconstitution, but 
prefera bly within a single month. Following reconstitution, the suspension in EVERY glass bottl e 
should be shaken EVERY day , irrespective of whether doses are being taken from that particular 
bottle. Failure to follow this instruction may lead to variability in dosing.  
 
 
IMPAACT P1093, Version 5.0  Page 49 of 135 12 July 2018   5.2.3 Dolutegravir Dispersible Tablets  
 
Dolutegravir dispersible tablet , 5 mg per tablet . Product may be stored at  temperatures up to 30ºC 
(86ºF) . Storage in a refrigerator is fully acceptable, if available. Once a bottle is opened the 
product has an in -use shelf life of 60 days providing the product is stored in the original package 
to protect from moisture,  with the bottle tightly closed. Do not remove the desiccant.  
 
In Stage I and prior to intensive PK sampling each tablet is to be dispersed using 2 to 5 mL of 
water.  There are two options for dispensing described below.    
 
• Option 1: for older children, po ur drinking water into the dosing cup. For 1 -2 tablets use 5 mL 
of water. For 3 -4 tablets use 10 mL of water  and for 5 -6 tablets use 15 mL of water. Add the 
prescribed number of tablets to the water. Swirl the cup gently for 1 -2 minutes to fully 
disperse the tablets. The medicine will be cloudy. If any lumps of tablet remain, swirl the cup 
gently until they are gone. Give the prepared dose t o the child. Rinse the dosing cup before 
next use.  
 
• Option 2: for infants and younger children, prepare medicine in dosing cup as directed in 
Option 1. Draw up all the medicine into the syringe.  Place the tip of the syringe against the 
inside of the infa nt’s cheek to give the dose slowly. Swirl a further 2 mL of water into the 
dosing cup, draw it into the syringe, and give it all to the infant. Wash cup and syringe 
thoroughly.  
 
After intensive PK sampling and in Stage II each tablet can continue to be dis persed as described 
above or each tablet can be placed directly on the tongue and directly swallowed.  
 
Dispersible t ablets may be given as multiples (up to a maximum of 6 tablets), depending on the 
weight of the child. Once dispersed, the medication should  be consumed from the supplied dosing 
cup or syringe within five minutes.  
 
5.3 Study Product Supply, Acquisition and Accountability  
 
5.3.1 Study Product Supply and Acquisition  
 
Dolutegravir study products will be supplied by GSK. All DTG  study products are available 
through the NIAID Clinical Research Products Management Center (CRPMC) .  
 
Other components of the ARV regimen will not be supplied by the protocol .  
 
The IMPAACT pharmacist can obtain  DTG  by following the instructions in the manual 
"Pharmacy Guidelines and Instructions for DAIDS Clinical Trials Networks" in the section Study 
Product Management.  
 
Oral syringes and dosing cups in which to measure water for dispersion and to administer the 
dispersed product will be packaged with the dispersible tablets and will be provided to the 
parent/caregiver.  Additional instructions for administration of DTG  for the parent/caregiver can 
be found  in the Manual of Procedures.  
 
 
IMPAACT P1093, Version 5.0  Page 50 of 135 12 July 2018   5.3.2 Study Product Accountability  
  
The IMPAACT pharmacist is required to maintain complete records of all study products 
received from C RPMC. All unused DTG  must be returned to the C RPMC after the study is 
completed or terminated  at domestic sites . The procedures to be followed are given in the manual, 
"Pharmacy Guidelines and Instructions for DAIDS Clinical Trials Networks" in the section Study 
Product Control.  
 
Non-US IMPAACT pharmacists should follow the instructions on the Study Product Destruct ion 
Form . The only study products for this protocol to be included on the Study Product Destruction 
Form are the DTG  study products .  The procedures to be followed are given in the manual, 
"Pharmacy Guidelines and Instructions for DAIDS Clinical Trials Net works".  
 
 
6.0 PARTICIPANT MANAGEMENT  
  
6.1 Toxicity Management   
 
Refer to Section 7.3 for guidance on toxicity grading. Management of adverse experiences will be 
according to the best clinical practice and the judgment of the site investigator. Alternate explanations for 
clinical and laboratory abnormalities must be sought. Laboratory normal ranges will be the institutional 
values. Abnormal clinical and laboratory findings should be followed until resolution to < Grade 2 .  
 
The remainder of this section provides further guidanc e on reporting and management of adverse events. 
General guidance is provided in Section s 6.1.1  and 6.1.2 . With respect to management, the guidance in 
6.1.2 should be followed for all adverse events except the following:  
 
• Liver toxicity (follow Section 6.1.3 ) 
• Decline in renal function  (follow Section 6.1.4 ) 
• Proteinuria (follow Section 6.1.5 ) 
• Peptic ulcer disease  (follow Section 6.1.6 ) 
• Abacavir hypersensitivity (follow Section 6.1.7 ) 
 
Additional considerations for management of participants co -infected with TB are provided in Section 
6.1.8 .   
  
6.1.1 Reporting  
 
All adverse events occurring from  the start of DTG study drug and until the final follow -up visit  
will be source documented and recor ded on case report forms (CRFs).   
 
• Grade s 1 and 2: All AEs should be recorded on Case Report Forms (CRFs) at each visit .  
 
• Grade s 3, 4 and 5: 
 
o All AEs should be recorded on CRFs at each visit.  
o The Protocol Team  must be notified of AEs within  72 hours of awareness .  
o The investigator should attempt to confirm any laboratory test results , as soon as 
possible , but always within 72 hours .   
 
 
IMPAACT P1093, Version 5.0  Page 51 of 135 12 July 2018   6.1.2 Management  
 
Grade 1  – Continue study drug; routine monitoring.  
 
Grade 2  – Continue study drug; monitor closely with more frequent visits as per site PI, work -up 
to exclude other causes.  
 
For Grade 3  laboratory AEs  – Continue study drug while awaiting confirmatory results unless the 
clinician believes that remaining on study drug would be unsafe  and that continuing them would 
pose little additional risk.  Notify the Protocol Team of the confirmatory results within 7 2 hours 
of awareness.  
 
For Grade 3 clinical AEs and confirmed Grade 3 laboratory AEs  – hold the study drug and 
concomitant ARV  therapy until t he abnormalities decrease to a G rade 2 or below unless the site 
clinician  believes holding ARV  therapy (including study drug) would be harmful to the 
participant  and that continuing them would pose little additional risk.   
 
The Protocol Team should be informed of all Grade 3 clinical AEs and confirmed Grade 3 
laboratory AEs, within 72 hours of awareness, and the site’s plan to hold or continue study drug 
and concomitant ARV  therapy .    
 
Grade 4  – Hold study drug and concomitant ARV s immediately unless the site clinician  believes 
that holding ARV  therapy (including study drug) would be harmful to the participant  and that 
continuing them would pose little additional risk . Attempt to confirm Grade 4 laboratory AEs as 
soon as possible, but always within 72 hours of the initial result.   
 
The Protocol Team  should be notified of the  initial and confirmatory results within 72 hours of 
awareness.   
 
For Grade 4 clinical AEs and confirmed Grade 4 laboratory AEs that are determined to be 
probably  or definitely related to study drug, study drug should be permanently discontinued . For 
Grade 4 adverse events that are determined to be  possibly, probably not, or not related to study 
drug, the site investigator should contact the team to determine whether and when study drug may 
be safely continued (if not previously held) or resumed (if held).  
 
All ARV  therapy including study drug should be started or stopped together whenever possible, 
except when  one ARV  agent can be substituted for another within class when the etiology of the 
toxicity can be determined.  
 
6.1.3 Liver Toxicities    
 
Liver chemistry threshold stopping criteria have been designed to assure participant  safety and to 
evaluate liver event eti ology .  If any of the  following liver chemistry stopping criteria are met 
study drug ( DTG ) should be held  unless continuation is approved by the Protocol Team :  
• Hy’s Law : ALT>3xULN and bilirubin>2xULN; Direct Bilirubin > 35% of Total Bilirubin.  
NOTE : Hy’s Law is a prognostic indicator that a pure drug -induced liver injury (DILI) 
leading to jaundice, without a hepatic transplant, has a case fatality rate of 10 -50%. Increased 
ALT or total bilirubin are relatively common ( in HIV/AIDS) but the combination  of 
ALT>3xULN and total bilirubin > 2xULN is rare in drug development and of clinical 
concern .  
 
IMPAACT P1093, Version 5.0  Page 52 of 135 12 July 2018   • ALT  10xULN; In this case, if another cause of ALT elevation is identified, the participant  
may be re -challenged after receiving the approval of the Protocol Team .   
• ALT > 3xULN with symptoms of hepatitis or hypersensitivity (e.g., fatigue, nausea, 
vomiting, right upper quadrant pain, fever, rash or eosinophilia) . In this case, if another cause 
of ALT elevation is identified, the participant  may be re -challenged after receiving the 
approval of the Protocol Team.  
• ALT >  5xULN for more than 2 weeks . In this case, if another cause of ALT elevation is 
identified, the participant  may be re -challenged after receiving the approval of the Protocol 
Team.  Partic ipant s who develop ALT  5xULN should be followed weekly until resolution 
or stabilization (ALT <  5xULN on 2 consecutive evaluations) .  
 
If any of the above  liver chemistry stopping criteria are met, sites are instructed to do the 
following:  
• Immediately hold study drug  unless continuation is approved by the Protocol Team.  
• Report the event to the Protocol Team  by email within 24 hours of learning of its occur rence .   
• Report Hy’s Law liver toxicities (see above) to the RSC as an EAE  
• If possible, collect a 2-mL blood draw for pharma cokinetic analysis from the participant  
within 72 hours of the last dose taken , and record  the date and time of the last dose taken as 
well as the date and time of the pharmacokinetic sample collected . NOTE : If the timeframe is 
greater than 72 hours since the last dose, the specimen should not be collected.  
• Complete  and submit  the liver toxicity CRFs within 1 week to the DMC  
 
6.1.4 Decline in Renal Function   
 
Participant s who experience an increase to Grade 2 from a baseline normal or Grade 1 serum 
creatinine level, or an increase to Grade 3 or higher from a baseline Grade 2 level, must return for 
a conf irmatory assessment within 2 to 4 weeks . A urinalysis and urine microalbumin /creatinine 
ratio, as well as serum creatinine  should be done at this confirmatory visit . If the creatinine 
elevation is confirmed  (with or without proteinuria) , the investigator should contact the Protocol 
Team  to discuss additional follow -up and medical management.  
 
Participant s who experience progression to an estimated GFR (calculated by the Schwartz 
formula) of <50 mL/min (1.73m2) must return for a confirmatory assessment within 2  to 4 weeks . 
A urinalysis and urine microalbumin /creatinine ratio should be done at this confirmatory visit  (in 
addition to the serum  creatinine) . If an estimated GFR of <50 mL/min (1.73m2) is conf irmed, then 
DTG should be withheld and the investigator should contact the Protocol Team  to discuss 
additional follow -up and management, which may include resumption of DTG if agreed to be 
appropriate .  
 
Schwartz formula: GFR ( mL/min/  1.73 m2) = K x Ht cm/P creat 
 
K=constant    Cr mg/ mL 
Infants < 1 year    0.45 
Children 1-12 years   0.55 
Female 13 -21 years   0.55 
Males 13 -21 years   0.70 
 
Consideration for confounding factors (e.g. background ART therapy; other medications; 
dehydration and concurrent condition s) should be considered , and a nephrology consult may be 
obtained . If participant s are also receiving TDF, then a switch to an alternative nucleoside should 
 
IMPAACT P1093, Version 5.0  Page 53 of 135 12 July 2018   be considered if restarting DTG . Current local prescribing information should be consulted for 
additional details on dosing background ART therapy in renal -impaired participant s. If DTG is 
re-initiated, it should have been withheld for no more than 4 weeks , unless approved by the 
P1093 Team.  
 
6.1.5 Proteinuria  
 
Participant s with an abnormal urine  microalbumin /creatinine ratio (> 300 mcg/mg) that represents 
a change from a normal baseline and no associated increase in creatinine should have a repeat 
spot urine microalbumin /creatinine ratio and serum creatinine assay performed within 2 to 4 
weeks . If confirmed, the  investigator should contact the Protocol Team to discuss additional 
follow -up and management . Additional follow -up may include nephrology referral .  
Participant s with an abnormal urine microalbumin /creatinine ratio (> 300 mcg/mg representing a 
change from baseline) and a serum creatinine increase to grade 2 toxicity or above, should have 
confirmation of both results within 2  to 4 weeks . If confirmed, DTG should be held, and the 
investigator should immediately contact  the Protocol Team to discuss additional follow -up and 
management, which may include resumption of DTG if agreed to be appropriate.  
  
6.1.6 Peptic Ulcer Disease  
 
Symptoms suggestive of peptic ulcer disease (e.g., epigastric pain, nausea, vomiting, bloating, 
etc.) are relatively common but are also non -specific.  
 
Participant s with such symptoms should be treated symptomatically as appropriate (e.g., H 2 
blockers or p roton pump inhibitors) and be evaluated and treated as appropriate for H. pylori . 
However, patients with these symptoms should not be prescribed cation -containing antacids for 
concomitant use, because significant reduction in DTG exposure has been observed  when these 
drugs were co -administered . If deemed necessary, DTG should be administered 2 hours before or 
6 hours after taking antacid products.  
 
If symptoms consistent with peptic ulcer disease persist or worsen on symptomatic therapy, the  
investigator should consult the Protocol Team  to discuss additional management, which may 
include but is not limited to discontinuation of DTG . 
 
6.1.7 Abacavir (ABC) Hypersensitivity (HSR)  
 
The most significant toxicity associated with ABC is the well -character ized drug -related 
hypersensitivity reaction (HSR) .  
Where HLA -B*5701 screening is considered standard of care, it is recommended that 
investigators screen for the presence of the HLA -B*5701 allele in any participant  for whom an 
Abacavir  (ABC) -containing pr oduct (e.g., ZIAGEN™, TRIZIVIR™, EPZICOM™, KIVEXA™) 
may be considered as part of the optimized background regimen and HLA -B*5701  status is 
unknown (even if the participant  has previously tolerated ABC) . Use of ABC in participant s 
known to carry HLA -B*5701 is not recommended and should be considered only under 
exceptional circumstances where potential benefit outweighs the risk and only under close 
medical supervision.  
 
IMPAACT P1093, Version 5.0  Page 54 of 135 12 July 2018   Reporting of Abacavir Hypersensitivity Reactions  
 
All cases of potential abacavir  hypersensitivity MUST be reported as an EAE , refer to Section 
7.2. In addition, the ABC HSR CRF must be completed and submitted to the DMC within one 
week of the onset of the hypersensitivity reaction .  
 
6.1.8 Management of Participant s Co-infected with TB  
 
Parti cipant s presenting at the Screening visit with active Tuberculosis (TB) co -infection are not 
eligible to participate in the study due to multiple drug interactions, overlapping toxicities, and 
other complications affecting treatment outcomes . Participant s who are already enrolled and are 
on therapy who become exposed to TB, and subsequently require an anti -TB treatment that 
includes the use of rifampin, may be allowed to continue in the study if their ART options are 
compatible with co -administration of rif ampin . Continuation requires the approval of t he Protocol 
Team . Management of these participant s is as follows:  
 
• When administration of the rifampin -containing anti -TB treatment begins, participant s will 
switch to the Schedu le of Evaluations in Appendix IG   
Schedule of Evaluations  
Participant s who Start Rifampin as  Part of Treatment for Active Tuberculosis and will 
increase their DTG dose from once daily to twice daily (dose is based on weight) . DTG study  
drug continues to be administered twice daily while participant  is on the rifampin containing 
anti-TB therapy .  
 
• While on the rifampin -containing anti -TB therapy, to ensure the DTG dose is appropriate, 
intensive pharmacokinetic sampling will occur two weeks after the sta rt of anti -TB treatment 
at the following times , per Appendix IG  : Pre-dose, and at 1, 2, 3, 4, 6, 8, and 12 hours post -
dose will be performed.  
 
• Individual dose adjustments may be made to the initial DTG dose following the Week 2 
intensive pharmacokinetic study  and is participant  to approval of the Protocol Team . If the 
participant  assessed is adherent to therapy but does n ot achieve the minimum AUC 0-24 of 
25 µg.h/mL  after dose adjustment they may continue on study drug after consideration of the 
clinical, pharmacologic, immunologic and virologic data, and upon agreement of the site 
investigator, study co -chairs, pharmacologist and medical officers, a given participant  may be 
allowed to continue with the study drug at the dosing that resulted in the exposures below the 
minimum target.  
 
• Population PK time points at weeks 4 and 12 should remain the same as the Schedule of 
Evaluations ( Appendix IG  ).  
 
• It is estimated the participant  will be on anti -TB treatment for approximately 24 weeks . Upon 
discontinuation of the rifampin containing anti -TB therapy , the participant ’s DTG dose will 
revert back to once daily administration  unless on EFV, FPV/r, or TPV/r . The participant  
should complete the remainder of the first 48 weeks of DTG therapy on their original 
schedule of evaluations, or if they have completed 48 weeks of DTG therapy, they should 
move to long term follow -up (Appendix IE  ). For example, if the participant  was at week 16 
when they were started on rifampin, and they complete 24 weeks of rifampin therapy, they 
would then go back to week 40 of their original S chedule  of Evaluation (SoE) . 
 
 
IMPAACT P1093, Version 5.0  Page 55 of 135 12 July 2018   6.2 Screening  
 
The DMC will maintain a web page informing sites as to the availability of enrollment slots per cohort.  
Participant s screened for enrollment in the mini -cohort of Stage I but cannot enroll because the mini -
cohort is filled will be given priority  to enroll when the remaining slots are opened for that cohort. If 
Stage I enrollment is completed before a screened participant  can enroll, that participant  will be given 
priority  for enrollment on Stage II. The Protocol Team will maintain a waiting list for each cohort to 
ensure faci litated enrollment as well as informing sites and potential participant s as to the status of the 
various cohorts and stages as the study progresses.   
 
Participant s will be asked to undergo the following evaluations at screening to be eligible for enrollme nt: 
 
• Medical history and physical exam  
• Pregnancy test ( for females of child bearing age ) 
• Confirmation of two methods of contraception for participants of reproductive potential and who are 
engaging in sexual activity that could lead to pregnancy   
• Hematol ogy, chemistr ies, lymphocyte  subsets  and lipid profiles  
• Urinalysis  
• Confirmation of HIV -infection  
NOTE: for participant s ≤ 18 months of age results may be pending at the time of enrolment: see 
Section 4.1.2 . 
• HIV-1 RNA PCR  
NOTE: for participant s < 2 years of age results may be pending  at the tim e of enrolment: see Section  
4.1.5 .  
• Real time genotyping for resistance testing  
NOTE: for all naïve parti cipants and participant s < 2 years of age ( Cohorts IV, IV -DT, and V -DT) 
results may be pending at the time of enrolment; see Section 4.1.10 .  
• Phenotyping where possible  
 
6.3 Initiation of Dolutegravir  and Management of B ackground ART  
 
DTG is initiated by all participants on the day of enrollment.  Additional ARV’s taken as background 
ART vary depending on timing during follow up, age, ARV -treatment history, and availability of 
genotype results .  Detailed instructions on DTG and background ART administration follow.  
 
6.3.1 Optimized B ackground Therapy (OBT)  
 
The OBT  regimen should ideally include one ARV with predicted antiviral activity and (at least) 
one additional ARV , for a total two ARV drugs given in addition to DTG.  The HIV -1 genotype 
obtained at screening, as well as participant histor y of virologic and medication tolerance should 
be used to determine an appropriate OBT regimen .  All OBT regimens must be approved by the 
Protocol Team. Sites are requested to send the proposed OBT regimen along with resistance 
profiles by email to the Protocol Team for approval , as soon as possible , once screening genotype 
results are available; the team will respond within two business days. Additional details about the 
OBT are based on cohort and ARV experience, as follows .   
 
• The OBT  regimen  for ARV -treatment -experienced participants in Cohorts I,  II, III, III -DT 
must  contain at least one fully active drug AND one additional drug , and be approved by the 
Protocol Team.   
 
IMPAACT P1093, Version 5.0  Page 56 of 135 12 July 2018   • The OBT regimen for ARV -treatment -experienced participants in Cohorts IV, IV -DT, and V -
DT AND  treatment naïve participants in all cohorts will ideally  contain AT LEAST one fully 
active drug AND one additional drug , and be approved by the P rotocol Team.  The 
determination of OBT for these cohorts can be made before enrollment (if genotype results 
are available) or after enrollment (once screening genotype results are available); at either 
time point, the site proposes a n OBT regimen  that must be approved b y the Protocol T eam.  
Notably, the protocol permits Stage I participants to be receiving empiric regimens while 
awaiting genot ype results  and OBT determination .  If the screening genotype result s 
ultimately do not demonstrate any available active drug s, a participant can either discontinue 
DTG  (Section 6.9) or can continue on the regimen until the 4 -week HIV RNA testing result s 
are available .  At tha t point the s ite should propose OBT and the P rotocol Team will make a 
case-specific determination of OBT acceptability taking into consideration results of the 
screening genotype, historical genotypes (up to one year prior), 4 -week  virologic response 
(e.g. viral load decrease of > 1 log drop or a VL <400 at the four week visit) , and other 
clinical factors.  
• For participants in Cohorts I, II, III, III -DT, the prescriptions should have already been 
obtained from a pharmacy and the dru gs must be available during the intensive PK visit to 
have the first dose observed immediately upon completion of the PK evaluations. For 
participants in Cohorts IV, IV -DT, and V -DT, the PK should be completed on day 5 -10, and 
OBT initiated as soon as poss ible thereafter when results are back from screening genotype 
and when agents are available , as outlined below.  
• To minimize the impact of drug -drug interactions on PK variability, use of ATV, FPV, EFV, 
boosted (ritonavir or cobicistat) ATV, FPV, and TPV wi ll not be allowed PRIOR to the initial 
PK evaluation in Stage I but may be added as part of the OBT regimen after completing the 
intensive PK or as part of the OBT regimen for those in Stage II.  Refer to Section 4.3.2  and 
Table 11 for a description of the medications that are disallowed during Stage I and/or Stage 
II of each cohort.  
 
6.3.2 Empiric Background Therapy  
 
For ART naïve participants and ARV experienced participants  < 2 years of age (C ohorts IV and 
V) the empiric background ther apy regimen should be chosen by site investigators, per country 
guidelines  and provider  discretion .  In choosing the regimen consideration should be given to the 
regimen most likely to be considered effective , but it must not include disallowed medications  
(Section 4.3.2  and Table 11) and must be approved by the Protocol Team .  
 
6.3.3 Stage I: Initiation of DTG  
 
The timing and management of DTG and background ART is outlined in Table 12 below . Note 
that a ge ≥ 2 years effectively applies Cohorts I, II, and III -DT and age < 2 year applies to 
participants in Cohorts IV -DT and V -DT. 
 
 
IMPAACT P1093, Version 5.0  Page 57 of 135 12 July 2018   Table 12. Stage I T iming and Management of DTG and B ackground ART  
ARV Exposure 
Group  
(Section 4.1)  Age at 
Enrollment  ARV at Entry  ARV Management 
Immediately after  
Intensive PK Visit  
on day 5 -10 Subsequent ARV 
Modifications 
Based on 
Screening 
Genotype  
(if necessary)  
ARV -treatment 
experienced 
participants, not 
currently receiving 
ARVs  ≥ 2 years    Start DTG alone.  
No other ARVs.  Continue DTG.  
Start OBT.  
 Not applicable  
< 2 years  Start DTG.  
Start empiric 
background ART.  Continue DTG.  
Either change background ART 
to OBT, or continue empiric 
ART (if screening genotype 
results pending).  Change 
background ART 
to OBT when 
genotype available 
and OBT 
approved.  
ARV -treatment 
experienced 
participants currently 
receiving a failing 
regimen of ARVs (all 
ages) or who recently 
started an empiric 
regimen (<2 years old 
only) . 
 ≥ 2 years    Start DTG.  
Continue current 
ARV regimen.  Continue DTG.  
Change background ART to 
OBT. 
 Not applicable  
< 2 years  Start DTG.  
Continue current 
ARV regimen.  Continue DTG.  
Either change background ART 
to OBT, or continue empiric 
ART (if screening genotype 
results pending)  Change 
background ART 
to OBT when 
genotype available 
and OBT 
approved.  
ARV -naïve 
participants  
  ≥ 2 years  Start DTG alone.  
No other ARVs.  Continue DTG.  
Start OBT or start empiric 
background ART if screening 
genotype results pending.  
 Change 
background ART 
to OBT when 
genotype available 
and OBT 
approved.  
< 2 years  Start DTG.  
Start OBT or 
empiric 
background ART 
if screening 
genotype results 
pending.  Continue DTG.  
Continue OBT, start OBT or 
continue empiric background 
ART if screening genotype 
results pending.  
 Change 
background ART 
to OBT when 
genotype availabl e 
and OBT 
approved.  
 
6.3.4 Stage II : Initiation of DTG  
 
During stage II, all participants initiate DTG on enrollment.  ARV -treatment experienced 
participants  in Cohorts I, II, III and III -DT will be based on screening results, and the regime will 
start simultaneously with DTG . ARV -naïve participants of Cohorts II and III, and all participants 
in Cohorts  IV, IV-DT, and V -DT can start OBT on enrollment, or start empiric ART and change 
to OBT as soon as genotype results are available .  
 
6.3.5 Permitted Chang es to ARV Regimens (Stages I and II)  
 
No changes, re -optimization or intensification in background ARV therapy after initial 
optimization will be permitted prior to protocol -defined virologic failure, with the exception of a 
single su bstitution of a component of OBT  with another approved compound for the management 
of drug toxicity . Formula substitutions (substituting single agents for fixed dose combinations and 
 
IMPAACT P1093, Version 5.0  Page 58 of 135 12 July 2018   vice versa of the same ARV) are not class ified as a change and are permitted during the s tudy. 
Any changes must be discussed with the Protocol Team . Unless the change is specifically 
permitted, participant s who have one or more new agents added to the optimized backgro und 
HAART regimen will be considered virologic failures.  
 
6.4 Dose Adjustments  
 
Dose modifications will be considered after the Protocol Team reviews the intensive PK parameters and 
safety data  as part at any stage of analysis (mini-cohort, interim , full cohort  or weight band group ) in 
Stage I . If a dose is deemed unacceptable then t he Team will review the clinical,  virologic and PK data 
for individual participants who are currently receiving the dose deemed  unacceptable and decide whether 
a modification is in th e participant’s best interest. If the dose is modified in these participants, additional 
PK sampling may be requested by the team.  The type of PK sampling (intensive, specific timed samples) 
will be determined by the Protocol Team on an individual basis and communicated to the site.  
Participants who undergo a dose increase will have an additional study visit four weeks after the dose 
modification to monitor safety and then continue follow -up with no further changes in the visit schedule.  
Refer to schedule of evaluations for procedures in dicated for a dose modification.  
 
In addition, at any point during study follow -up, an individual participant’s dose may be modified on a 
case-by-case basis by the Protocol Team if determined to be in the individua l’s best interest. As specified 
above, th e Protocol Team  may request additional PK sampling  and a ll participants who undergo a dose 
increase will have an additional visit for safety.  
 
6.5 Virologic Failure for Participant  Management   
 
All HIV-1 RNA PCR  test results should be reviewed and entered into the Lab Data Management System 
(LDMS) within two weeks of specimen collection.  If extenuating circumstances prevent results from 
being entered during this timeframe, the Protocol Team should be notified.   
 
Virologic FAILURE in this study is defined as:  
 
• A confirmed decrease in HIV RNA of < 1.0 log10 at or after  week 12 unless the HIV R NA is <  400 
copies/mL.  
 
OR 
 
• A confirmed HIV RNA > 400 copies/mL starting at Week 24 or beyond on 2 consecutive 
measurements  at least 1 week and within 4 weeks  apart ; 
 
Virologic REBOUND  in this study is defined as:  
 
• Confirmed HIV-1 RNA >  400 copies/mL (on 2  consecutive measurements at least 1 week apart) after 
an initial confirmed response  (on 2 consecutive measurements at least 1 week apart)  of HIV -1 RNA <  
400 copies/mL;  
 
OR 
 
• Confirmed >  1.0 log10 increase in HIV -1 RNA above nadir level (on 2 consecutive measurements at 
least 1 week apart) . For the purposes of this study, nadir is defined as the lowest HIV -1 RNA while 
on study drug  that is >  400 copies/mL . 
 
IMPAACT P1093, Version 5.0  Page 59 of 135 12 July 2018   NOTE: A confirmatory HIV -1 RNA sample is to be collected ≥ 1 week to ≤ 4 weeks after the date of 
the HIV sample suggesting HIV virologic failure or rebound.  
 
NOTE: Participants should continue to be evaluated for virologic failure beyond Week 48 as part of 
their schedules of evaluations.  This includes participants who experience their initial or subsequent 
virologic failure (if they suppressed after a prior fa ilure), provided that at least 24 weeks have lapsed 
from the prior virologic failure drug resistance samples.  
 
Participants, who are confirmed as  virologic failures as defined above, should undergo a Virologic 
Failure Visit, as described in the Schedules of Evaluations.  At this visit, a specimen should be drawn 
for resistance testing (genotyping and phenotyping), as described in the Schedules of Evaluations. Sites 
should notify the Protocol Team of all virologic failures. Participants may then, at the dis cretion of the 
participant’s clinician and with the approval of the Protocol Team : 
• Be taken off study drug and followed as per Appendix IF  . 
 
OR 
 
• Have background therapy re -optimized, with the participant  remaining on study drug;  
 
OR 
 
• Continue with no changes made to the current regimen.  
 
Any re -optimization of background therapy must first be approved by the Protocol Team .   
 
6.5.1 Viral Resistance Samples/Testing  
 
For all participant s, blood samples for viral resistance assays and integrase resistance will be 
collected and stored at entry . In addition, to evaluate development of resistance to DTG  and to 
other ARV  therapies, used in the treatment regimen, blood samples will be collected at the 
Virologic Failure visit (as defined above) and at the Premature D iscontinuation of Study Drug (if 
not already obtained at virologic failure) to assess development of genotypi c or phenotypic 
resistance to DTG and/or OBT.  
  
6.5.2 Algorithm for Resistance Testing  
 
• If a participant  reaches  virologic failure at or after 24 weeks and discontinues because of viral 
failure, the earliest sample with a corresponding HIV -1 RNA result above 400 copies/ mL 
should be sent for all resistance testing, as outlined in the Laboratory Processing Chart which 
can be found on the P1093 protocol specific webpage: 
http://impaactnetwork.org/studies/P1093.asp  
 
• If a participant  is a virological  failure but continues in the study  (on study drug) , the second 
consecutive sample with a corresponding HIV RNA result above 400 copies  /mL will be sent 
for all testing . In addition, resistance  testing will be done for participant s who continue on 
study af ter confirmation of virologic failure if HIV RNA is >400 copies/ mL.  
 
• If a participant  discontin ues from the study early,  a sample will be sent for resistance testing 
if the participant 's HIV RNA level is above  400 copies  /mL at the time of discontinuation .  
 
IMPAACT P1093, Version 5.0  Page 60 of 135 12 July 2018    
6.6 Long Term Safety Follow -up   
 
Participant s who successfully complete 48 weeks of DTG treatment will continue on the study in long-
term follow -up and will be seen in clinic every 12 weeks  for approximately  3 additional years (192 weeks  
total follow -up) per Appendix IE Appendix IE Schedule of Evaluations  
Long -term Safety Follow -up for Participant s Who Continue to Receive  Dolutegravir Study drug will be 
provided for the durati on of the study . Thereafter, participant s will b e transitioned into care and treatment 
outside of the study , refer to Section 10.7. 
 
6.7 Pregnancy and Contraception    
 
6.7.1 Pregnancy Testing  and Contraception  
 
A female participant is considered to be of reproductive potential if she has reached menarche.  
The protocol includes mu ltiple measures to prevent and monitor for pregnancy in study 
participants , as there is concern for potential toxicity of DTG early in gestation ( Section 1.5). 
 
During follow -up, a ll female participants over the age of 9 years are asked about menarche at 
each visit (until it occurs) . 
 
 At each visit, all female participants  of reproductive potenti al 
• must have a test for pregnancy  
• are asked about sexual activity that could lead to pregnancy  
• must have their choice of TWO contraceptives (see below) documented if they are currently 
or could possibly be engaging in sexual activity that could lead to p regnancy  
• are reminded that if they change their minds (since enrollment) and now seek pregnancy they 
should inform the  study staff  
 
One of the TWO forms of contraception must be highly effective, such as hormonal birth control 
(e.g., pills, shots, or slow release inserts placed under/on the skin) and/or an intrauterine device 
(IUD).  The second form contraception is ideally an accepted  barrier method (e.g. female/male 
condoms, diaphragm or cervical cap with a cream or gel that kills sperm [excluding nonoxydyl -
9]). Condoms are recommended because their appropriate use is the only contraception method 
effective for preventing HIV -1 transm ission. Use of an IUD  may increase the risk of pelvic 
inflammatory disease.   
 
Female participants with reproductive potential who are currently or could possibly engage in 
sexual activity that could lead to pregnancy and are unable  to utilize two forms of  contraception 
for some reason (such as local availability),  alternative contraceptive management can be 
discussed with and approved by the Protocol  Team.  Any female participant with reproductive 
potential who is sexually active in a way that could lead t o pregnancy AND is unwilling or unable 
to take effective contraception must stop taking DTG .   
 
Pregnancy testing will be conducted , per the relevant Schedule of Evaluations for females with 
reproductive potential and at any time during the study when preg nancy is suspected. 
Additionally, a pregnancy test should also be performed prior to DTG re-administration, when 
dosing is disrupted for more than 7 days. Pregnancy tests may be performed on either blood or 
urine. At every visit (or some other more frequen t interval), pregnancy prevention will be 
 
IMPAACT P1093, Version 5.0  Page 61 of 135 12 July 2018   discussed with the participants, including specific counseling, provision of information and 
advice as needed. This discussion should be documented in the participant’s study record.  
 
  
6.7.2 Pregnancy  
 
Any participant  who becomes pregnant while participating in this study should discontinue study 
drug immediately . However , these participant s should remain on study but off study drug  and 
followed per  Appendix IF  Appendix IF  Schedule of Evaluations  
Participant s who Prematurely Discontinue Dolutegravir , to monitor for any safety issues  until the 
birth of the baby . Any pregnancy that occurs during study participation must be reported to the  
Protocol Team . All pregnancy complications, elective terminations for medical reasons and 
spontaneous abortions must be reported as an EAE.   
 
Pregnancy test results and pregnancy outcomes should be ascerta ined and entered into eCRFs.  
Outcomes may be ascertained based on maternal report but medical records should be obtained 
whenever possible to supplement maternal reports.   
 
Note:  Study sites will also be encouraged to prospectively register the particip ant’s pregnancy in 
the Antiretroviral Pregnancy Registry: http://www.apregistry.com/ (in U.S.: 1 -800-258-4263 ; 
non-US: 1-910-679-1598 ).  
 
6.8 Criteria for Study Discontinuation  
 
6.8.1 The participant  or legal guardian refuses further treatment and/or follow -up eval uations.  
 
6.8.2 The participant  fails to comply with the study requirements so as to cause harm to 
him/herself or seriously interfere with the validity of the study results.  
 
6.8.3 The participant  requires treatment with medications that are disallowed while on this 
study.  
 
6.8.4 Virologic failure  and participant  does not meet the criteria for continuation of study drug.  
 
6.8.5 Non-adherence of study medications . 
 
6.8.6 The Protocol Te am has determined  that there would be no benefit to continue on study 
and receive DTG .  
 
6.9 Criteria for Treatment Discontinuation   
 
6.9.1 Pregnancy , refer see Section 6.7. 
 
6.9.2 New data become available that indicate treatment should be discontinued.  
 
6.9.3 Drug toxicity that requires permanent study drug discontinuation , see Section 6.1. 
 
6.9.4 Liver toxicities , see Section 6.1.3 . 
 
6.9.5 The investigator determines that further participation would be detrimental to the 
participant 's health or well -being.  
 
IMPAACT P1093, Version 5.0  Page 62 of 135 12 July 2018    
6.9.6 HIV infection not confirmed , see Section 4.1.2 . 
 
6.9.7 Participant  was enro lled but found to have HIV RNA ≤  1000 copies / mL at screening 
(applies only to Cohorts IV, IV -DT, and V -DT).  
 
6.9.8 Participant  was enrolled but found to have no active drugs per genotype performed at 
screening (applies only to Cohorts IV, IV -DT, and  V-DT who enrolled with genotype 
results pending); and whom the Protocol Team determined the proposed OBT as non -
acceptable , see Section 6.3.1 .   
 
NOTE: In the event of treatment discontinuation, participant s will be asked to continue on study for 4 
weeks  after they discontinue study drugs or un til the adverse event resolves.  
 
 
7.0 EXPEDITED ADVERSE EVENT REPORTING   
 
7.1 Adverse Event Reporting to DAIDS    
 
Requirements, definitions, and methods for expedited reporting of adverse events are outlined in Version 
2.0 of the Manual for Expedited Reporting of Adverse Events to DAIDS (DAIDS EAE Manual), which is 
available on the DAIDS RSC website at http://rsc.tech -res.com/clinical -research -sites/safety -
reporting/manual . 
 
The DAIDS Adverse Experience Reporting System (DAERS), an internet -based reporting system, must 
be used for EAE reporting to DAIDS. In the event of system outages or technical difficulties, EAEs ma y 
be submitted using the DAIDS EAE Form. This form is available on the DAIDS RSC website at 
http://rsc.tech -res.com/clinical -research -sites/safety -reporting/daids/paper -eae-reporting .  
 
For questions about DAERS, please contact NIAID CRMS Support at CRMSSupport@niaid.nih.gov. 
Queries may also be sent from within the DAERS application itself.  
 
For questions about expedited reporting, please contact the DAIDS RSC Safety Office at 
DAIDSRSCS afetyOffice@tech -res.com.  
 
7.2 Reporting Requirements for this Study   
 
The SAE Reporting Category, as defined in Version 2.0 of the DAIDS EAE Manual, will be used for this 
study .   
 
The study agents for which expedited reporting are required are DTG tablets, DTG granules for 
suspension  (granules mixed with liquid) and DTG dispersible tablets for oral administration . 
 
In addition to the EAE Reporting Category identified above, other adverse events that must be reported in 
an expedited manner are:  
• All grade 4 toxicities,  
• Hy’s law liver toxicities , see Section 6.1.3 ,  
• Abacavir (AB C) hypersensitivity (HSR) , see Section 6.1.7 , and 
• All pregnancy complications , elective terminations and spontaneous abortions . 
 
 
IMPAACT P1093, Version 5.0  Page 63 of 135 12 July 2018   7.3 Grading Severity of Events    
 
The DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events  (DAIDS AE Grading 
Table), Version 1.0, December 2004, Clarification August 2009, will be used to grade all adverse events 
except for psychiatric events  listed in Table 13 below, which will be graded as shown. The DAIDS AE 
Grading Table is available on the RSC website at  http://rsc.tech -res.com/clinical -research -sites/safety -
reporting.  
 
Table 13: Supplemental Table for Grading of Psychiatric Events  
 Parameter  Grade 1  
Mild  Grade 2  
Moderate  Grade 3  
Severe  Grade 4  
Potentially  
Life-Threatening  
Insomnia  
  
 Mild difficulty 
falling asleep, 
staying asleep, or 
waking up early 
causing no or 
minimal interference 
with usual social & 
functional activities   Moderate difficulty 
falling asleep, staying 
asleep, or waking up 
early causing more 
than minimal 
interference with 
usual social & 
functional activities  Severe difficulty falling 
asleep, staying asleep, or 
waking up early causing 
inability to perform usual 
social & functional 
activities requiring 
intervention or 
hospitalization  NA 
Psychiatric 
Disorders 
(includes 
anxiety, 
depression, 
mania, and 
psychosis)  
Specify 
disorder  Symptoms with 
intervention not 
indicated OR 
Behavior causing no 
or minimal 
interference with 
usual social & 
functional activities  Symptoms with 
intervention indica ted 
OR Behavior causing 
greater than minimal 
interference with 
usual social & 
functional activities  Symptoms with 
hospitalization indicated 
OR Behavior causing 
inability to perform usual 
social & functional 
activities  Threatens harm to 
self or others OR 
Acute psychosis OR 
Behavior causing 
inability to perform 
basic self -care 
functions  
Suicidal 
Ideation or 
Attempt  
Report only 
one  Preoccupied with 
thoughts of death 
AND No wish to kill 
oneself  
 Preoccupied with 
thoughts of death 
AND Wish to kill 
oneself w ith no 
specific plan or intent  Thoughts of killing 
oneself with partial or 
complete plans but no 
attempt to do so OR 
Hospitalization indicated  Suicide attempted  
 
7.4 Expedited AE Reporting Period    
 
• The expedited AE reporting period for this study is the duration of the study.  
• After the protocol -defined AE reporting period, unless otherwise noted, only SUSARs as defined in 
Version 2.0 of the EAE Manual will be reported to DAIDS if the study staff bec ome aware of the 
events on a passive basis (from publicly available information).  
 
NOTE : For reporting of all adverse experiences the Investigator will determine the causality and 
relationship to study drug . However, regarding  participant  safety and PK eva luations which will support 
the selection of a dose for a given cohort, the Protocol Team  will also have input as to the causality and 
drug relation of specific adverse experiences.  
 
 
 
IMPAACT P1093, Version 5.0  Page 64 of 135 12 July 2018   8.0 STATISTICAL CONSIDERATIONS  
 
8.1 General Design Issues  
 
This is a Phase I/II study whose primary objectives are to assess the safety and pharmacokinetics of DTG 
administered to HIV -1-infected infants, children and adolescents with ages ranging from 4 weeks to <  18 
years . The sample will be stratified into the f ollowing groups:  
 
Cohort I :  Adolescents ≥ 12 to <18 years of age (tablets)   
 
Cohort IIA:  Children ≥ 6 to <12 years of age (tablets)  
 
Cohort IIB:  Children ≥ 6 to <12 years of age ( granules for suspension ) 
 
Cohorts III:   Children ≥ 2 to < 6 years of age  (granules for suspension  or dispersible tablets )  
 
Cohort III -DT: Children ≥ 2 to < 6 years of age (dispersible tablets)   
      
Cohort IV :   Children ≥ 6 months to < 2 years ( granules for suspension ) 
 
Cohort IV -DT:  Children ≥ 6 months to < 2years of age (dispersible tablets)  
 
Cohort V -DT:  Infants > 4 weeks to < 6 months (dispersible tablets)  
 
A minimum of ten participant s will be enrolled into each  age cohort in Stage I for purposes of dose 
finding. Under Version 5, for stage I enrollment i ntro Cohorts III -DT, IV -DT, and V -DT, there is also a 
requirement to enroll a minimum of eight participants (which may include those already enrolled into the 
age cohort) into each of the following weight band  groups : 
 
1) 3 to <6 kg  
2) 6 to <10 kg  
3) 10 to <14kg  
4) 14 to <20 kg  
 
To this end, o nce a cohort has enrolled 10 participants, additional participants will be allowed to enroll 
during Stage I only if their weights fall within a weight band that has not yet reached its enrollment target 
of N=8 with evaluab le PK and safety data; enrollment of up to 2 additional participants to a total of 10 per 
weight band will be allowed while evaluation of the minimum of 8 is ongoing  (i.e. to confirm data are 
evaluable) . Additional participant s will be enrolled into Stage II of the study and treated at the doses 
determined optimal for their cohorts based on  Stage I results. The total sample will provide a minimum of 
120 evaluable participant s (Stage I + Stage II)  who have been treated exclusively at the doses judged to 
be optimal for their age cohorts (see Schema for breakdown by cohort)  and weight band groups.   
 
Under previous protocol versions, a ccrual to Stage I follow ed an algorithm in which younger children’s 
exposure to the study medication was contingent upon success in meeting safety and pharmacokinetic 
guidelines in the older strata. Thus,  Cohort I was the first to opened with enrollment in Cohort IIA 
contingent upon whether members of Cohort I me t the guidelines for safety and PK parameters . Cohort 
IIB then open ed once members of Cohort IIA pass ed safety and PK criteria and a pediatric formulation 
was available . A similar approach was used for the rest of the younger cohorts, each of whose opening 
was contingent upon successful results from the next older age cohort . Because data have already now 
 
IMPAACT P1093, Version 5.0  Page 65 of 135 12 July 2018   been obtained from all cohorts, u nder protocol Version 5.0 a ccrual to Stage I for Cohorts III -DT, IV -DT 
and V -DT will be simultaneous, rather than sequenti al.   
 
The data from Stage I is analyzed in three steps, a mini -cohort analysis, a n interim cohort analysis, and 
the full cohort and weight band group analysis ( Section 3.1). For the mini-cohort analysis , the overall 
safety and PK data of the first 4 participant s with evaluable data in a given cohort will be evaluated with 
respect to the safety guidelines , per Section 8.5 and the PK guidelines , per Section 9.3. If the first 4 
evaluable participant s of this cohort meet both sets of guidelines, then  accrual will continue and no dose 
adjustments will be made.   If the first 4 evaluable participant s of the older cohort fail either the safety or 
the PK guidelines in this initial test, then the starting dose will be adjusted in the appropriate direction, 
(e.g. upwards for inadequate PK values; downwards for safety failure), if this is feasible . New doses w ill 
be tested in the same manner, enrolling new participant s and reviewing PK and safety data from the first 4 
participants with evaluable data.  The evaluation will proceed as described above .   
 
The interim cohort  analysis occurs when there are 10 participants with evaluable data in an age cohort. 
Data will be evaluated, and safety guidelines, per Section 8.5 and the PK guidelines, per Section 9.3. If 
there are no concerns, enrollment continues but additional participants can only into a cohort if they also 
contribute to meeting the w eight band group minimums.  
 
For the full Stage I cohort and weight band group  analysis , the starti ng dose of fully accrued cohort s are 
evaluated by BOTH cohort and weight band group on the basis 4 wee k safety (as per  Section 8.5) and 
intensive PK data (as per Section 9.3). As of Version 5.0, the full analysis of Stage I data for Cohorts III -
DT, IV -DT and V -DT occurs when all cohorts and weight band groups have met minimum enrollment 
targets and achieved 4 -weeks of follow up (See Section 3.1 for more details).   The purpose of this review 
process is to take account of all available information in determining whether the dose finding algorithm 
has converged on the best dose for further study in Stage II or whether adjustments are needed. As part of 
this review process, safety and PK data will be broken down based on  the dosing adjustments that have 
been made because of the inducing or inhibiting effects of the background regimens. If there is evidence 
that some adjustments may have been associated with undesirable PK levels or with safety concerns, 
these adjustments may b e modified for Stage II or further data may be gathered prior to opening Stage II.     
 
If a dose is “failed” by the P rotocol T eam, considering  the safety and/or PK targets ( refer to Section 3.1) 
at the mini -cohort , interim or full cohort analysis stages, a new test dose will be examined. New 
participants will be started on the new dose and evaluations will proceed as described above. For 
participants who meet PK targets, safety will be evaluated based on  all available data collected through 4 
weeks on that dose. For participants who fail to me et PK targets and are required to have a dose 
adjustment, safety will be evaluated based on  data gathered until the time of the visit at which the dose is 
adjusted.  
 
If the Protocol Team  deems a given participant ’s PK data to be unevaluable (e.g. , because  of reported 
non-adherence  or PK results that would be physiologically implausible with good adherence ), that 
participant  will be replaced for dose finding purposes  (but will continue in the study and contribute to the 
safety analyses) . Note that the participant  would be replaced for evaluating safety, as well as PK, criteria, 
if unevaluable PK data reflect uncertainty about appropriate exposure to the study medication.  
 
If the dosing recommendation for a given subgroup of participants should differ between  that based on 
age cohort vs. that based on weight band, the Protocol Team will review all relevant data and make a final 
dosing recommendation . In a situation where a final dosing recommendation cannot be made with 
available data, the Protocol Team  can enroll additional cohorts or weight band groups until a dosing 
recommendation can be made.  
 
 
IMPAACT P1093, Version 5.0  Page 66 of 135 12 July 2018   Participant s accrued to Stage II of the study will be ad ministered the doses determined for their age 
cohorts, with no individual dose adjustments based on  PK allowed. For purposes of analysis, data from 
these participant s will be combined with the data from the Stage I participant s who have been treated at 
the doses accepted for their cohorts and weight bands and who have not required individual PK 
determined dose adjustments, such that their total exposure to the study drug has been at the accepted 
dose. Sensitivity analyses will be performed to determine whet her the exclusion of participant s whose 
doses have been adjusted creates a selection bias which impacts upon any results.  
 
Participant s who switched formulation will be included in  sensitivity analyses  whose purpose would be to 
(1) identify safety issues for all children exposed to the study drug, and (2) determine whether the results 
of those switching formulations differed descriptively from those of the primary analysis.  
 
Participants with no study drug dose  adjustments, except for those due to change in age and/or weight 
where the adjusted doses conform those to be recommended for the resulting group, will be included in 
the primary analysis and classified in the original cohort and weight band in which they  enrolled. For 
participants whose study drug dose is adjusted due to PK outcomes (after the week 4 visit), safety data up 
to the date of dose adjustment will be analyzed in the original cohort/weight band, and sensitivity 
analyses will be performed to asse ss whether conclusions drawn from primary dose confirmation 
evaluations would be affected by inclusion of these data.  
  
Study accrual is designed to yield at least 120 evaluable participants for the weeks 24 and 48 safety 
analyses: some participating in St age I and some participating in Stage II.  In order to ensure that the 
primary safety analyses will yield results that can be generalized to the overall patient population, the 
“evaluable” participants for the primary analysis will be defined as those part icipants whose treatment 
will conform to the final dosing recommendation that will result from this protocol.  This sample will 
consist of participants : 1) whose starting dose was the dose determined to be the final confirmed starting 
dose of DTG for their  cohort/weight band; 2) whose dose may have been changed, due to changes in age 
and/or weight, provided that the dose they received at that cohort/weight band is the dose that will be 
recommended for members of the treatment population who experience a sim ilar progression.  
Participants whose treatment regimens conform to those described in #1 and #2, above, but who leave the 
study due to treatment failure or toxicity prior to completing 24 weeks or 48 weeks of treatment, will be 
included in the sample for the primary analyses and will be treated as failures in those analyses.”  
 
8.2 Endpoints and Outcome Measures  
 
For safety reporting and monitoring purposes, a drug related adverse event is defined as an adverse event 
that is judged to be definitely , probably , or possibly related to the study drug.  Endpoints and outcome 
measures are generally to be assessed by cohort, unless otherwise specified.  
 
8.2.1 Primary Endpoints  - presented aggregated and by cohort  
 
8.2.1.1  Toxicity through Week 24  
• All adverse events or lab toxicities of Grade 3 or higher severity  
• Adverse events or lab toxicities of Grade 3 or higher severity judged to be at least 
possibly attributable to the study medication  
• Termination from treatment due to a  drug-related adverse event  
• Death  
 
 
IMPAACT P1093, Version 5.0  Page 67 of 135 12 July 2018   8.2.2 Primary Respon se Variables  
 
8.2.2.1  Pharmacokinetics  
• C24h, AUC 0-24 
 
8.2.3 Secondary Endpoints  -  presented aggregated, by cohort, and by weight band  
 
8.2.3.1  Toxicity through week 48 and beyond  
• All adverse events or lab toxicities of grade 3 or higher severity.  
• Adverse events or lab toxicities of grade 3 or higher severity judged to be at least 
possibly attributable to the study medication.  
• Termination from treatment due to a drug-related advers e event.  
• Death  
 
8.2.3.2   Plasma  HIV-1 RNA (copies/ mL) <400 copies/ mL and <50 copies/ mL 
 
8.2.3.3  Pharmacokinetics  
• AUC 0-24, C24h, C0, Cmin, Cmax, CL/F, Vz/F and t 1/2 
 
8.2.4 Secondary response variables  
• CD4/8 counts and percent  
• Genotypic and phenotypic measures of resistance at baseline and at virologic failure  
• Disease progression as measured by change in CDC category  
 
8.3 Randomization and Stratification  
 
There will be no randomization . In each stage, participant s will be stratified into cohorts defined by age 
and formulation, as described in Section 8.1. In addition, under Version 5, enrollment of particip ants by 
weight band will be monitored.  
 
8.4 Sample Size and Accrual  
 
Total accrual will depend upon the number of participant s who must be accrued to yield at least 1 20 
evaluable participant s for purposes of the primary safety analyses  and the regulatory submi ssions . There 
is some uncertainty concerning the number needed to complete the dose finding procedures in Stage I and 
the number who may be lost to follow -up for reasons other than treatment failure. Each successful cohort 
on Stage I will include a minimum of 10 participant s; the majority of whom will have been treated 
continuously on the dose that has been chosen for Stage II . This will likely yield additional participant s 
from Stage I who will contribute to the evaluation of the optimal dose. Thu s, approximately 300 
participant s will be accrued  to ensure that the total sample includes at  least 120 evaluable participant s 
who have been treated only on the optimal dose and that the quotas for each cohort, specified in the 
Schema, have been filled.  
 
The selection of a sample size of ten  participant s in Stage I for each age cohort is based on feasibility and 
the historical pediatric recruitment experience of GSK and IMPAACT, as well as justification to target a 
95% confidence interval (CI) within 60% an d 140% of the point estimate for the geometric mean 
estimates of clearance (CL/F) and volume of distribution (Vd) for DTG with an at least 78% power .  
 
 
IMPAACT P1093, Version 5.0  Page 68 of 135 12 July 2018   Variability (CV%) in CL/F and Vd for each age cohort are predicted based on the population PK model 
deve loped using adult data from ING111521 and ING112276 . In the adult population PK model, CL/F 
and Vd are modeled as the following:  
 
CL/F (L/hr)  =  0.873 * (WT/70)^0.713*EXP(eta1), eta1 ~ N (0, 0.0857)  
Vd (L) = 17.5 * (WT/70)^1.02 * EXP(eta2) + 1.6, eta2 ~ N  (0, 0.0365)  where WT is body weight 
in kg.  
 
Using predicted variability in CL/F and Vd, simulations (10 ,000 simulations with a sample size of 10 for 
each simulation) were performed to estimate % chance for 95% CI of geometric mean estimates of 
simulated CL/F and Vd to fall within 60% to 140% of the point estimates (equivalent to power) .  
 
Table 14 presents the projected weight range, predicted mean and variability (coefficient of variability, 
CV) in CL/F and Vd, and estimated power for a sample size of 10 in each age cohort.  
 
Table 14: Power Estimation based on Proposed Sample Size of 10 Per Cohort for Stage I  
Age Cohort  Projected 
Weight Range 
(kg) PK Parameter  Predicted 
Mean  Predicted CV  Power (%)  
12-18yr 30-100 CL/F  0.85 0.38 94.1 
  Vd 18.1 0.34 98.5 
6-<12yr  17-52 CL/F  0.54 0.38 95.1 
  Vd 10.3 0.30 99.7 
2-<6yr  10.7-23 CL/F  0.21 0.34 98.4 
  Vd 5.77 0.21 100 
6mo-<2yr  6.75-15.1 CL/F  0.13 0.34 98.2 
  Vd 4.28 0.19 100 
4wk-<6mo  3.77-9.26 CL/F  0.084  0.35 97.5 
  Vd 3.18 0.16 100 
 
Power for a sample size of 10 and CV of 0.45, which is 20% higher than the highest predicted CV, was 
estimated to be >78% . Power for a sample size of 9 and CV of 0.45, was estimated to be >68%.  
 
8.5 Safety Guidelines for the Evaluation of Stage I Starting Doses  
 
The attribution of serious adverse events to study drug  for the purposes of employing the start, stop and 
pause rules will be by consensus among the site investigator  and the Protocol Team . If unanimous 
agreement between them cannot be established, the relevan t data will be reviewed by the P1093 Study 
Monitoring Committee, which will make the final judgment concerning the relationship between study 
drug and the adverse event. Within this committee the decision will be determined by the majority 
opinion of the P 1093 Study Monitoring Committee clinicians. Gradation of relationship will use the 
following terminology: ‘Not related’, ‘Probably not related’, ‘Possibly related’, ‘Probably related’ or 
‘Definitely related’.  
 
Table 15 and Table  16 below use a multinomial response model to assess the probability of faili ng the 
safety criteria under each of the hypothetical situations  specified  in those tables. The calculations are 
performed as follows : Each of the total number of participant s represents a trial, which may have 1 of 3 
mutually exclusive outcomes: (1) a lif e threatening drug -related adverse event or a grade 4 event judged 
to be at least probably related to treatment; (2) a Grade 3+ event, not satisfying the criteria set forth in #1, 
immediately above, but judged to be at least possibly related to study drug and resulting in termination of 
 
IMPAACT P1093, Version 5.0  Page 69 of 135 12 July 2018   study drug; and (3) a relatively benign outcome, satisfying neither the criteria in #1 nor #2, immediately 
above .  
 
Each table has its sets of results under which the set of trials would pass the safety criteria. The 
probability of passing the safety criteria represents the sum of the probabilities of these sets of results, and 
“1 minus the probability of passing the safety criteria” represents the probability of failing them. The 
“True Toxicity Rates” presented in the  tables, along with the true rate of having neither of the types of 
toxicity represented by the true toxicity rates (which is 1 - the sum of the true toxicity rates), provide the 
probabilities for the outcomes which are used in the multinomial calculations  for each of the hypothetical 
situations .  
 
8.5.1 Safety Guidelines for the First Four Participant s Started at a Given Dose Level in Each Stage I 
Cohort  
 
For each Cohort,  for the mini -cohort analysis (see Stage I Study Design 3.1), the frequency of 
adverse reactions to the starting do se of the study medication will be evaluated on the first 4 
participant s with evaluable data . The data will extend to the week 4 visit for participant s not 
requiring PK determined dose adjustment or until the visit on which the dose is adjusted, as 
described above. Further accrual into this cohort will be contingent upon meeting the following 
safety guidelines.  
 
If any of the first 4 participant s has a life threatening drug-related adverse event or any Grade 4 
event that is probably or definitely attributable to the study medication, or  in the first four 
evaluable participants 2  or more have terminated study drug due to a grade 3+ drug-related 
adverse event  stop accrual into this dose group, until a safety review by the Protocol Team  has 
been conducted.   All of the relevant safety and pharmacokinetic data wi ll be reviewed to 
determine whether it is safe to continue the attempt to find an optimal dose for this cohort. If the 
team determines that it is safe to proceed, it will make any changes in the dosing and monitoring 
procedures which have been judged to be  necessary. If there are any concerns regarding safety, 
the P1093 Study Monitoring Committee will then review all relevant safety and pharmacokinetic 
data, along with the recommendations of the Protocol Team , and will determine whether and 
under what condi tions further dose finding activities for this cohort may proceed.  
 
The protocol will only proceed if this review has led to a recommendation that it is safe to do so 
and the team  agree s. The safety review may lead to a recommendation that the dose be de -
escalated . Before implementing such a recommendation, the Protocol Team  will review the PK 
data to determine whether a lower dose is likely to achieve adequate drug exposure.  
 
If none of the first 4 participant s has experienced a life -threatening drug-related adverse event or 
a Grade 4 event that is probably or definitely attributable to the study medication and fewer than 
2 of these 4 participant s have terminated study drug due to a grade 3+ drug-related adverse event , 
then this group has passed the initia l interim safety guidelines. If these 4 participant s also meet 
the PK guidelines, the cohort will continue to enroll a minimum of 10 participants to evaluate the 
safety and PK . 
 
Given the small sample sizes within each cohort, the information available for preliminary safety 
decisions will be imperfect . Two types of sampling errors are possible:  
1) In a group where the true rate of toxicity is too high to warrant increased exposure to the 
current starting dose of the medication, the sample data m ay pass the safety guidelines;  
2) In a group where the true rate of toxicity is low enough that further exposure to the current 
starting dose is warranted, the sample data may fail the guidelines .  
 
IMPAACT P1093, Version 5.0  Page 70 of 135 12 July 2018    
The extent to which the safety guidelines protect against the errors described above can be 
assessed by examining various hypothetical rates of "true toxicity" which could occur, if the 
study medication were used extensively among the participant  populatio n at the dose level under 
question . The hypothetical situations presented in  Table  15 range from conditions under which a 
given dose level would cause a high incidence of severe and life threatening drug-related adverse 
events  to conditions under which severe drug-related adverse events would be relatively rare and 
would not be life threate ning. For each of these hypothetical situatio ns, a sample of four  
participant s is drawn from the participant  population and that the safety guidelines  is assumed , 
summarized above, are followed.  
 
For example, Table 15 shows that there is a 78% chance of failing the safety guidelines under 
conditions in which the true rate of life -threatening toxicity is 5% and the rate of non -life 
threatening drug-related adverse event is 50%.  
 
Table 15: Probabil ity of Failing Dose Escalation Guidelines under Potential Rates of True 
Toxicity  
True Toxicity Rates  
Probability of 
Failing Safety 
Guidelines  Non-Life Threatening drug -related 
adverse events that would result in Tx 
discontinuation, excluding Grade 4 event s 
probably or definitely attributable to study 
medication  Life Threatening drug -related 
adverse events (including death) 
or Grade 4 events probably or 
definitely attributable to study 
medication  
.50 .00 .69 
.50 .05 .78 
.50 .25 .96 
.25 .00 .26 
.25 .05 .42 
.25 .25 .81 
.05 .00 .01 
.05 .05 .20 
.05 .25 .69 
.00 .05 .19 
.00 .25 .68 
 
Assuming that it would be undesirable to accrue additional participant s at a dose that had these 
true rates of adverse events, the 22% chance of NOT failing the safety guidelines would represent 
the probability of error. The table also shows that there is a 1 % chance of failing, when the true 
rate of non -life threatening drug-related adverse events  is only 5% and the true rate of life 
threatening drug-related adverse events is  zero. Assuming that the potential benefits associated 
with exposing additional participant s to this dose of the drug would outweigh the risks associat ed 
with this relatively low rate of toxicity, failing the safety guidelines under these conditions would 
be an error.  
 
8.5.2 Safety Guidelines for the Interim and Full Cohort Analyses , with a Minimum  of Ten Participant s 
Started at a Given Dose Level in Each Stage I Cohort  
 
The safety guidelines applied to a given starting dose of the study medication within a cohort for 
either the interim cohort analysis or full cohort analysis ( see Section  3.1), will make use of data 
from all participant s started at that dose. The data will extend to the week 4 visit for participant s 
not requiring PK determined dose adjustment or until the visit on which the dose is adjusted, as 
 
IMPAACT P1093, Version 5.0  Page 71 of 135 12 July 2018   described above. If any of these participant s has a life threatening drug-related adverse event or 
any Grade 4 event that is probably or definitely attributable to the study medication, or more than 
25% ter minated study drug due to grade 3+ drug-related adverse event, this starting dose will fail 
the safety guidelines for the cohort under investigation . If none of these participant s has 
experienced a life -threatening drug-related adverse event or a Grade 4 event that is probably or 
definitely attributable to the study medication and no more than 25% terminated study drug due 
to Grade 3+ drug-related adverse events, then this starting dose will pass the safety guidelines for 
the group under inves tigation.  
 
If any of these participant s has a life threatening drug-related adverse event  or any Grade 4 event 
that is probably or definitely attributable to the study medication or more than 25% terminated 
study drug due to Grade 3+ drug-related adverse event,  this starting dose will fail the safety 
guidelines for the cohort under investigati on. Should this occur , the Protocol Team  will review all 
the relevant safety and pharmacokinetic data to determine whether it is safe to continue the 
attempt to find an optimal dose for this cohort . If the team determines that it is safe to proceed, it 
will make any changes in dosing and monitoring procedures which are judged to be necessary . If 
there are any concerns regarding safety, the P1093 S tudy Monitoring Committee  (SMC) will then 
review all of the relevant safety and pharmacokinetic data, along with  the recommendations of 
the Protocol Team , and will determine whether and under what conditions further dose finding 
activities for this cohort may proceed.  
 
Following  Table 16, the hypothetical rates of "true toxicity" which could occur if the study 
medication were used extensively among the participant  population at the dose level are again 
presented in  Table 16, this t ime assuming that a sample of ten  participant s is drawn from the 
participant  population and the safety guidelines allows no participant  with life threatening drug-
related adverse event  or any Grade 4 event tha t is probably or definitely attributable to the study 
medication or no more than 2 participant s who  terminated study drug due to Grade 3+ drug-
related adverse event .   
 
Table 16: Probability of Failing Dose Escalation Guidelines Under Potential Rates of True 
Toxicity  with n=10 participant s 
True Toxicity Rates  
Probability of Failing 
Safety Guidelines  Non-life threatening drug -related adverse 
event that would result in treatment 
discontinuation, excluding Grade 4 
events probably or definitely attributable 
to study medication  Life threatening drug -
related adverse event or 
Grade 4 events probably 
or definitely attributable 
to study medication  
.50 .00 .95 
.50 .05 .98 
.50 .25 1.00 
.25 .00 .47 
.25 .05 .71 
.25 .25 .98 
.05 .00 .01 
.05 .05 .41 
.05 .25 .95 
.00 .05 .40 
.00 .25 .94 
 
 
IMPAACT P1093, Version 5.0  Page 72 of 135 12 July 2018   For example, Table  16 shows  that there is a 98 % chance of failing the safety guidelines under 
conditions in which the true rate of life -threatening toxicity is 5% and the rate of non -life 
threatening drug-related adverse event is 50% .  
 
8.5.3 Safety Guidelines for Minimum Eight Participa nts Started at a Given Dose Level in Each Weight 
Band  
 
Under protocol Version 5, a secondary examination of safety data by weight band will be 
performed .  An a dditional safety assessment of a given starting dose of the study medication 
within a weight ban d will make use of data from all participants within that weight band who 
started at that dose. The data will extend to the week 4 visit for participant s not requiring PK 
determined dose adjustment or until the visit on which the dose is adjusted , if adjus tment occurs 
prior to 4 weeks on study . If any of these participant s has a life-threatening  drug-related adverse 
event or any Grade 4 event that is probably or definitely attributable to the study medication, or 
more than 25% terminated study drug due to g rade 3+ drug -related adverse event, this dose will 
fail the safety guidelines for the weight band under investigation. If none of these participant s has 
experienced a life -threatening drug -related adverse event or a Grade 4 event that is probably or 
defini tely attributable to the study medication and no more than 25% have terminated study drug 
due to Grade 3+ drug -related adverse events, then this dose will pass the safety guidelines for the 
weight band under investigation.  
 
If any of these participant s has a life-threatening  drug-related adverse event or any Grade 4 event 
that is probably or definitely attributable to the study medication or more than 25% terminated 
study drug due to Grade 3+ drug -related adverse event, this dose will fail the safety guidelines for 
the weight band under investigation. Should this occur, the Protocol Team will review all the 
relevant safety and pharmacokinetic data to determine whether it is safe to continue the attempt to 
find an optimal dose for this weight band. If the team determines that it is safe to proceed, it will 
make any changes in dosing and monitoring procedures which are judged to be necessary. If there 
are any concerns regarding safety, the P1093 SMC will then review all the relev ant safety and 
pharmacokinetic data, along with the recommendations of the Protocol Team, and will determine 
whether and under what conditions further dose finding activities for this weight band may 
proceed.  
 
8.6 Analyses  
 
8.6.1 Summary of Dose Finding Data  
 
The analysis of dose finding data will consist of descriptive statistics summarizing the safety and 
PK data from the dose finding phase of the study , see Section  0 for PK analysis .  The safety data 
will be broken down by cohort and by weight band, and will present the results of the safety 
evaluations applied to each starting dose tested within each cohor t/weight band , including 
information indicating which starting doses have passed or failed the safety guidelines. For each 
starting dose within each cohort /weight band , every adverse event of Grade 3 or higher will be 
listed, along with participant  demographics, the dose prescribe d to the participant  at the time of 
the event and the Protocol Team ’s assessment of the probability that this event was due to the 
study drug (not related, possibly related, probably related or definitely related).  
 
8.6.2 Analysis of Data Representing Exposure to the Doses Judged to be Optimal for Each Cohort  
 
These analyses will be stratified by Age Cohort. The findings will be presented both in aggregate 
and broken down by this stratification factor, with estimates bounded by 95% confidence limits. 
 
IMPAACT P1093, Version 5.0  Page 73 of 135 12 July 2018   Given that the small sample sizes within strata will provide limited power for statistical tests of 
differences across age groups, interpretation of the results will depend upon whether differences 
across strata are great enough to be considered to be clinically sign ificant. If no such differences 
are observed, then the clearest interpretation of the findings will come from the aggregated data, 
where analyses will have the greatest statistical precision. However, if results vary across strata to 
a clinically important  extent, interpretation of results should take account of the issues 
represented by the stratification factor.  
 
8.6.2.1  Primary Analyses (performed on data through the W eek 24 visit)  
 
Safety  
The primary safety analysis will include only participant s whose startin g doses have been 
those judged to be optimal for their groups. Stage I participant s whose doses have been 
adjusted for inadequate PK will be excluded. Stage I participant s who have been removed 
from treatment due to toxicities while on the optimal dose wil l be included and treated as 
safety failures in the primary safety analysis. Sensitivity analyses will be performed to 
determine whether the exclusion of participant s whose doses have been adjusted creates a 
selection bias which impacts upon any results.  
 
Each participant ’s safety data will be summarized as: the worst grade of adverse event 
experienced during the first 24 weeks (and 48 weeks) of exposure to the optimal dose of 
the study drug and the worst grade of adverse event judged to be at least possibl y due to 
study drug during this time period. Frequency distributions of these safety outcomes will 
be presented in the aggregate and broken down by age cohort. Listings of all Grade 3+ 
events will be provided, broken down by type of toxicity (hepatic, hema tologic, etc.).  
 
The proportions of participant s experiencing Grade 3+ adverse events will be presented 
in aggregate and broken down by age, with these proportions bounded by exact 95% 
confidence intervals. Similar analyses will present the proportions of participant s 
exhibiting Grade 3+ events which have been judged to be at least possibly related to 
study medication, again bounded by exact 95% confidence intervals.  
 
 
IMPAACT P1093, Version 5.0  Page 74 of 135 12 July 2018   Table 17: Percent of Participant s Experiencing Grade 3+ Adverse Events (or Grade 3+ 
Adverse Events Attributed to the Study Medication) With Exact 95% Confidence Intervals  
N % With  Grade 3+ 
Adverse Events  95% C.I.  
10 0% 0% -- 31% 
20 0% 0% -- 17% 
40 0% 0% -- 9% 
60 0% 0% -- 6% 
90 0% 0% -- 4% 
150 0% 0% -- 2% 
   
10 10% 0.3% -- 45% 
20 10% 1% -- 32% 
40 10% 3% -- 24% 
60 10% 4% -- 21% 
90 10% 5% -- 18% 
150 10% 6% -- 16% 
   
10 20% 3% -- 56% 
20 20% 6% -- 44% 
40 20% 9% -- 36% 
60 20% 11% -- 32% 
90 20% 12% -- 30% 
150 20% 14% -- 27% 
   
10 30% 7% -- 65% 
20 30% 12% --54% 
40 30% 17% -- 47% 
60 30% 19% -- 43% 
90 30% 21% -- 41% 
150 30% 23% -- 38% 
 
Table 17 presents exact 95% confidence intervals around various potential rates of grade 
3+ adverse events which might be observed in a total sample of 100 evaluable 
participant s, a sample of 10 participant s representing the minimal sample that could be 
accrued within any of the Stage I stratification factors and potential sample sizes that 
might occur if subgroups are analyzed (N = 20, 40, 60, 90) This table indicates that 
confidence intervals will be  quite wide around the minimal sample size of 10 participant s 
within a given stratum, but would be reasonably precise around samples of 90-150 
participant s. 
 
8.6.2.2  Key Secondary Analyses  
 
Safety  
 
Safety assessments will be performed on data collected through Week 48 and on long 
term data. These analyses will be similar to the Week 24 analyses described in  Section 
 
IMPAACT P1093, Version 5.0  Page 75 of 135 12 July 2018   8.6.2  above.  In addition, these analyses will also be performed with participant s 
classified by weight band.  
 
Viral Load  
 
Virologic outcomes, based on HIV -1 RNA (copies/ mL), will be assessed at weeks 24 and 
48. Virologic outcomes at additional time points might also be evaluated. For regulatory 
submission purposes, at both of these time points the primary definition of virologic 
outcome will be calculated according to FDA’s snapshot algorithm. Participant s will b e 
classified as virologic failures if they have missing HIV -1 RNA data throughout the 
window surrounding the time point of interest. (This window will be defined in the 
analysis plan.) In addition,  participant s will be classified as virologic failures at e ither of 
these time points if they meet any of the following conditions prior to that time point:  
 
a) Discontinuation of drug;  
b) Change in background t herapy not allowed in the protocol;  
c) Change in background ART substitutions permitted per protocol, unless t he decision 
to switch is documented as being before or at the first on -treatment visit after 
switching to OBT where HIV -1 RNA is assessed (Week 4)  or participant ’s HIV -
RNA is <400/<50 copies/mL before the switch . 
 
Participant s who only discontinued a backg round ARV or who had formula substitutions 
(substituting single agents for fixed dose combinations and vice versa of the same ARV) 
in their OBT are not considered as having OBT changes and will not be analyzed as 
virologic failures. Otherwise, virologic su ccess or failure will be determined by the last 
available HIV -1 RNA assessment while the participant  is on -treatment within the visit of 
interest window. The proportions of participant s meeting the criteria for virologic success 
at each of these time point s will be bounded by exact 95% confidence intervals, and will 
be presented in the aggregate and broken down by age cohort  and by weight band.  
 
 
IMPAACT P1093, Version 5.0  Page 76 of 135 12 July 2018   Table 18: Percent of Participant s Meeting Criterion for Virologic Success with Exact 95% 
Confidence Intervals  
N % Undetectable RNA  95% C.I.  
10 10% 0.3% -- 45% 
20 10% 1% -- 32% 
40 10% 3% -- 24% 
60 10% 4% -- 21% 
80 10% 4% -- 19% 
100 10% 5% -- 18% 
10 30% 7% -- 65% 
20 30% 12% -- 54% 
40 30% 17% -- 47% 
60 30% 19% -- 43% 
80 30% 20% -- 41% 
100 30% 21% -- 40% 
10 50% 19% -- 81% 
20 50% 27% -- 73% 
40 50% 34% -- 66% 
60 50% 37% -- 63% 
80 50% 39% -- 61% 
100 50% 40% -- 60% 
10 70% 35% -- 93% 
20 70% 46% -- 88% 
40 70% 53% -- 83% 
60 70% 57% -- 81% 
80 70% 59% -- 80% 
100 70% 60% -- 79% 
10 90% 55% -- 99.7%  
20 90% 68% -- 99% 
40 90 % 76% -- 97% 
60 90% 79% -- 96% 
80 90% 81% -- 96% 
100 90% 82% -- 95% 
 
Table 18 presents exact 95% confidence intervals around various potential rates of 
virologic success which might be observed in a total sample of 100 participant s or in 
subsamples of various sizes (N= 10, 20, 40, 60, 80). Participant s whose OBT is changed 
after initial optimization will be considered treatment failures in these analyses, unless 
the change is one specifically allowed by the protocol.  
CD4/8    
 
Change in CD4/8 count and percent from baseline to weeks 24 and 48 will be bounded by 
95% confidence intervals and presented in the aggregate and broken down by age cohort , 
by accrual to Stage I vs. Stage II  and by weight band.  
 
 
IMPAACT P1093, Version 5.0  Page 77 of 135 12 July 2018   HIV Drug Resistance    
 
The incidence of HIV drug resistance will be presented descriptively at baseline and at 
the point of failure for participant s who meet the criteria for virologic failure . Participant s 
will be evaluated for HIV genotypic and phenotypic drug resistance to the OBT and to 
DTG . Analysis results will be  presented in aggregate, by cohort and by weight band.  
 
Interim Analysis of Data from Cohort I  
 
An interim analysis based upon the 24 week data from Cohort s I and IIA  was performed . 
This focus of this analysis was primarily on safety data, presented as des cribed in Section 
8.6.2.1  and pharmacokinetic data, as described in Section 0. A secondary  analysis of 
virologic success, as described in Section 8.6.2.2  was also p erformed .  The results of 
these analyses w ere used as part of a regulatory submission for pediatric use of DTG .  
 
8.7 Monitoring  
 
The study will be monitored by the Protocol Team, which includes Protocol Co -Chairs, Medical Officers, 
Pharmacologists, Statisticians, Data Managers, and GlaxoSmithKline  representat ives. The Protocol Team 
will review safety and pharmacokinetic data with the aim of determining the optimal dose for each cohort  
and weight band , while protecting participant  safety.  
 
Participant Safety  
 
The Protocol Team will closely monitor participant safety through routine review of safety and toxicity 
reports summarizing laboratory and clinical data from the study data base (CRFs and laboratory data).  
The Protocol Team will review these reports via conference call or other meeting at least twice a mon th 
during the dose finding stage (Stage I)  and less frequently  thereafter . The data required for the toxicity 
reports must be entered into the database within 48 hours of the time at which the results of the laboratory 
tests or clinical examinations become available.   
 
In addition to regular safety and toxicity reviews by the Protocol Team, according to standard IMPAACT 
proce dures an SMC  will provide impartial independent reviews in situations where participant  safety is in 
question .   
 
If the Protocol Team  identifies any potentially treatment -related toxicities, which may compromise 
participant  safety, it will determine wheth er the study needs to be suspended or modified . If this occurs, 
the SMC  will review all relevant data and will determine whether, and under what conditions, the study 
will be allowed to proceed . 
 
8.7.1 Rules for Suspending Accrual to Assess Safety Following an Adverse Event  
 
Accrual will be temporarily suspended if any participant  has a life threatening drug-related 
adverse event or any Grade 4 event that may not be judged to be life -threatening but is judged to 
be probably or definitely attributabl e to the study medication . Following temporary suspension of 
accrual, the team will further review the safety data within 48 hours of notification of the event to 
determine if continuation of accrual is appropriate . If the team  agrees that the study drug i s likely 
to be safe for additional participant s, they may allow accrual to resume . The SMC will be 
informed of this decision, and the study will not reopen without the approval of th e SMC.  
Regulatory agencies will be notified of the event and the team’s d ecision after this review of the 
safety data has taken place .  
 
IMPAACT P1093, Version 5.0  Page 78 of 135 12 July 2018    
8.7.2 Accrual Rate Evaluation  
 
Accrual to this study will be monitored by the IMPAACT leadership in accordance with standard 
operating procedures. The team will monitor feasibility quarterly  based on accrual .  If any open 
Cohort has not accrued half its participant s within 6 months of opening, the team will identify the 
reasons for lack of accrual and determine whether/how the issues can be addressed with the SMC.  
 
 
9.0 CLINICAL PHARMAC OLOGY PLAN  
 
9.1 Pharmacology Objectives  
 
The clinical pharmacology objectives are:  
 
1. To evaluate the steady -state pharmacokinetics of DTG and its various formulations  in combination 
with other ARV s in treatment -experienced HIV -1 infected infants, children and adolescents and to 
determine the dose of DTG that achieves a targeted C24h (primary PK endpoint) and AUC0 -24 
(secondary PK endpoint) in this population .  
 
2. To evaluate the steady state plasma concentration profiles and pharmacokinetic parameters of DTG  
administered as the film-coated tablet , the oral-granules for suspension  and the dispersible tablet -  
pediatric  formula tions . 
 
3. To determine DTG exposure, its variability and clinical covariates that impact DTG disposition (e.g. 
age, weight) using intensive and sparse sampling and population pharmacokinetic analysis . 
 
9.2 Primary and Secondary Data  
 
All concentration -time samples will be registered in the LDMS database. All PK samples (including 
intensive and population PK) will be sent to the University of Alabama (UAB) Laboratory  (see the 
Laboratory Processing Chart) . The study database will be kept  up to date by close tracking of samples. As 
part of Stage I, the i ntensive PK sample assays and pharmacokinetic calculations will be performed in 
real-time and the results will be reported and discussed with the Protocol Team .  
 
9.2.1 Intensive PKs (Stage I onl y) 
 
Steady -state pharmacokinetic parameters will be determined from plasma concentration -time 
profiles using non -compartmental methods ( Phoenix WinNonlin 8.0, Certara, Princeton, NJ) . 
Calculated pharmacokinetic parameters will be: area -under -the-curve (AUC 0-24), maximum 
plasma concentration (C max), time to C max (tmax), plasma concentration observed at end of 24 hour 
dosing interval (C 24h), plasma concentration observed immediately to dosing of 24 hour dosing 
interval (C 0), minimum plasma concentration (C min), apparent clearance (CL/F), apparent volume 
of distribution (Vz/F), and terminal half -life ( t1/2). AUC 0-24 will be determined using the linear -log 
trapezoidal rule. Cmax, Tmax , C0, C24h, and C min will be taken directly from the ob served 
concentration -time data.  
 
Intensive PK sampling will be conducted between days 5 and 10 , after study drug i nitiation , and 
over the course of approximately 24 hours . The pharmacokinetic evaluation should be schedule d 
so that a witnessed dosing of DTG is as close as possible to 24 hours (generally 22 -26 hours) after 
the previous dosing.  One sample will be collected pre -dose and 7 samples will be collected post -
 
IMPAACT P1093, Version 5.0  Page 79 of 135 12 July 2018   dose, at 1, 2, 3, 4, 6, 8 and 24 hours  post-dosing, per fo otnotes in  Appendix  IA and Appendix IC  
The 24 -hour sample must be collected prior to the next dose. To allow for some flexibility, the 8 -
hour sample can be collected with a window of 7 -9 hours post -dose and the 24 -hour sample 
within a window of 22 -26 hours.  Actual sampling time will be recorded and used in the PK 
analysis.   US sites will ship intensive PK samples in real time to UAB; all non -US sites will ship 
PK samples in real time to  the BRI repository for a ‘pass -through’ (see LPC for instructions).  
 
Study staff will review the r egimen, dosage, dosing intervals, and timing relative to meals with 
participants or their caregivers in advance of the visit. The importance of adherence to the study 
drug and of reporting non -adherence will be emphasized. The date and time of doses taken 3 days 
prior to the PK visit should be recorded. The a ctual sampling time recorded on the CRF will be 
used in the PK analysis.  Participants should have no missed doses 3 days prior to the scheduled 
intensive PK visit. The PK visit  should be scheduled so t hat the pre -dose PK samples and the 
witnessed dosing of DTG are as close as possible to 24 hours (generally 22 -26 hours) after the 
previous dosing. Participants should have been adherent in taking their medications for 3 days 
prior to the intensive PK visit; otherwise the intensive PK visit should be re -scheduled. 
Participants who vomited within 4 hours after dosing, or who cannot complete the PK that day for 
any other reason, the PK shoul d be cancelled and MUST be rescheduled AND completed within 
the following 7 days.  
 
Additionally, any participant who cannot have  the intensive PK visit completed within 5 -10 days 
of study drug initiation, must have the visit completed within 17 days of stu dy drug initiation . 
The participant will remain on study and be included for safety analyses but will be replaced for 
PK analyses.  
 
Intensive PK sampling will be done in a fasting state and sites will follow the instructions as 
described below in Sections 9.2.1.1  and 9.2.1.2 . If upon review of PK data, the Protocol Team 
determines that an additional evaluation of PK should be performed in a non -fasted state , the 
team will notify the sites to which cohorts or weig ht bands this will apply and sites will follow the 
instructions in Section 9.2.1.3 . 
 
9.2.1.1  Sampling with Fasting ( Cohorts I, II III , and III -DT) 
 
The guidelines for intensive PK sampling in Cohorts I, II, III and III -DT while fasting 
follow:  
 
• Participants must be fasted for 6 hours prior to dosing  on the intensive PK day .  
• ≥6 hours PRIOR to dosing – participants may eat and drink without restriction  
• ≥4 to <6 hours PRIOR to dosing – milk, apple/orange juice and water may be 
consumed; No food  
• <4 hours PRIOR to dosing – water ONLY  
• From dosing to <2 hours POST dose – apple/orange juice and water may be 
consumed; No food  
• From ≥2 to <4 hours POST dose – participants may drink apple/orange juice and eat 
a snack/light meal (around 100 -150 calories). High fat foods should be avoided.  
• From ≥4 hours POST dose onwards – participants may eat and drink without 
restriction  
 
 
IMPAACT P1093, Version 5.0  Page 80 of 135 12 July 2018   9.2.1.2  Sampling with Fasting (Cohorts IV , IV-DT, and V -DT) 
 
The guidelines for intensive PK  sampling in Cohorts IV, IV -DT, and V -DT while fasting 
follow:  
 
• Participant s should not ingest breastmilk, formula or any other high fat food/liquid) 
for 2 hours prior to and 1 hour after dosing on the intensive PK day.  
• Water and other fluids (i.e. apple/orange juice (with the exceptio n of grapefruit juice) 
and oral rehydration solution) ) can be taken at any time.   
• Participant s may consume a light meal of their choice four hours after dosing on the 
intensive PK day.  
 
9.2.1.3  Sampling Non-Fasting (All Cohorts)  
 
If upon review of PK data, the P rotocol Team determines that collected PK data supports 
an additional evaluation of PK in a non -fasted state, the Protocol Team will notify the 
sites to which cohorts or weight band groups this will apply.  Sites will be informed if 
there are restrictions on the choice or quantity of food permitted prior to, and during the 
day of intensive PK sampling.  However, all food must be consumed within 30 minutes 
prior to dose administration. All PK sample collection and processing procedures will 
remain the same a s for fasting.  
 
9.2.2 Population PK (Stage I and II) 
 
Population pharmacokinetic ev aluations will be scheduled at W eeks 4, 12 and 24 . In addition 
population PK sampling will be scheduled for participant s who have completed 24 weeks of 
follow -up and who have switched from granules for suspension  to dispersible tablets. Population 
PK will be collected at the 2 -week post -switch visit and at the next scheduled visit per footnotes 
in the relevant Schedules of Evaluations.  These evaluations should be scheduled so that the pre -
dose PK sample and the witnessed dosing of DTG are as close to possible to 24 hours (generally 
22-26 hours) after the previous dose.  
 
9.2.2.1  Cohorts I, II, and III  
 
In all cases, the participant  will need to provide a self -reported time and date of their last 
dose. Appendix  IA and Appendix IB  footnotes describe the sampling time points  for 
Stage I and II respectively .  
 
9.2.2.2  Cohorts IV , IV-DT and V -DT 
 
In all cases, the participant  will need to provide a self -reported time and date of their last 
dose.  Appendix IC  andAppendix ID  Schedule of Evaluations   
Cohorts IV, IV -DT, and V -DT – Stage IIAppendix ID  footnotes describe the sampling 
time points  for Stage I and II respectively .  
 
These data will be pooled to build a population pharmacokinetic model to assess pediatric 
DTG exposure and possible changes in exposure during the study. This population 
pharmacokinetic model will be created using NONMEM version V II (or similar 
software) or higher  software program. The model may also be used to determine if 
covariates, such as age, weight, sex, BSA, and  concomitant medications alter DTG 
pharmacokinetic parameters in pediatric participant s.  
 
IMPAACT P1093, Version 5.0  Page 81 of 135 12 July 2018    
9.3 Evaluation of PK Exposures for Cohorts and Weight Bands  
 
The target population exposure (GM) for C 24h is 995 ng/mL, with an acceptable range of 697– 2,260 
ng/mL. The target population exposure (GM) for AUC 0-24 target is 46 µg.h/mL, with an acceptable range 
of 37 -134 µg.h/mL.  Rationale for these targets is provided in Section 1.6.  At the mini -cohort stage, the 
PK parameters for the four participants will be reviewed to ensure that individual  PK parameter values are 
not so extreme as to be unsafe for the participant or make attainment of the target values for the 
population exposure - the GM of all participants at the end of Stage I - unlikely.  At the completion of 
Stage I, the GMs  of C 24h and AUC 0-24 of cohorts and independent weight  bands will be evaluated by the 
Protocol Team  to determine if a dose is acceptable or not  for that respective group .  As the primary target, 
the GM C 24h will be weighted most heavily in this decision, but AUC 0-24 as well as participant specific 
factors that may have altered the PK data will also be considered.  
 
If on review of all PK and safety data the dose is not acceptable, a  new test dose (i.e. dosing table) will be 
determined .  
The ultimate decision about a new test dose may also be guided by other data from this study (e.g. drug 
clearance , CV in different ages) as well as information about DTG metabolism, safety, or efficacy 
generated outside the context of this protocol.  Additionally, PK m odeling work will be used to assist in 
new dose decisions.  If there is disagreement among the Protocol Team, the study monitoring committee 
(SMC) will be asked to review the data . Further information on the SMC can be found in Section 8.7. 
 
Of note, DTG is dosed for P1093 participants according to dosing tables in which participants within a 
given weight range are given the same quanti ty of a formulation  (DT, film -coated tablets). While dosing 
tables may target a certain mg/kg dose overall, individual participants with weights on the edges of 
weight bands will inevitably receive a range o f mg/kg dosing  which may result in a wide range of drug 
exposure, espe cially in younger populations. The Protocol T eam will monitor the range of exposures 
within age cohorts and within weight band  groups  that cross age cohorts.  In addition, enrollment within a 
cohort or weight band might be evenly distributed or  skewed towards an extreme, which could limit 
generalization for populations likely to be treated with DTG in the future. The Protocol Team will 
continue to monitor enrollment to ensure that information from a normally distributed population is 
collected s o that appropriate dosi ng guidelines can be formulated  If this goal is not being met, the 
Protocol Team reserves the right to reopen an age or weight band cohort to include a subset o f 
participants who were underrepresented in that full group’s analysis . For example, this may include the 
smallest infants within the 3 -6 kg weight band.   
 
9.4 Evaluation of PK Exposures for Individual Dose Modification  
 
If the C 24h and/or AUC 0-24 of any individual participant fall s outside of the  individual target ranges  (refer 
to Table 9) the Protocol Team will consider all clinical, pharmacologic, immunologic and virologic data  
to determine if it in the participants b est interest to continue or if the dose should be modified.  Additional 
PK sampling may be performed , at the discretion of the Protocol Team and site investigators, if felt to be 
in the best interest of participants , refer to Section 6.4.  
 
 
10.0 HUMAN SUBJECTS PROTECTIONS     
 
The Division of AIDS has concluded that this protocol does NOT meet Federal requirements governing 
prisoner participation in clinical trials and should NOT be considered by local IRBs / ECs for the 
recruitment of prisoners.  
 
IMPAACT P1093, Version 5.0  Page 82 of 135 12 July 2018    
10.1 Institutional Review Board/Ethics Committee Review and Approval  
 
Prior to study initiation, site investigators must obtain IRB/EC review and approval of this protocol and 
site-specific I CFs in accordance with 45 CRF 46; subsequent to initial review and approval, IRBs/ECs 
must review the study at least annually . Site investigators must also promptly report to the IRB/EC any 
changes in the study and any unanticipated problems involving risk s to participant s or others.  
 
All IRB/EC policies and procedures must be followed and complete documentation of all correspondence 
to and from the IRBs/ECs must be maintained in site essential document files . Sites must submit 
documentation of both initial review and approval and continuing review to the DAIDS Protocol 
Registration Office (PRO) in accordance with the DAIDS Protocol Registration Manual (see also Section 
4.4). 
 
10.2 Vulnerable Participant s  
 
The NIH is mandated by law to ensure that children be included in clinical research when appropriate. 
This study responds to that mandate and will provide clinical research  data to inform ARV treatment 
guidelines for pediatric populations . Nonetheless, the children who take part in this study are considered 
vulnerable participant s per the U .S. Code of Federal Regulations, and site IRBs/ECs must consider the 
potential risks a nd benefits to infant and child participant s as described in 45 CFR 46 Subpart D (for 
children).  
 
With respect to 45 CFR 46 Subpart D, IRBs/ECs must determine the level of risk to children in the 
categories specified in 45 CFR 46.404 -407. Documentation of this determination is required to complete 
the DAIDS protocol registration process described in Section 4.4, and the risk category assigned by the 
IRB/EC further d etermines the parental informed consent requirements for the study at each site . Per 45 
CFR 46.408 (b), the IRB/EC may find that the consent of one parent is sufficient for research to be 
conducted under 46.404 or 46.405 . If the IRB/EC finds that the research is covered by 46.406 or 46.407, 
both parents must give their consent, unless one parent is deceased, unknown, incompetent, or not 
reasonably available or when only one parent has legal responsibility for the care and custody of the child 
(as deter mined locally) . IRBs/ECs must document their risk determination, and study sites should adapt 
the signature pages of their site -specific ICFs as needed to accommodate the parental consent 
requirements associated with the IRB/EC determination . However, it i s generally expected that the 
consent of one parent is sufficient for this study.  
 
Study sites must comply with the requirements of the DAIDS policy on Enrolling Children (including 
Adolescents) in Clinical Research, which is available at: https://www.niai d.nih.gov/research/daids -
clinical -research -policies -standard -procedures . 
 
10.3 Informed Consent   
 
Written informed consent for study participation will be obtained before any study -specific procedures 
are performed . The informed consent process will be conduct ed prior to screening .  
 
The informed consent process will include information exchange, detailed discussion, and assessment of 
understanding of all required elements of informed consent, including the potential risks, benefits, and 
alternatives to study participation . Written informed consent must be obtained from the participant  (or 
parents or legal guardians of participant s who cannot consent for themselves, such as those below the 
legal age). The participant 's assent must also be obtained if he or she is able to understand the nature, 
significance, and risks of the study. The informed consent will describe the purpose of the study, the 
 
IMPAACT P1093, Version 5.0  Page 83 of 135 12 July 2018   procedures to be followed, and the risks and benefits of participation. A copy of the consent for m will be 
given to the participant  (or parent or legal guardian).  
  
Participant s providing assent or parents or legal guardians will also be asked whether they agree to 
storage and future research testing of biological specimens remaining after all protoc ol-specified testing 
has been completed . Future research testing of residual specimens may be declined with no impact on 
other aspects of study participation .  
 
It is generally expected that only one parent or legal guardian will provide informed consent f or the 
child’s participation in this study . However, parental consenting requirements at each site will depend on 
the IRB/EC risk determination described in Section 10.2; all IRB/EC requirements will be followed .  
 
Should the consenting parent (or guardian) of a participant die sites should follow the guidelines 
described by their IRBs/ECs.  Study sites may continue to provide care for the participant as needed and 
appropriate (outside of the study), consistent with local standard of care.  If a guardian cannot be 
identified, or if the guardian does not consent to continued study participation, the participant must be 
withdrawn from the study.  In accordance with the DAIDS policy on Enrolling Children (including 
Adole scents) in Clinical Research (available at the website referenced in Section 10.2, all sites must 
establish and maintain written procedures describing the standard s that will be followed to identify who 
may serve as guardian for an enrolled child or adolescent, reflective of applicable IRB/EC guidance for 
conduct of human subjects research within the context of available local law, regulation, or government 
policy.   
 
Participants  may also reach the legal age of consent during follow -up.  In this case, written informed 
consent for continued participation and specimen storage and future use will be obtained from participants 
once they reach legal age at their next stu dy visit.  If participants do not consent for continued study 
participation, they should be discontinued from the study; similarly, if they do not consent for specimen 
storage and future use, all specimens will be destroyed after all protocol -related testi ng is complete.  
 
10.4 Essential and Source Documents and Access to Source Data  
 
All DAIDS policies referenced in this section are available at:  
https://www.niaid.nih.gov/research/daids -clinical -research -policies -standard -procedures  
 
Study sites must comply with DAIDS policies on Requirements for Essential Documents at Clinical 
Research Sites Conducting DAIDS Funded and/or Sponsored Clinical Trials and Requirements for 
Source Documentation in DAIDS Funded and/or Sponsored Clinical Tria ls. In its policy on 
Requirements for Manual of Operational Procedures, DAIDS requires sites to establish SOPs for 
maintaining essential and source documents in compliance with these policies. Site SOPs should be 
updated and/or supplemented as needed to de scribe roles, responsibilities, and procedures for this study, 
and site SOPs should be followed throughout the study.  
 
Per the DAIDS policy on Storage and Retention of Clinical Research Records, study records must be 
stored in a manner that ensures privac y, confidentiality, security, and accessibility during the conduct of 
the study and after the study is completed. Records must be retained for a minimum of three years after 
the completion of the study. Per 21 CFR 312.62, records must be maintained for two  years after the date 
a marketing application is approved for one or more of the study products for the indication for which it 
is evaluated in this study; or, if no application is filed, or if the application is not approved for this 
indication, records m ust be retained two years after the study is discontinued and the FDA is notified.  
 
 
IMPAACT P1093, Version 5.0  Page 84 of 135 12 July 2018   All study records must be accessible for inspection, monitoring, and/or auditing during and after the 
conduct of the study by authorized representatives of the study spons ors and their contracted monitors, 
IMPAACT, GSK,  the FDA, site drug regulatory authorities, site IRBs/ECs, OHRP, and other US, local, 
and international regulatory entities. Records must be kept on -site throughout the period of study 
implementation; thereaf ter, instructions for off -site storage may be provided by NIAID or NICHD. No 
study records may be removed to an off -site location or destroyed prior to receiving approval from 
NIAID or NICHD . 
 
10.5 Participant  Confidentiality   
 
Study procedures will be conducted in private and every effort will be made to protect participant privacy 
and confidentiality to the extent possible. Participant information will not be released without written 
permission to do so except as necessary for review, monitoring, and/o r auditing. If any photographs of 
observed reactions are taken, standard precautions will be followed to ensure that participant privacy and 
confidentiality are protected.  
 
All study -related information will be stored securely. Participant research records  will be stored in locked 
areas with access limited to study staff. All laboratory specimens, CRFs, and other documents that may be 
transmitted off -site (e.g., EAE report forms) will be identified by PID only. Likewise, communications 
between study staff a nd Protocol Team members regarding individual participants will identify 
participants by PID only.  
 
Study sites are encouraged but not required by DAIDS policies to store study records that bear participant 
names or other personal identifiers separately f rom records identified by PID. All local databases must be 
secured with password protected access systems. Lists, logbooks, appointment books, and any other 
documents that link PID numbers to personal identifying information should be stored in a separate,  
locked location in an area with limited access.  
 
10.6 Study Discontinuation    
 
The study may be discontinued at any time by NIAID, the IRB or EC, GSK, the FDA, OHRP,  IMPAACT  
or other country -specific governmental agencies as part of their duties to ensure th at research participant s 
are protected.  
 
10.7 Access to Dolutegravir at the Close of the Study  
 
Participant s will be transitioned into care and treatment outside of the study at the end of the study as per 
local standards. If the DTG formulations are not locally available  for a participant  completing study then 
DTG will be provided by the pharmaceutical partner s following the participant ’s completion of  the study 
through a mechanism outside of the protocol, or until one or more of the following events occur:  
 
• Until the age -appropriate formulations provided by the study are available from another source (e.g. 
government programs, aid programs, assistance programs etc.) to all participant s in each specific 
country; OR  
• Until participant s are no longer deriving benefit; OR  
• Until clinical development of DTG is terminated .  
 
 
IMPAACT P1093, Version 5.0  Page 85 of 135 12 July 2018   10.8 Reimbursement/Compensation  
 
Pending IRB/EC a pproval, participants will be reimbursed for costs associated with completing study 
visits (e.g., transport costs). Reimbursement amounts will be specified in site -specific informed consent 
forms and/or other materials as applicable per IRC/EC policies and  procedures. (3) 
 
10.9 Management of New Information Pertinent to Study Participation  
 
Study staff will provide parents or guardians with any new information learned over the course of the 
study that may affect their willingness to allow their children to continue receiving study drug and/or 
remain in follow -up in the study . 
 
 
11.0 PUBLICATION OF RESEARCH FINDINGS    
 
Publication of the results of this trial will be governed by IMPAACT policies . Any presentation, abstract, 
or manuscript will be made available for review by the GlaxoSmithKline  prior to submission.  
 
 
12.0 BIOHAZARD CONTAINMENT    
 
As the transmission of HIV and other bloo d borne pathogens can occur through contact with 
contaminated needles, blood, and blood products, appropriate blood and secretion precautions will be 
employed by all personnel in the drawing of blood and shipping and handling of all specimens for this 
study, as currently recommended by the Centers for Disease Control and Prevention.  
All infectious specimens will be transported in compliance with Federal Regulations and the International 
Air Transport Association Dangerous Goods Regulations -Packing Instructi on 602. Refer to individual 
carrier guidelines (e.g. Federal Express or Airborne) for specific instructions and to the ACTN Guidelines 
for Shipment and Receipt of Category B Biological Substance Shipment  and ACTN Instruction for 
Overnight Shipments documen ts at: 
http://www.hanc.info/labs/labresources/procedures/Pages/actnShippingDemo.aspx  
 
 
13.0 REFERENCES    
 
1. Services USDoHaH. Guidelines for the Use of Antiretroviral Agents in Pediatric 
HIV2018 17 Mar 2018. Available from: 
https://aidsinfo.nih.gov/contentfiles/lvguidelines/PediatricGuidelines.pdf . 
2. Organization WH. Consolidated guidelines for the use of antiretroviral drugs for treating 
and preventin g HIV infection. 2016.  
3. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio MA, et al. Decline in 
the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 
2003;362(9377):22 -9. 
4. Mocroft A, Ledergerber B, Katlama C, Kir k O, Reiss P, d'Arminio Monforte A, et al. 
Decline in the AIDS and death rates in the EuroSIDA study: an observational study. 
Lancet. 2003;362(9377):22 -9. 
 
IMPAACT P1093, Version 5.0  Page 86 of 135 12 July 2018   5. Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GR, III, et al. Effect 
of combination therapy including protease inhibitors on mortality among children and 
adolescents infected with HIV -1. NEnglJ Med. 2001;345(21):1522 -8. 
6. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, et al. Inhibitors of 
strand transfer tha t prevent integration and inhibit HIV -1 replication in cells. Science. 
2000;287(5453):646 -50. 
7. Zolopa AR, Berger DS, Lampiris H, Zhong L, Chuck SL, Enejosa JV, et al. Activity of 
elvitegravir, a once -daily integrase inhibitor, against resistant HIV Type 1: results of a 
phase 2, randomized, controlled, dose -ranging clinical trial. J InfectDis. 2010;201(6):814 -
22. 
8. Seki T, Kobayashi M, Wakasa -Morimoto C, Yoshinaga T, et.al. S /GSK1349572 Is a 
Potent Next Generation HIV Integrase Inhibitor and Demonstrates  a Superior Resistance 
Profile Substantiated with 60 Integrase Mutant Molecular Clones. 17th Conference on 
Retroviruses and Opportunistic Infections, 2010. 2010.  
9. Fransen S, Gupta S, Danovich R, Hazuda D, Miller M, Witmer M, et al. Loss of 
raltegravir su sceptibility by human immunodeficiency virus type 1 is conferred via 
multiple nonoverlapping genetic pathways. J Virol. 2009;83(22):11440 -6. 
10. Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, et al. 
Broad antiretroviral activity and resistance profile of the novel human immunodeficiency 
virus integrase inhibitor elvitegravir (JTK -303/GS -9137). J Virol. 2008;82(2):764 -74. 
11. Sato A, et.al. S/GSK1349572 is a potent next generation HIV integrase inhibitor. 5th IAS 
Conference , Cape Town , 2009. 2009.  
12. Lalezari J, Sloan L, DeJesus E, et.al. Potent antiviral activity of S/GSK1349572, a next 
generation integrase inhibitor (INI), in INI -na‹ve HIV -1 infected patients. 5th IAS 
Conference on HIV Pathogenesis, Treatment, and Prevention; July 2 009; Cape Town, 
South Africa. 2009.  
13. Song I, et.al. Pharmacokinetic (PK) and pharmacodynamic (PD) relationship of 
S/GSK1349572, a next generation integrase inhibitor (INI), in HIV -1 infected patients. 
5th IAS Conference, Cape Town, 2009. 2009.  
14. Raffi  F, Jaeger H, Quiros -Roldan E, Albrecht H, Belonosova E, Gatell JM, et al. Once -
daily dolutegravir versus twice -daily raltegravir in antiretroviral -naive adults with HIV -1 
infection (SPRING -2 study): 96 week results from a randomised, double -blind, non -
inferiority trial. The Lancet Infectious diseases. 2013;13(11):927 -35. 
15. Raffi F, Jaeger H, Quiros -Roldan E, Albrecht H, Belonosova E, Gatell JM, et al. Once -
daily dolutegravir versus twice -daily raltegravir in antiretroviral -naive adults with HIV -1 
infecti on (SPRING -2 study): 96 week results from a randomised, double -blind, non -
inferiority trial. The Lancet Infectious diseases. 2013;13(11):927 -35. 
16. Stellbrink HJ, Reynes J, Lazzarin A, Voronin E, Pulido F, Felizarta F, et al. Dolutegravir 
in antiretrovira l-naive adults with HIV -1: 96 -week results from a randomized dose -
ranging study. Aids. 2013;27(11):1771 -8. 
17. Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, et al. Safety and efficacy 
of dolutegravir in treatment -experienced subjects with ra ltegravir -resistant HIV type 1 
infection: 24 -week results of the VIKING Study. The Journal of infectious diseases. 
2013;207(5):740 -8. 
18. GlaxoSmithKline. Investigator's Brochure for GSK1349572. Supplement 01, 11 
December 2017 ed2017.  
 
IMPAACT P1093, Version 5.0  Page 87 of 135 12 July 2018   19. Buchanan AM, Holt on M, Conn I, Davies M, Choukour M, Wynne BR. Relative 
Bioavailability of a Dolutegravir Dispersible Tablet and the Effects of Low - and High -
Mineral -Content Water on the Tablet in Healthy Adults. Clin Pharmacol Drug Dev. 2017.  
20. Song I, et.al. Evaluation  of Antacid and Multivitamin (MVI) Effects on S/GSK1349572 
Pharmacokinetics (PK) in Healthy Subjects. Antimicrob Agents Chemother, 2010. 2010.  
21. Shapiro R. Birth Outcomes Surveillance in Botswana. United States National Institutes of 
Health; 2018.  
22. Zash R, Jacobson DL, Diseko M, Mayondi G, Mmalane M, Essex M, et al. Comparative 
Safety of Antiretroviral Treatment Regimens in Pregnancy. JAMA Pediatr. 
2017;171(10):e172222.  
23. WHO Statement on DTG: Potential safety issue affecting women living with HIV us ing 
dolutegravir at the time of conception [press release]. Geneva, 18 May 2018 2018.  
24. Shapiro R, Zash R. Personal communication. RE: DTG and NTD in Tsepamo study 
edMay 2018.  
25. Mofenson L. Personal communication  May 2018.  
26. Zash R, Jacobson DL, Mayo ndi G, Diseko M, Makhema J, Mmalane M, et al. 
Dolutegravir / tenofovir / emtricitabine (DTG/TDF/FTC) started in pregnancy is as safe 
as efavirenz / tenofovir / emtricitabine (EFV/TDF/FTC) in nationwide birth outcomes 
surveillance in Botswana.  Internationa l AIDS Conference; 23 -26 July 20172017.  
27. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry 
International Interim Report for 1 January 1989 through 31 January 2017. Wilmington, 
NC: Registry Coordinating Center2017.  
28. Kobbe RS, Stein; Dunay, Gabor; Eberhard, Johanna M.; Schulze -Sturm, Ulf; Hollwitz, 
Bettina; Degen, Olaf; Teulen, Marga; Colbers, Angela; Burger, David. Dolutegravir in 
breast milk and maternal and infant plasma during breastfeeding. AIDS. 
2016;30(17):27 31-3. 
29. Fettiplace A, Stainsby C, Winston A, Givens N, Puccini S, Vannappagari V, et al. 
Psychiatric Symptoms in Patients Receiving Dolutegravir. Journal of acquired immune 
deficiency syndromes (1999). 2017;74(4):423 -31. 
30. Viani RM, Alvero C, Fenton T,  Acosta EP, Hazra R, Townley E, et al. Safety, 
Pharmacokinetics and Efficacy of Dolutegravir in Treatment -experienced HIV -1 Infected 
Adolescents: Forty -eight -week Results from IMPAACT P1093. The Pediatric infectious 
disease journal. 2015;34(11):1207 -13. 
31. UNAIDS. 2015 progress report on the global plan towards the elimination of new HIV 
infections among children and keeping their mothers alive  2015.  
32. Fitzgerald F, Penazzato M, Gibb D. Development of antiretroviral resistance in children 
with HIV in lo w- and middle -income countries. The Journal of infectious diseases. 
2013;207 Suppl 2:S85 -92. 
33. Kuhn L, Hunt G, Technau KG, Coovadia A, Ledwaba J, Pickerill S, et al. Drug resistance 
among newly diagnosed HIV -infected children in the era of more efficacious 
antiretroviral prophylaxis. Aids. 2014;28(11):1673 -8. 
34. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for 
treating and preventing HIV infection: What's New. 2015.  
35. Penazzato M, Prendergast A, Tierney  J, Cotton M, Gibb D. Effectiveness of antiretroviral 
therapy in HIV -infected children under 2 years of age. The Cochrane database of 
systematic reviews. 2012;7:Cd004772.  
 
IMPAACT P1093, Version 5.0  Page 88 of 135 12 July 2018   36. Newell ML, Coovadia H, Cortina -Borja M, Rollins N, Gaillard P, Dabis F. Mortality  of 
infected and uninfected infants born to HIV -infected mothers in Africa: a pooled 
analysis. Lancet. 2004;364(9441):1236 -43. 
37. Panel on Opportunistic Infections in HIV -Exposed and HIV -Infected Children. 
Guidelines for the Prevention and Treatment of Op portunistic Infections in HIV -Exposed 
and HIV -Infected Children. Department of Health and Human Services. 2013.  
38. National Department of Health SA. National Consolidated Guidelines for the prevention 
of mother -to-child transmission of HIV (PMTCT) and the  management of HIV in 
children, adolescents and adults. 2015.  
39. The Integrated National Guidelines on Antiretroviral Therapy, Prevention of Mother to 
Child Transmission of HIV and Infant & Young Child Feeding. The Republic of Uganda 
Ministry of Health. 2 011;1st, edition.  
40. Guidelines for the Use of Antiretroviral Agents in HIV -1-Infected Adults and 
Adolescents. U.S. Department of Health and Human Services; 2015.  
41. (EMA) EMA. Summary of Product Characteristics, Delamanid. . 2014.  
42. Services USDoHaH. Dolutegravir (TIVICAY) Drug Information 2018 [Available from: 
https://aidsinfo.nih.gov/drugs/509/dolutegravir/167/professional#nlm34069 -5. 
43. World Health O. Antiretroviral therapy of HIV infection in infants and children: Towards 
universal access. 2006.  
 
 
IMPAACT P1093, Version 5.0   Page 89 of 135  12 July 2018  Appendix IA  Schedule of Evaluations   
Cohorts I, IIA, IIB, III and III -DT – Stage I  
 
Screen through Week 48  
 
 
Screen  1 Entry 
12 
Day 0  Intensive 
PK  
Day 5 -10 Week  
4 Week  
8 Week 
12 Week 
16 Week 
24 Week 
32 Week 
40 Week 
48 
Visit Windows  - - - ±1 
wk ±1 wk ±1 wk ±1 
wk ±2 wks ±2 
wks ±2 
wks ±2 wks 
CLINICAL EVALUATIONS             
Informed Consent  X           
History and Physical exam 2 X X X X X X X X X X X 
Tanner Staging 3  X         X 
Adherence Questionnaire    X X X X X X X X X 
CDC Classification   X      X    
Palatability Assessment    X X    X    
LABORATORY EVALUATIONS            
Hematology   1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 
Chemistries 4 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 
Lipid profiles 5 1mL       1mL   1mL 
PBMCs / plasma for storage 
(includes integrase resistance 
sample)   7mL       6.5mL   6.5mL 
Urinalysis  X    X   X   X 
Microalbumin/creatinine ratio  
urine6  X   X   X   X 
Pregnancy test7 X X X X X X X X X X X 
Virology             
HIV-1 RNA PCR  3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 
Genotyping   2mL           
Phenotyping 8 2mL           
Immunology             
Lymphocyte subsets 9 1mL 1mL    1mL  1mL 1mL 1mL 1mL 
Pharmacokinetic studies             
STAGE I - Intensive PK 10   4mL         
STAGE I - Population PK 11    1mL  0.5mL  1mL    
Total Maximum Blood 
Volumes  20 11mL 13mL 9mL 6mL 5mL 6.5mL 5mL 14.5mL 6mL 6mL 13.5mL 
  
 
IMPAACT P1093, Version 5.0   Page 90 of 135  12 July 2018   
Appendix IA Schedule of Evaluations  (cont’d)  
Cohorts I, IIA, IIB, III and III -DT – Stage I   
Virologic Failure, Dose Adjustment and Premature/DC of Study Drug Visits  
 
 
Confirm  
Suspected virologic failure  13 Virologic Failure  
14 [Dose Adjustment  
PK Visit ]  15 [Dose 
Adjustment  
Safety 
Visit]  16 Premature /DC 
of Study Drug  
On study  17 
Visit Windows   - If requested, 5 to 14 days after initiation 
of the dose adjustment  4 weeks 
post dose 
modification  
(-1 wk/ + 2 
wk)  - 
CLINICAL EVALUATIONS       
Informed Consent       
History and Physical exam 2  X  [X] X 
Tanner Staging 3      
Adherence Questionnaire   X  [X] X 
CDC Classification   X   X 
Palatability Assessment       
LABORATORY EVALUATIONS      
Hematology    1mL   1mL 
Chemistries 4  1mL   1mL 
Lipid profiles 5      
PBMCs / plasma for storage 
(includes integrase resistance 
sample)   
6.5mL   
 
Urinalysis       
Micro albumin/creatinine ratio -  
urine6      
Pregnancy test7  X   X 
Virology       
HIV-1 RNA PCR  3mL 3mL   3mL 
Genotyping    2mL18   2mL18,19 
Phenotyping 8  2mL   2mL19 
Immunology       
Lymphocyte subsets 9  1mL   1mL 
Pharmacokinetic studies       
STAGE I - Intensive PK 10   [4mL]   
 
IMPAACT P1093, Version 5.0   Page 91 of 135  12 July 2018  STAGE I - Population PK 11   [0.5 – 1mL]   
Total Maximum Blood 
Volumes  20 3mL 16.5mL [0.5 – 4mL]  10mL 
Appendix IA Footnotes  
 
1. After obtaining Informed Consent, evaluations should be completed within 30 days prior to study entry.  
 
2. History and physical exam (including height, weight, vital signs [temperature, pulse, respirations and blood pressure ), occurrence of adverse events si nce last study 
visit and HIV -1 associated conditions). Weight should be measured without shoes and with minimal clothing.   For female participants 9 years of age and older, 
menarche status and for participants who have reached menarche;  sexual activity and  contraceptive use.  
 
3. For information on Tanner Staging assessment, see P1093 MOP.  
 
4. Electrolytes (sodium, potassium, and HCO 3), glucose, creatinine, lipase, phosphorus, and LFTs. LFTs should include total bilirubin, indirect bilirubin, direct bilirubin, 
alkaline phosphatase, AST, ALT, and albumin. If indirect bilirubin is not reported by the site laboratory, it should be calcu lated at the site and documented.  
 
 The following (listed in order of preference) should be used to determine the upper limit of normal (ULN) values for indirect  bilirubin.  
a. “ULN ” values reported by the laboratory report for the test, or  
b. “ULN ” values routinely used/established by the site, or  
c. “ULN ” values as per the Harriet Lane Handbook (e.g. the current "ULN" for indirect bilirubin as per Harriet Lane Handbook is 0.4)  
 Sites must be consistent with the way toxicities are evaluated for all participant s in the study; sites should use the s ame source throughout the study. Remember to 
have documentation of calculated indirect bilirubin and source of "ULN", when not reported by your laboratory.  
 
5. Lipid Profile (triglycerides, cholesterol, HDL, LDL) will be drawn in a non -fasting state. However , if triglycerides are grade 2 (using DAIDS toxicity table for fasting 
triglycerides), a complete fasting state lipid profile (triglycerides, cholesterol, HDL, and LDL) must be drawn. Fasting inte rvals will be overnight or at least 8 hours. 
After a partici pant has had a grade 2 triglycerides in non -fasting state, all future triglycerides must be obtained in fasting state.   
 
6. M/C ratio – microalbumin / creatinine ratio (mcg/mg creatinine)  
 
7. Pregnancy test (urine or serum beta hCG) must be performed on all fema les of reproductive potential within 72 hours prior to enrollment. Subsequent tests should be 
performed at each visit. If a blood test is performed, collect 1.0 mL in a red top serum tube.  
 
8. Phenotyping will occur where there is sufficient blood volume colle cted. HIV-1 phenotyping will NOT be performed in real time and will NOT be used to determine 
optimized background therapy (OBT). Specimens should be stored at the local site and shipped in batches when requested by the  Protocol Team.  
9. Lymphocyte subset blood samples should be collected in EDTA tubes. These samples will be analyzed for CD4 and CD8.  
 
10. Refer to Section  9.2 for additional instru ctions  around intensive PK sampling.  
 
The pharmacokinetic evaluation should be scheduled so that witnessed dosing of DTG is as close as possible to 24 hours (gener ally 22 -26 hours) after the previo us 
dosing. Participants should have been compliant in taki ng their medications for 3 days prior to the intensive PK visit; otherwise the intensive PK visit should be re -
scheduled.  
 
Intensive PK should be done in a fasted state following the guidelines below and Section 9.2.1.1 , unless instructed otherwise by the Protocol Team .  
 
IMPAACT P1093, Version 5.0   Page 92 of 135  12 July 2018  • ≥6 hours PRIOR to dosing – participants may eat and drink without restriction  
• ≥4 to <6 hours PRIOR to dosing – milk, apple/orange juice and water may be consumed; No food  
• <4 hours PRIOR to dosing – water ONLY  
• From dosing to <2 hours POST dose – apple/oran ge juice and water may be consumed; No food  
• From ≥2 to <4 hours POST dose – participants may drink apple/orange juice and eat a snack/light meal (around 100 -150 calories)  
• From ≥4 hours POST dose onwards – participants may eat and drink without restriction  
 
For participants who vomit within 4 hours after dosing; PK must be cancelled and may be rescheduled. Blood samples (0.5 mL) will be collected at the following 
timepoints: pre -dose, 1, 2, 3, 4, 6, 8 and 24 hours post dosing . The 24 -hour sample must be coll ected prior to the next dose. To allow for some flexibility, the 8 -hour 
sample can be collected with a window of 7 -9 hours post -dose and the 24 -hour sample with a window of 22 -26 hours. US sites will ship intensive PK samples in real 
time to UAB; all non -US sites will ship PK samples in real time to BRI repository for a ‘pass -through’ (see LPC for instructions ). 
 
11. Blood samples (0.5mL per sample) will be collected per time point at Weeks 4, 12 and 24.  Participant s will have 2 blood sample collected at week 4: pre -dose and 2 -
4 hours post dose. At week 12, 1 blood sample will be collected at any time point post dose.  At week 24, 2 blood samples will be collected two hours apart between 
12 and 26 hours post -dose. Samples to be batched and shipped as described in the LPC. For sample collection timepoints for the ‘Two Weeks Post Swi tch Visit’ and 
‘Next Scheduled Visit af ter Post Switch Visit’ refer to footnotes 14 and 15 below. For participant s on BID dosing refer to the study MOP for sampling time points.  
 
12. Entry must occur within 30 days of screening.  
 
13. If a participant  meets a criterion for suspected virologic failure , as defined in Section 6.5, collect a confirmatory HIV -1 RNA PCR sample at least 1 week but not 
more than 4 weeks from the date of  specimen collection of the initial RNA PCR test. If a sample cannot be obtained within weeks, samples should be collected as 
soon as possible beyond 4 weeks.  
 
14. If a participant  is confirmed as having virologic failure , as defined in Section 6.5, conduct a Virologic Failure Visit at least one week and within four weeks later.  
 
15. Per Section 6.4, participants who underwent a dose modification and for whom additional PK sampling (intensive or population sampling) was requested by the 
Protocol Team  collect intensive or population PK samples (per Protocol Team request  only) 5 – 14 days after initiation of the DTG dose  adjustment . (If this visit is 
scheduled to occur during another scheduled visit a combined visit can be done and procedures do not need to be duplicated. )  
 
16. Per Section 6.4, for participant s who underwent a dose modification , as requested by the Protocol Team , a safety visit should be done 4 weeks ( - 1 wk/+ 2 wks) after 
initiation of the DTG dose adjustment. (If this visit is scheduled to occur during another scheduled visit a combined visit can be done and procedures do not need t o 
be duplicated.)  
 
17. Participant s, who discontinue study drug early, should remain on study a nd follow Appendix IF  .  
 
18. A baseline specimen should also be sent with the genotype virologic failure specimen. This specimen may be a baseline (Day 0 entry)  storage sample or left over 
sample from baseline genotyping (screening). Please refer to the Laboratory Processing Chart (LPC) for additional details.  
 
19. Only if not done at virologic failure.  
 
20. The blood volumes listed are ideal, but may not always be possi ble due to site -specific regulations or challenges with phlebotomy in certain participant s.  For 
insufficient blood draws, priorities are as follows: hematology; chemistry; pharmacokinetic studies; HIV -1 RNA; genotyping; lymphocyte subsets; plasma and 
PBMCs/plasma for storage; phenotyping; lipid profiles.  
 
IMPAACT P1093, Version 5.0   Page 93 of 135  12 July 2018   
Appendix IB  Schedule of Evaluations   
Cohorts I, IIA, III and III -DT – Stage II 
 
 
Screen1 Entry11 
Day 0  Day 
10 Week 
4 Week 
8 Week 
12 Week 
16 Week 
24 Week 
32 Week 
40 Week 
48 Confirm  
Suspect 
Virologic 
Failure12 Virologic 
failure13 Pre-mature 
DC of Study 
Drug/  
On study14 
Visit Windows  - - ±3 
days ±1 
wk ±1 
wk ±1 wk  ±1 
wk ±2 
wks ±2 
wks ±2 
wks ±2 
wks - - - 
CLINICAL EVALUATIONS               
Informed Consent  X              
History and Physical 
exam2 X X X X X X X X X X X  X X 
Tanner Staging 3  X         X    
Adherence 
Questionnaire    X X X X X X X X X  X X 
CDC Classification  X X      X     X X 
Palatability Assessment    X X    X       
LABORATORY EVALUATIONS              
Hematology   1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL  1mL 1mL 
Chemistries4 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL  1mL 1mL 
Lipid profiles5 1mL       1mL   1mL    
PBMCs / plasma for 
storage  (includes 
integrase resistance 
sample)   7mL      6.5mL   6.5mL  6.5mL  
Urinalysis  X    X   X   X    
Microalbumin/creatinine 
ratio -  urine  6  X   X   X   X    
Pregnancy test  7 X X X X X X X X X X X  X X 
Virology                
HIV-1 RNA PCR  3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 
Genotyping   2mL            2mL15 2mL15,16 
Phenotyping  8 2mL            2mL 2mL16 
Immunology                
Lymphocyte subsets  9 1mL 1mL     1mL  1mL 1mL 1mL 1mL  1mL 1mL 
Pharmacokinetic studies                
STAGE II - Population 
PK10    1mL   0.5mL  1mL       
 
IMPAACT P1093, Version 5.0   Page 94 of 135  12 July 2018  Total Maximum Blood 
Volumes  17 11mL 13mL 5mL 6mL 5mL 6.5mL 5mL 14.5 
mL 6mL 6mL 13.5 
mL 3mL 16.5mL 10mL 
Appendix IB Footnotes  
 
1. After obtaining Informed Consent, evaluations should be completed within 30 days prior to study entry.  
 
2. History and physical exam (including height, weight, vital signs [temperature, pulse, respirations and blood pressure], occur rence of adverse events since  last study 
visit and HIV -1 associated conditions). Weight should be measured without shoes and with minimal clothing.  For female participants 9 years of age and older, 
menarche status and for participants who have reached menarche ; sexual activity and con traceptive use.  
 
3. For information on Tanner assessment, see P1093 MOP.  
 
4. Chemistries will be performed at all visits. Electrolytes (sodium, potassium, and HCO3), glucose, creatinine, lipase, phospho rus, and LFTs. LFTs should include total 
bilirubin, indirect bilirubin, direct bilirubin, alkaline phosphatase, AST, ALT, and album in. If indirect bilirubin is not reported by the site laboratory, it should be 
calculated at the site and documented.  
 
The following  (listed in order of preference) should be used to determine the upper limit of normal (ULN) values for indirect bilirubin.   
a. "ULN" values reported by the laboratory report for the test, or  
b. “ULN" values routinely used/established by the site, or  
c. "ULN" values as per the Harriet Lane Handbook (e.g. the current "ULN" for indirect bilirubin as per Harriet Lane Handbook is 0.4)  
Sites must be consistent with the way toxicities are evaluated for all participant s in the study; sites should use the same source throughout the study. Remember to 
have documentation of calculated indirect bilirubin and source of "ULN", when not reported b y your laboratory.  
 
5. Lipid Profile (triglycerides, cholesterol, HDL, LDL) will be drawn in a non -fasting state. However, if triglycerides are grade 2 (using DAIDS toxicity table for fasting 
triglycerides), a complete fasting state lipid profile (triglyceri des, cholesterol, HDL, and LDL) must be drawn. Fasting intervals will be overnight or at least 8 hours. 
After a participant  has had a grade 2 triglycerides in non -fasting state, all future triglycerides must be obtained in fasting state.   
 
6. M/C ratio – microalbumin / creatinine ratio  
 
7. Pregnancy test (urine or serum beta hCG) must be performed on all fe males of reproductive potential within 72 hours prior to enrollment. Subsequent tests should be 
performed at each visit. If a blood test is performed, coll ect 1.0 mL in a red top serum tube.  
 
8. Phenotyping will occur where there is sufficient blood volume collected. HIV-1 phenotyping will NOT be performed in real time and will NOT be used to determine 
optimized background therapy (OBT). Specimens should be stor ed at the local site and shipped in batches when requested by the Protocol Team.  
 
9. Lymphocyte subset blood samples should be collected in EDTA tubes. These samples will be analyzed for CD4 and CD8.  
 
10. Blood samples (0.5mL per sample) will be collected per time point at Weeks 4, 12 and 24. All participant s will have 2 blood sample collected at week 4: pre -dose and 
2-4 hours post dose. At week 12, 1 blood sample will be collected at any time point post do se. At week 24, 2 blood samples will be collected two hours apart between 
12 and 26 hours post -dose.  Samples to be batched and shipped as described in the Laboratory Processing Chart (LPC). For sample collection timepoints for  the ‘Two 
Weeks Post Switch V isit’ and ‘Next Scheduled Visit after Post Switch Visit’ refer to footnotes 13 and 14 below. For participant s on BID dosing refer to the study 
MOP for sampling time points . 
 
 
IMPAACT P1093, Version 5.0   Page 95 of 135  12 July 2018  11. Entry must occur within 30 days of screening.  
 
12. If a participant  meets a criterion  for suspected virologic failure , as defined in Section 6.5, collect a confirmatory HIV -1 RNA PCR sample at least 1 week but not 
more than 4 weeks from the date of the initial RNA PCR test. If a sample cannot be obtained within weeks, samples should b e collected as soon as possible beyond 4 
weeks)  
 
13. If a participant  is confirmed as having virologic failure  as defined , in Section  6.5, conduct a Virologic Failure Visit at least one week and within four weeks.   
 
14. Participant s, who discontinue study drug early, should remain  on study and follow  Appendix IF  Appendix IF  Schedule of Evaluations  
Participant s who Prematurely Discontinue Dolutegravir . 
 
15. A baseline specimen should also be sent with the genotype virologic failure specimen. This specimen may be a baseline (Day 0 entry) storage sample or left-over 
sample from baseline genotyping (screening). Please refer to the Laboratory Processing Chart (LP C) for additional details.  
 
16. Only if not done at virologic failure.  
 
17. The blood volumes listed are ideal, but may not always be possible due to site -specific regulations or challenges with phlebotomy in certain participant s.  For 
insufficient blood draws, pr iorities are as follows: hematology; chemistry; pharmacokinetic studies; HIV -1 RNA; genotyping; lymphocyte subsets; plasma and 
PBMCs/plasma for storage; phenotyping; lipid profiles.  
 
  
 
IMPAACT P1093, Version 5.0   Page 96 of 135  12 July 2018  Appendix IC  Schedule of Evaluations   
Cohorts IV, IV -DT, and V -DT– Stage I  
Screen through Week 48  
 
 Screen1 Entry10 
Day 0  Intensive PK:  
Day 5 -10 Week  
4 Week  
8 Week 12  Week 16  Week 24  Week 32  Week 40  Week 48  
Visit Windows  - - - ±1 wk ±1 wk ±1 wk ±1 wk ±2 wk ±2 wk ±2 wk ±2 wk 
CLINICAL EVALUATIONS            
Informed Consent  X           
History and Physical exam 2 X X X X X X X X X X X 
Adherence Questionnaire    X X X X X X X X X 
CDC Classification   X      X    
Palatability Assessment    X X    X    
LABORATORY EVALUATIONS            
Hematology   0.5mL 0.5mL 0.5mL 0.5mL 0.5mL 0.5mL 0.5mL 0.5mL 0.5mL 0.5mL 0.5mL 
Chemistries 3 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 
Lipid profiles4 1mL       1mL   1mL 
PBMCs / plasma for storage  
(includes integrase resistance)   5mL      4.5mL   4.5mL 
Urinalysis  X    X   X   X 
Microalbumin/creatinine ratio  -urine5  X   X   X   X 
Virology             
HIV-1 RNA PCR  3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 
Genotyping  2mL           
Phenotyping6 2mL           
Immunology             
Lymphocyte subsets7 1mL 1mL    1mL  1mL 1mL 1mL 1mL 
Pharmacokinetic studies             
STAGE I - Intensive PK8   4mL         
STAGE I – Population PK9    1mL  0.5mL  1mL    
Total Maximum Blood Volumes18 10.5mL 10.5 
mL 8.5mL 5.5mL 4.5mL 6.0mL 4.5mL 12mL 5.5mL 5.5mL 11mL 
 
 
 
IMPAACT P1093, Version 5.0   Page 97 of 135  12 July 2018  Appendix IC  Schedule of Evaluations  (cont’d)  
Cohorts IV, IV -DT, and V -DT– Stage I  
Virologic Failure, Dose Adjustment and Premature/DC of Study Drug Visits  
 
 Confirm  
Suspected virologic 
failure11 Virologic Failure12 [Dose Adjustment  
PK Visit ]13 [Dose Adjustment  
Safety Visit]14 Premature/DC  
of Study Drug  
On study15 
Visit Windows   
- If requested, 5 to 14 
days after initiation of 
the dose adjustment  4 weeks post dose 
modification  
(-1 wk/+ 2 wk )  - 
CLINICAL EVALUATIONS       
Informed Consent       
History and Physical exam 2  X  [X] X 
Adherence Questionnaire   X  [X] X 
CDC Classification   X   X 
Palatability Assessment       
LABORATORY EVALUATIONS      
Hematology    0.5mL   0.5mL 
Chemistries 3  1mL   1mL 
Lipid profiles 4      
PBMCs / plasma for storage 
(includes integrase resistance 
sample)   
4.5mL   
 
Urinalysis       
Microalbumin/creatinine ratio -  
urine5      
Virology       
HIV-1 RNA PCR  3mL 3mL   3mL 
Genotyping    2mL16   2mL16,17 
Phenotyping 6  2mL   2mL17 
Immunology       
Lymphocyte subsets 7  1mL   1mL 
Pharmacokinetic studies       
STAGE I - Intensive PK 8   [4mL]   
STAGE I - Population PK 9   [0.5 – 1mL]   
Total Maximum Blood 
Volumes18 3mL 14mL [0.5 – 4mL]  9.5mL 
  
 
IMPAACT P1093, Version 5.0   Page 98 of 135  12 July 2018   
Appendix IC – Footnotes  
 
1. After obtaining Informed Consent, evaluations should be completed within 30 days prior to study entry.  
 
2. History and physical exam (including height, weight, vital signs [temperature, pulse, respirations and blood pressure], occur rence of adverse events since last study 
visit and HIV -1 associated conditions). Weight should be measured without shoes and with minimal clothing.  
 
3. Electrolytes (sodium, potassium, and HCO 3), glucose, creatinine, lipase, phosphorus, and LFTs. LFTs should include total bilirubin, indirect bilirubin, direct bilirubin, 
alkaline phosphatase, AST, ALT, and albumin. If indirect bilirubin is not reported by the site laboratory, it should be calcu lated at the site and documented.  
 
The following (listed in order of preference) should be used to determine the upper limit of normal (ULN) values for indirect  bilirubin.  
a. “ULN ” values reported by the laboratory report for the test, or  
b. “ULN ” values routin ely used/established by the site, or  
c. “ULN ” values as per the Harriet Lane Handbook (e.g. the current "ULN" for indirect bilirubin as per Harriet Lane Handbook is 0.4)  
Sites must be consistent with the way toxicities are evaluated for all participant s in the study, using the same source all the way through the study. Remember to have 
documentation of calculated indirect bilirubin and source of "ULN", when not reported by your laboratory.  
 
4. Lipid Profile (triglycerides, cholesterol, HDL, LDL) will be drawn in a non -fasting state. However, if triglycerides are grade 2 (using DAIDS toxicity table for fasting 
triglycerides), a complete fasting state lipid profile (triglycerides, cholesterol, HDL, and LDL) must be drawn. Fasting inte rvals will be overnight or at  least 8 hours. 
After a participant  has had a grade 2 triglycerides in non -fasting state, all future triglycerides must be obtained in fasting state.   
 
5. M/C ratio – microalbumin / creatinine ratio  
 
6. Phenotyping will occur where there is sufficient blood volu me collected. HIV-1 phenotyping will NOT be performed in real time and will NOT be used to determine 
optimized background therapy (OBT). Specimens should be stored at the local site and shipped in batches when requested by the  Protocol Team.  
 
7. Lymphocyte s ubset blood samples should be collected in EDTA tubes. These samples will be analyzed for CD4 and CD8.  
 
8. Refer to Section  9.2 for additional instructions around intensive PK sampling.  
 
The pharmacokinetic evaluation should be scheduled so that witnessed dosing of DTG  is as close as possible to 24 hours (generally 2 2-26 hours) after the previous 
dosing. Participants should have been compliant in taking their medications for 3 days prior to the intensive PK visit; other wise the intensive PK visit should be re -
scheduled.  
 
Intensive PK should be done in a fasted state following the guidelines below and Section 9.2.1.1 , unless instructed otherwise by the Protocol Team.  
 
• Participants should not ingest breastmilk, formula or any other high fat food/liquid) for 2 hours prior to and 1 hour after d osing on the intensive PK day.  
• Water and other fluids (i.e. apple/orange jui ce and oral rehydration solution) can be taken at any time.   
• Participants may consume a light meal of their choice four hours after dosing on the intensive PK day.  
 
For participant s who vomit within 4 hours after dosing ; PK must be cancelled and may be re scheduled. Blood samples (0.5mL per sample ) will be collected at the 
following time points: pre -dose, 1, 2, 3, 4, 6, 8 and 24 hours post dosing. The 24-hour sample must be collected prior to the next dose. To allow for some flexibility, 
 
IMPAACT P1093, Version 5.0   Page 99 of 135  12 July 2018  the 8 -hour sample c an be collected with a window of 7 -9 hours post -dose and the 24-hour sample with a window of 22 -26 hours. US sites will ship intensive PK 
samples in real time to UAB; all non -US sites will ship PK samples in real time to BRI repository for a ‘pass -through’  (see Laboratory Processing Chart (LPC).   
 
9. Blood samples (0.5mL per sample) will be collected per time point at Weeks 4, 12 and 24. All participant s will have 2 blood samples collected at week 4: pre -dose 
and 2 -4 hours post dose. At week 12, 1 blood sample  will be collected at any time point post dose. At week 24, 2 blood samples will be collected two hours apart 
between 12 and 26 hours post -dose.  Samples to be batched and shipped as described in the LPC. For sample collection timepoints for the ‘Two Weeks Post Switch 
Visit’ and ‘Next Scheduled Visit after Post Switch Visit’ refer to footnotes 13 and 14 below. For participant s on BID dosing refer to  the study MOP for sampling time 
points.  
 
10. Entry must occur within 30 days of screening  
 
11. If a participant  meets a criterion for suspected virologic failure , as defined in Section 6.5, collect a confirmatory HIV -1 RNA PCR sample at least 1 week but not 
more than 4 weeks from the date of specimen collection of the initial RNA PCR test. If a sample cannot be obtained within weeks, samples should be collected as 
soon as possible beyond 4 weeks).   
 
12. If a participant  is confirmed  as having virologic failure , as defined in Section 6.5, conduct a Virologic Failure Visit at least one week later, and within four weeks.   
 
13. Per Section 6.4, participants who underwent a dose modification and for whom additional PK sampling (intensive or population sampling) was requested by the 
Protocol Team  collect intensive or population PK samples (per Protocol Team request only) 5 – 14 days after initiation of the DTG dose adjustment. (If this visit is 
scheduled to occur during another scheduled visit a combined visit can be done and procedures do not need to be duplicated.)  
 
14. Per Section 6.4, for participants who underwent a dose modification, as requested by the Protocol Team, a safety visit should be done 4 weeks ( - 1 wk/+ 2 wks) after 
initiation of the DTG dose adjustment. (If this visit is scheduled to occur during another scheduled visit a  combined visit can be done and procedures do not need to 
be duplicated.)  
 
15. Participant s, who discontinue study drug early, should remain on study and follow  Appendix IF   
 
16. A baseline specimen should also be sent with the genotype virologic failure specimen. This specimen may be a baseline (Day 0 entry) storage sample or left over 
sample from baseline genotyping (screening). Please refer to the Laboratory Proce ssing Chart (LPC) for additional details.  
 
17. Only if not done at virologic failure.  
 
18. The blood volumes listed are ideal, but may not always be possible due to site -specific regulations or challenges with phlebotomy in certain participant s.  For 
insufficient blood draws, priorities are as follows: hematology; chemistry; pharmacokinetic stud ies; HIV -1 RNA; genotyping; lymphocyte subsets; plasma and 
PBMCs/plasma for storage; phenotyping; lipid profiles.  
  
 
IMPAACT P1093, Version 5.0   Page 100 of 135  12 July 2018  Appendix ID  Schedule of Evaluations   
Cohorts IV, IV -DT, and V -DT – Stage II 
 Screen1 Entry9 
Day 0  Day 
10 Week 
4 Week 
8 Week 
12 Week 
16 Week 
24 Week 
32 Week 
40 Week 
48 Confirm  
Suspected 
Virologic 
Failure10 Virologic 
failure11 Premature 
DC of 
Study 
Drug/  
On study12 
Visit Windows  - - ±3 
days ±1wk  ±1wk  ±1wk  ±1wk  ±2wk  ±2wk  ±2wk  ±2wk   - - 
CLINICAL EVALUATIONS               
Informed Consent  X              
History and Physical 
exam2 X X X X X X X X X X X  X X 
Adherence 
Questionnaire    X X X X X X X X X  X X 
CDC Classification   X      X     X X 
Palatability Assessment    X X    X       
LABORATORY EVALUATIONS              
Hematology   0.5mL 0.5mL 0.5mL 0.5mL 0.5mL 0.5mL 0.5mL 0.5mL 0.5mL 0.5mL 0.5mL  0.5mL 0.5mL 
Chemistries3 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL 1mL  1mL 1mL 
Lipid profiles4 1mL       1mL   1mL    
PBMCs / plasma for 
storage  
Includes integrase 
resistance)   5mL      4.5mL   4.5mL  4.5mL  
Urinalysis  X    X   X   X    
Microalbumin/  
creatinine ratio assay - 
urine5  X   X   X   X    
Virology                
HIV-1 RNA PCR  3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 
Genotyping   2mL             2mL13 2mL13,14 
Phenotyping6 2mL            2mL 2mL14 
Immunology                
Lymphocyte subsets7 1mL 1mL    1mL  1mL 1mL 1mL 1mL  1mL 1mL 
Pharmacokinetic studies               
STAGE II - Population 
PK 8    1mL  0.5mL  1mL       
Total Maximum Blood 
Volumes15 10.5mL 10.5mL 4.5mL 5.5mL 4.5mL 6mL 4.5mL 12mL 5.5mL 5.5mL 11mL 3mL 14mL 9.5mL 
Appendix ID – Footnotes  
 
IMPAACT P1093, Version 5.0   Page 101 of 135  12 July 2018   
1. After obtaining Informed Consent, evaluations should be completed within 30 days prior to study entry.  
 
2. History and physical exam (including height, weight, vital signs [temperature, pulse, respirations and blood pressure], occur rence of adverse events si nce last study 
visit and HIV -1 associated conditions). Weight should be measured without shoes and with minimal clothing.  
 
3. Blood Chemistries will be performed at all visits. Electrolytes (sodium, potassium, and HCO 3), glucose, creatinine, lipase, phosphorus, and LFTs. LFTs should 
include total bilirubin, indirect bilirubin, direct bilirubin, alkaline phosphatase, AST, ALT, and albumin. If indirect bilirubin is not reported by the site laboratory, it 
should be calcula ted at the site and documented.  
 
The following (listed in order of preference) should be used to determine the upper limit of normal (ULN) values for indirect  bilirubin.  
a. "ULN" values reported by the laboratory report for the test, or  
b. “ULN" values routin ely used/established by the site, or  
c. "ULN" values as per the Harriet Lane Handbook (e.g. the current "ULN" for indirect bilirubin as per Harriet Lane Handbook is 0.4)  
Sites must be consistent with the way toxicities are evaluated for all participant s in the study, using the same source all the way through the study. Remember to have 
documentation of calculated indirect bilirubin and source of "ULN", when not reported by your laboratory.  
 
4. Lipid Profile (triglycerides, cholesterol, HDL, LDL) will be drawn in a non -fasting state. However, if triglycerides are grade 2 (using DAIDS toxicity table for fasting 
triglycerides), a complete fasting state lipid profile (triglycerides, cholesterol, HDL, and LDL) must be drawn. Fasting inte rvals will be overnight or at  least 8 hours. 
After a participant  has had a grade 2 triglycerides in non -fasting state, all future triglycerides must be obtained in fasting state.   
 
5. M/C ratio – microalbumin / creatinine ratio  
 
6. Phenotyping will occur where there is sufficient blood volu me collected. HIV-1 phenotyping will NOT be performed in real time and will NOT be used to determine 
optimized background therapy (OBT). Specimens should be stored at the local site and shipped in batches when requested by the  Protocol Team.  
 
7. Lymphocyte s ubset blood samples should be collected in EDTA tubes. These samples will be analyzed for CD4 and CD8.  
 
8. Blood samples (0.5mL per sample) will be collected per time point at Weeks 4, 12 and 24. All participant s will have 2 blood samples collected at week 4:  pre-dose 
and 2 -4 hours post dose. At week 12, 1 blood samples will be collected at any time point post dose. At week 24, 2 blood samples wil l be collected two hours apart 
between 12 and 26 hours post -dose. Samples to be batched and shipped as described in  the LPC. For sample collection timepoints for the ‘Two Weeks Post Switch 
Visit’ and ‘Next Scheduled Visit after Post Switch Visit’ refer to footnotes 11 and 12 below. For participant s on BID dosing refer to the study MOP for sampling time 
points . 
 
9. Entry must occur within 30 days of screening . 
 
10. If a participant  meets a criterion for suspected virologic failure , as defined in Section 6.5, collect a confirmatory HIV -1 RNA PCR sample at least 1 week but not 
more than 4 weeks from the date of specimen collection of the initial RNA PCR test. If a sample cannot be obtained within weeks, samples should be collected as 
soon as possible beyond 4 weeks) . 
 
11. If a participant  is confirmed as having virologic failure , as defined in Section 6.5, conduct a Virologic Failure Visit at least one week later, and within four weeks.  
 
12. Participant s, who discontinue study drug early, should remain on study and follow  Appendix IF   
 
IMPAACT P1093, Version 5.0   Page 102 of 135  12 July 2018   
13. A baseline specimen should also be sent with the genotype virologic failure specimen. This specimen may be a baseline (Day 0 entry) storage sample or left over 
sample from baseline genotyping ( screening). Please refer to the LPC for additional details.  
 
14.  Only if not done at virologic failure.  
 
15. The blood volumes listed are ideal, but may not always be possible due to site -specific regulations or challenges with phlebotomy in certain participant s.  For 
insufficient blood draws, priorities are as follows: hematology; chemistry; pharmacokinetic studies; HIV -1 RNA; genotyping; lymphocyte subsets; plasma and 
PBMCs/plasma for storage; phenotyping; lipid profiles.  
 
 
IMPAACT P1093, Version 5.0   Page 103 of 135  12 July 
2018    
Appendix IE Schedule of Evaluations  
Long -term Safety Follow -up for Participant s Who Continue to Receive  Dolutegravir  
 
 Every 12 Weeks  
[Weeks 60, 72, 
84, 96, 108, 120, 
132, 144, 156, 
168,180, and 
192(End of 
Study Visit)]  Every 48 Weeks  
[Weeks 96, 144 
and 192 (End of 
Study Visit)]  Confirm 
suspected 
virologic failure6 Virologic failure7 Premature 
Discontinuati on 
of Study 
Drug/On Study9 
Visit Windows  ±4 wks  ±4 wks     
CLINICAL EVALUATIONS      
History and Physical1 X   X X 
Adherence Questionnaire  X   X  
Palatability Assessment       
LABORATORY EVALUATIONS      
HIV-1 RNA PCR  3mL  3mL 3mL  
PBMCs/plasma for storage     6.5mL  
Genotyping   2mL2  2mL3 2mL3,4 
Phenotyping     2mL 2mL4 
Lipid profiles   1mL    
Pregnancy test5 X X  X X 
Total Maximum Blood 
Volumes8 3mL 3mL  13.5mL 4mL 
 
  
 
IMPAACT P1093, Version 5.0   Page 104 of 135  12 July 
2018    
Appendix IE - Footnotes:  
1. History and physical exam (including height, weight, vital signs [temperature, pulse, respirations and blood pressure , occurrence of 
adverse events since last study visit and any HIV -1 associated conditions). Weight should be measured without shoes and with minimal 
clothing. For fe male participants 9 years of age and older, menarche status and for participants who have reached menarche, sexual 
activity and contraceptive use.  
2. Genotyping to be done for participants post virologic failure, ONLY if requested to do so by the Protocol Tea m.   
3. Specimens for genotyping and phenotyping should be obtained and stored at this visit, but only sent for processing if the con firmatory 
HIV RNA test at this visit is > 400 c/ml. Please refer to the Laboratory Processing Chart (LPC) for additional detai ls. 
4. Only if not done at virologic failure  visit. 
5. Pregnancy testing, after the initial 48 weeks of study drug, should be determined as per local practice. If pregnancy occurs, it is an event 
that should be captured on the CRFs.  
6. If a participant  meets a criterion for suspected virologic failure , as defined in Section 6.5, collect a confirmatory HIV -1 RNA PCR sample 
at least 1 week but not more than 4 weeks from the date of specimen collection of the initial RNA PCR test. If a sample cannot be 
obtained within weeks, samples should be collected as soon as possible beyond 4 weeks)  
7. If a participant  is confirmed as having virologic failure , as defined in Section 6.5, conduct a Virologic Failure Visit a t least one week and 
within four weeks.   
8. The blood volumes listed are ideal, but may not  always be possible due to site -specific regulations or challenges with phlebotomy in 
certain participant s.  For insufficient blood draws, priorities are as follows: pharmacokinetic studies; HIV -1 RNA; genotyping; plasma and 
PBMCs/plasma for storage; pheno typing; lipid profiles.  
9. Participants, who discontinue study drug early, should remain on study and follow  Appendix IF    
 
  
 
IMPAACT P1093, Version 5.0   Page 105 of 135  12 July 
2018    
Appendix IF  Schedule of Evaluations  
Participant s who Prematurely Discontinue Dolutegravir  
 
 
Participant s who continue DTG  will be followed as per Appendix IE  
 
 4 Week Follow -Up Visit2 Every 3 months until 
resolved (if applicable)3  
Visit Windows  ±2 wks ±4 wks 
History and Physical1 X X 
 
Appendix IF  - Footnotes:  
 
1. History and physical exam (including height, weight, vital signs [temperature, pulse, respirations and blood pressure], occurrence of adverse 
events since last study visit and any HIV -1 associated conditions). Weight should be measured without shoes and with minimal clothing.  
 
2. This follow up visit should be performed 4 weeks after the participant ’s last exposure to DTG . 
 
3. Participant s who are pregnant or who have a drug related adverse event that has not resolved within 3 months of stopping study drug, sho uld 
come back to clinic every 3 months for follow -up until the AE is resolved or the mother delivers the baby. Study required tests  are an interim 
history and physical exam at these visits. If sites perform safety tests at these visits as a result of standard of care, sit es should document all 
results in the case report forms. If the participant  discontinues for any reason other than pregnancy or drug related AE, no other visit after the 4 
week visit is required.  
  
 
IMPAACT P1093, Version 5.0   Page 106 of 135  12 July 
2018    
Appendix IG   
Schedule of Evaluations  
Participant s who Start Rifampin as Part of Treatment for Active Tuberculosis  
 
 Study Visits Following Initiation of Rifampin Therapy   
Virologic 
failure 11 Premature 
Discontinua
tion of 
Study 
Drug/  
On study 12 Day 1 of 
rifampin 
therapy 1 Week 2  Week 4  Week 12  Every 8 
weeks until 
end of 
rifampin 
therapy  Confirm 
Suspected 
Virologic 
Failure10 
Visit Windows   ±1 wk ±1 wk ±1 wk ±2 wks  - - 
CLINICAL EVALUATIONS  
History and Physical exam 2 X X X X X  X X 
Adherence Questionnaire  X X X X X  X X 
LABORATORY EVALUATIONS  
Hematology   1mL 1mL  1mL  1mL  1mL   1mL  1mL  
Chemistries3 1mL 1mL  1mL  1mL  1mL   1mL  1mL  
Lipid profiles4 1mL   1mL      
Microalbumin/creatinine ratio 
assay – urine5   X X X  X  
PBMCs / plasma for storage        6.5mL   
Pregnancy test6 X X X X X  X X 
Virology  
HIV-1 RNA PCR  3mL 3mL 3mL 3mL 3mL 3mL 3mL 3mL 
Immunology  
Lymphocyte subsets7    1mL 1mL  1mL  1mL  
Pharmacokinetics  
Intensive PK8  8mL       
Population PK 9   1mL 1mL     
Total Maximum Blood 
Volumes  13 6mL 13mL 6mL 8mL 6mL  12.5mL 6mL 
NOTE: Participant s who are diagnosed with active tuberculosis while taking DTG  as part of P1093, will have their medications changed as per Section 
6.1.8  and should be followed as per  Appendix IG  . It is estimated the participant  will be on anti -TB treatment for approximately 24 weeks. Upon 
discontinuation o f the rifampin containing anti -TB therapy , the participant ’s DTG  dose will revert back to once daily administration. The participant  
should complete the remainder of the first 48 weeks of DTG  therapy on their original schedule of evaluations, or if they ha ve completed 48 weeks of 
DTG  therapy, they should move to l ong- term follow -up (Appendix IE ). For example, if the participant  was at week 16 when they were started on 
rifampin, and they complete 24 weeks of rifampin therapy , they would then go back to week 40 of their original SOE.  
 
 
IMPAACT P1093, Version 5.0   Page 107 of 135  12 July 
2018    
Appendix IG Footnotes:  
 
1. Participant s who are already enrolled in P1093 and become exposed to TB, and subsequently require an anti -TB treatment that includes the use of 
rifampin, may be allowed to continue in the study if their ART options are compatible with  co-administration of rifampin. Continuation requires the 
approval of the Protocol Team .   
 
2. History and physical exam (including height, weight, vital signs [temperature, pulse, respirations and blood pressure], occur rence of adverse events 
since last study visit and HIV -1 associated conditions). Weight should be measured without shoes and with minimal clothing.  
3. Chemistries will be performed at all visits. Electrolytes (sodium, potassium, and HCO 3), glucose, creatinine, lipase, phosphorus, and LFTs. LFT s should 
include total bilirubin, indirect bilirubin, direct bilirubin, alkaline phosphatase, AST, ALT, and albumin. If indirect bilirubin is not reported by the site 
laboratory, it should be calculated at the site and documented.  
The following (listed in  order of preference) should be used to determine the upper limit of normal (ULN) values for indirect bilirubin.  
a. "ULN" values reported by the laboratory report for the test, or  
b. “ULN" values routinely used/established by the site, or  
c. "ULN" values as per the Harriet Lane Handbook (e.g. the current "ULN" for indirect bilirubin as per Harriet Lane Handbook is 0.4)  
Sites must be consistent with the way toxicities are evaluated for all participant s in the study; sites should use the same source throughout the study. 
Remember to have documentation of calculated indirect bilirubin and source of "ULN", when not reported by your laboratory.  
 
4. Lipid Profile (triglycerides, cholesterol, HDL, LDL) will be  drawn in a non -fasting state. However, if triglycerides are grade 2 (using DAIDS toxicity 
table for fasting triglycerides), a complete fasting state lipid profile (triglycerides, cholesterol, HDL, and LDL) must be d rawn. Fasting intervals will be 
overnigh t or at least 8 hours. After a participant  has had a grade 2 triglycerides in non -fasting state, all future triglycerides must be obtained in fasting 
state.   
 
5. M/C ratio – microalbumin / creatinine ratio  
 
6. Pregnancy test (urine preferably) must be performed on all females of reproductive potential at each visit. If a serum beta hCG test is performed, collect 
1.0mL in a red top serum tube.  
 
7. Lymphocyte subset blood samples should be collected in EDTA tubes. These samples will be analyzed for CD4 and CD8.  
 
8. The p harmacokinetic evaluation should be scheduled so that witnessed dosing of DTG  is as close as possible to 24 hours (generally 22 -26 hours) after 
the previous dosing. Participant s should have been compliant in taking their medications for 3 days prior to the  intensive PK visit; otherwise the 
intensive PK visit should be re -scheduled.  For participant s who vomit within 4 hours after dosing; PK must be cancelled and may be rescheduled. Blood 
samples (0.5 mL per sample) will be collected at the following time poin ts: pre -dose, and at 1, 2, 3, 4, 6, 8, and 12 hours post -dose. To allow for some 
flexibility, the 8 -hour sample can be collected with a window of 7 -9 hours post -dose and the 12 hour sample with a window of 11 -13 hours. US sites 
 
IMPAACT P1093, Version 5.0   Page 108 of 135  12 July 
2018    
will ship intensive PK sampl es in real time to UAB; all non -US sites will ship PK samples in real time to BRI repository for a ‘pass -through’ (see LPC 
for instructions).  See dosing and fasting instructions for Cohorts I -III and Cohorts IV -V-DT, below.  
Instructions for Cohorts I -III: 
• ≥6 hours PRIOR to dosing – participant s may eat and drink without restriction  
• ≥4 to <6 hours PRIOR to dosing – milk, apple/orange juice and water may be consumed; No food  
• <4 hours PRIOR to dosing – water ONLY  
• From dosing to <2 hours POST dose – apple/orange juice and water may be consumed; No food  
• From ≥2 to <4 hours POST dose – participant s may drink apple/orange juice and eat a snack/light meal (around 100 -150 calories)  
• From ≥4 hours POST dose onwards – participant s may eat and drink without r estriction  
 
Instructions for Cohorts IV -V-DT: 
 
Participant s should not ingest breastmilk, formula or any other high fat food/liquid) for 2 hours prior to and 1 hour after dosing on th e intensive PK day. 
Water and other fluids (i.e. apple/orange juice and oral rehydration solution) can be taken at any time.   
 
9. All participant s will have 2 blood samples (0.5mL per sample) collected at weeks 4 and 12: pre -dose and 8 -14 hours post dose. Samples to be batched 
and shipped as described in the LPC.  
 
10. If a participant  meets a criterion for suspected virologic failure , as defined in Section 6.5, collect a confirmatory HIV -1 RNA PCR sample at least 1 
week but not more than 4 weeks from the date of specimen collection of the initial RNA PCR test. If a sample cannot be obtained within weeks, samples 
should be collected as soon as possible beyond 4 weeks)  
 
11. If a participant  is confirmed as having virologic failure , as defined in Section  6.5, conduct a Virologic Failure Visit at least one week and within four 
weeks.   
 
12. Participant s who discontinue study drug ( DTG ) early are required to come back to  clinic four weeks after stopping study drug or after resolution of any 
adverse event.  
 
13. The blood volumes listed are ideal, but may not always be possible due to site -specific regulations or challenges with phlebotomy in certain participant s.  
For insuffi cient blood draws, priorities are as follows: pharmacokinetic studies; HIV -1 RNA; genotyping; plasma and PBMCs/plasma for storage; 
phenotyping; lipid profiles.  
 
1. F
 
IMPAACT P1093, Version 5.0  Page 109 of 135 12 July 2018   Appendix II  
Sample Consent Form f or Participant s Enrolling in S tage I  
 
DIVISION OF AIDS  
INTERNATIONAL MATERNAL PEDIATRIC ADOLESCENT AIDS CLINICAL TRIALS GROUP 
(IMPAACT)  
 
Phase I/II, Multi -Center, Open -Label Pharmacokinetic, Safety, Tolerability and  
Antiviral Activity of dolutegravir, a Novel Integrase Inhibitor, in Combinati on Regimens in HIV -1 
Infected Infants, Children and Adolescents  
 
Participant s Enrolling in STAGE ONE  
P1093 Version 5.0, dated 12 July 2018    
 
SHORT TITLE FOR THE STUDY : Safety and PK of dolutegravir in HIV -1 Infected Children  
 
INTRODUCTION  
You are/your ch ild is being asked to take part in this research study because you have /your child has the 
Human Immunodeficiency Virus (HIV), which is the virus that causes AIDS, and because the drugs 
currently available may not keep the amount of HIV in your / your chi ld’s blood low enough or may 
cause side effects too difficult to deal with. This study is sponsored by the National Institutes of Health 
(NIH). The doctor in charge of this study at this site is: (insert name of Principal Investigator). Before you 
decide i f you want to be/want your child to be a part of this study, we want you to know about the study.  
 
This is a consent form. It gives you information about this study. The study staff will talk with you about 
this information. You are free to ask questions about this study at any time. If you agree to/agree to allow 
your child to take part in this study, you will be asked to sign this consent form. You will get a copy to 
keep.  
 
WHY IS THIS STUDY BEING DONE?  
This study is being done to study a new antiretroviral HIV medication called dolutegravir. This drug is a 
type of medicine called an integrase inhibitor. Integrase inhibitors work by blocking integrase, a protein 
that HIV needs to enter human cells and mak e more copies of itself. The study will help find the best 
amount or dose of dolutegravir for infants, children and teenagers, when it is taken on its own as well as 
with other antiretroviral medications. This study will also find out the safety of using t his medication in 
infants, children and adolescents and if there are any side effects from the medication. Dolutegravir has 
been tested in adults and children. The study drug (dolutegravir) is approved for use in children 12 years 
and older by the FDA [and /or local regulatory authorities].  
 
WHAT DO I / DOES MY CHILD HAVE TO DO IF I AM / HE / SHE IS IN THIS STUDY?  
If you decide to (allow your child to) enroll in this study, you / your child will be asked to come to the 
clinic at least 10 times over 48 weeks  and then every 12 weeks for three more years. You / your child will 
be given dolutegravir and you / your child will be asked to take it once or twice a day for the entire study, 
in addition to your / your child’s regular HIV medicines. Dolutegravir is available in 3 different 
formulations : 1) a film -coated tablet which cannot be crushed or dissolved, 2.) a liquid suspension and, 3) 
a tablet that can be dissolved in water . If you are/your child is 12 up to 18 years old, you/your child wil l 
take the film -coated tablet formulation of dolutegravir . You will be given instructions on how to give 
dolutegravir to your child and how to store the dolutegravir. If your child is between 6 to less than 12 
years of age and was prescribed the liquid or dissolvable tablets of dolutegravir he/she may be allowed to 
switch to the film -coated tablet formulation at a later time. The study staff will let you know when your 
child can switch and if you request to do so.  
 
IMPAACT P1093, Version 5.0  Page 110 of 135 12 July 2018    
Although the study will p rovide you/your c hild with dolutegravir, other antiretrovirals will not be 
provided by the study.  
 
This study will be done in two parts – Stage one and Stage two. Stage one will enable the doctors to find 
the right dose of study drug for you/your child and then will keep y ou on that dose to look for any side 
effects that you/your child might experience. In Stage two the doctors will know the right dose to put 
you/your child on and will look at any side effects that you / your child might experience as well as how 
well the d rug is controlling your HIV infection. You/your child will be enrolled into either Stage one or 
Stage two, depending on when you/your child enroll and your age / the age of your child. This consent 
form is for Stage one.  
 
In this study there are 8 cohorts in Stage I – enrolling infants, children, and adolescents from 4 weeks to 
less than 18 years of age. Participant s who have had their 18th birthday by the entry visit will not be 
enrolled into the study.  
 
Screening:  
If you are interested in taking part / a llowing your child to enroll in this study, we will see if you are / 
your child is eligible for the study:  
 
• We will ask your / your child’s medical history including questions about your /your child’s 
health and what symptoms, medications, and illnesses yo u have/ your child has had.  
• We will do a physical exam including height, weight and vital signs (temperature, blood pressure, 
pulse and respiratory rate). Doses may be modified based on the results of the weight.  
• We will take a little more than 2 teaspoons  (11mL) of blood, to check for the following:  
o The amount of HIV in the blood,  
o The amount of cholesterol and triglycerides (types of fat) in the blood,  
o How well your immune system, liver and kidneys are working,  
o Other routine tests .  
You will be given th e results of these tests. We will also ask you/your child to provide a urine sample for 
routine tests. Girls and women who can have a baby will also be asked to provide a urine or blood sample 
to test for pregnancy.  If you are / your child is engaged in s exual activity that could lead to pregnancy, 
you / your child will be asked to take birth control precautions throughout the study period.  
 
On Study:  
If you are/your child is eligible for this study, you/your child will come to the clinic at least 10 times  in 
about 1 year . Most of the visits will last about 1 -2 hours. More visits will be needed if the amount of 
study drug in your blood is too low or too  high and your dose needs to be adjusted. You/your child will 
come to the clinic for the first study visit within 30 days of the screening visit.  
• At each visit, a medical history will be taken and you/your child will have a physical exam. At the 
enrollmen t visit and at the week 48 visit, you/your child’s stage of sexual development will be 
determined. For girls/women, this will be done by looking at how developed the breasts are. For 
boys/men, this will be done by measuring the size of the testes.  
 
IMPAACT P1093, Version 5.0  Page 111 of 135 12 July 2018   • We will  draw blood at each visit. Depending upon your/your child’s age, between 1 - 4 teaspoons 
(5-17mLs) of blood will be drawn at these visits; you will be informed of results of routine blood 
tests. Some of the blood drawn will be stored and tested to find out how your/your child’s 
immune system is affected by the study drug. This testing will be done after the study is over, and 
you will not be given the results of these tests.  
• A palatability assessment will be done at Day 10, Week 4 and Week 24 to find out wh at you/your 
child thinks about the taste of the study drug.  
• You/your child will be asked to come to the clinic to have blood drawn 8 times over 24 hours 
during one visit, approximately 5 -10 days after you / your child started taking the study 
medication. T his visit is known as an ‘intensive PK visit’ . Depending on your/your child’s age, 
up to 9mLs (about 2 teaspoons ) of blood will be drawn at this visit  and you will be as ked to 
withhold certain liquids and food. The study staff will give you instructions about this .  These 
blood tests are done to measure the amount of study drug in your/your child’s blood. A small 
plastic catheter (a needle that is placed in a vein for an extended period of time, so that blood can 
be drawn multiple times, with out having to stick you with a needle several times) will be placed 
in your/your child’s arm to draw these blood samples. The needle will stay in place until all of the 
blood samples are drawn.  
• If the amount of study drug in your/your child’s blood is not  enough or is too high, you/your child 
may be asked to take a different dose and  may be asked to return to the clinic for another 
‘intensive PK visit’. You/your child may have blood to be drawn again 8 times over 24 hours. 
This is to make certain that the new dose is safe.  The same procedures above will be followed . 
• The current instructions on what you/your child can eat and drink around the intensive PK draws 
are below, but these may change.  If these instructions change, the study staff will let you know  
and provide you with different instructions.     
If you are/yo ur child is older than 2 years old and having intensive PKs done you/your child may 
be asked to follow the guidelines below regarding eating and drinking around the intensive PK 
visit.  
• ≥6 hours  PRIOR to taking your medication – you/your child may eat and drink without 
restriction  
• ≥4 to <6 hours PRIOR to taking your medication – milk, apple/orange juice and water may be 
consumed; No food  
• <4 hours PRIOR to taking your medication – water ONLY  
• From dosing to <2 hours AFTER taking your medication – apple/orange juice and water may 
be consumed; No food  
• From ≥2 to <4 hours AFTER taking your medication – you may drink apple/orange juice and 
eat a snack/light meal (around 100 -150 calories)  
• From ≥4 hours AFTER taking your medication onwards – you may eat and drink without 
restriction  
If your child is 4 weeks to less than 2 year s old and having intensive PKs done, you/your child 
may be asked to  follow the guidelines below  regarding eating and drinking aroun d the intensive 
PK visit.  
 
IMPAACT P1093, Version 5.0  Page 112 of 135 12 July 2018   • No breastmilk, formula or any other high fat food/liquid for 2 hours prior to and 1 hour 
after dosing on the intensive PK day .  
• Water and other fluids (i.e. apple/orange juice and oral rehydration solution) can be taken 
at any tim e.   
• You will have extra blood draws at three visits (week 4, week 12 and week 24). At weeks 4 and 
24, you will have two blood draws .  At week 12 you will only have one blood draw. The amount 
of blood drawn at the different study visits will be less than 1  teaspoon  (0.5-1mL) depending on 
your /your child’s age.  
• If the amount of HIV virus in your/your child’s blood increases too much while on this study 
drug, you/your child may be asked to come back to clinic to have your blood drawn to confirm 
the level of HIV in your blood. If the level of HIV virus in your bloo d is still too high, your study 
doctor may ask you to stop taking the study medicine and to come back to the clinic for another 
visit. As part of this visit, you/your child will have an interim medical history, physical exam and 
approximately 3 teaspoons o f blood (1 4-16.5mL) will be drawn for testing and storage.  
• If you/your child experiences a severe liver reaction or inflammation while on the study, you/your 
child may be asked to come back to clinic to have less than one teaspoon of blood (2mL) drawn 
to check the level of dolutegravir in the blood. Additional testing as part of routine assessments 
for liver inflammation (e.g. checking for viruses that cause liver inflammation) may be performed 
as well.  
Long Term Follow -Up 
After you have been on study dru g for approximately 48 weeks, you will enter the long term follow -up 
phase of the study. You will be asked to come back into clinic every  12 weeks (every 3 months) for 3 
more years. Most visits will last about 30 mins.  
• At each visit, a medical history wil l be taken and you/your child will have a physical exam. You 
will also be asked if you have missed taking any of your medications.  
• We will draw less than 1 teaspoon of blood (3 -4mL) at each visit. You will be informed of results 
of routine blood tests.  
• As before, if the amount of HIV virus in your/your child’s blood increases too much while on this 
study drug, you/your child may be asked to come back to clinic to have your blood drawn to 
confirm the level of HIV in your blood (see above).  
You/your child m ust continue to take your/his/her anti -HIV medications during the study as prescribed by 
your/your child’s HIV care provider. If your/your child’s HIV care provider changes your/your child’s 
anti-HIV medications during the study, you/your child can still t ake the study drug. You/your child will 
be asked questions about taking your/his/her anti -HIV medications and the times you take/he/she takes 
them and if you have/he/she has missed any medications.  
 
If you/your child can become pregnant, we will collect ur ine or blood to test for pregnancy at each visit. 
We will also ask you/your child about contraception use.  If you think you/if your child thinks she may be 
pregnant at any time during the study, tell the study staff right away.  
 
Blood and Urine Samples  
Some of your / your child’s blood and urine samples will be shipped out of the country to the USA for 
specialized tests. These tests will tell the doctors how much study drug is in your / your child’s blood and 
if the study drug is causing any chan ges in your kidneys.  
 
IMPAACT P1093, Version 5.0  Page 113 of 135 12 July 2018    
For Participants Receiving Granules for suspension  only 
 
If your child is receiving the liquid he/she will need to switch to the dissolvable tablet. The study staff 
will inform you when your child will need to switch . This is because  the company will not be making the 
(granule) liquid form of dolutegravir any longer. The study staff will provide instructions on how to 
dispense the dissolvable tablet and on the day you are scheduled to come to the clinic to begin taking the 
dissolvable  tablets you will be asked to not give the (granule ) liquid dose to your child . The first dose of 
the dissolvable tablet will be given in the clinic. You will be asked to come back to the clinic about 2 
weeks later and will have a palatability assessment and blood drawn to confirm the level of HIV in your 
child’s blood . If you have been on the study for more than 24 weeks at each of these visits, blood samples 
will be drawn at two separate times. The amount of blood drawn will be less than 1 tea spoon ( 0.5 -1mL)].   
 
WHAT DO I / DOES MY CHILD HAVE TO DO IF I AM / HE / SHE BECOMES INFECTED WITH 
TUBERCULOSIS WHILE ON THIS STUDY?  
If you become/your child becomes exposed to Tuberculosis (TB) while on study and requires anti -TB 
treatment that includes Rifampin you/your child will have to increase the dose of dolutegravir from once a 
day to twice a day while taking Rifampin. After you /your child complete(s) treatment with Rifampin, 
you/your child will go back to taking the dolutegravir once a day depending on what other medications 
you/your child is taking.  
 
You/your child will also be required to return for at least five additional f ollow -up visits after starting 
Rifampin.  
• At each of these visits, a medical history will be taken and you/your child will have a physical 
exam and a pregnancy test .  We will draw approximately 1 -3 teaspoons of blood to look at the 
following:  
o The amount of  HIV, cholesterol and triglycerides (types of fat) in your blood  
o How well your immune system, liver and kidneys are working, as well as other routine 
tests 
• At each visit you will be asked whether you are taking your medication as instructed.  
• You/your child  will be asked to come to the clinic to have blood drawn 8 times over 12 hours 
during one visit, approximately 5 -10 days after you/ your child started taking anti -TB medication. 
For this visit, you/your child will be asked to fast for 6 hours before your d aily dose of study 
medication.  
• The study staff will give you more instructions about this. Depending on your/your child’s age, 
up to 13 mL (about 3  teaspoons) of blood will be drawn at this visit.  
• You will have extra blood draws at two visits. At weeks 4 and 12, you will have two blood draws  
-  blood will be drawn once before you take dolutegravir and about 12 hours later.  The amount of 
blood drawn at the different study visits will be less than 1 teaspoon ( 1mL) depending on your 
/your child’s age.  
OTHER INFORMATION  
The information collected in this study may be used for other IMPAACT -approved HIV -related research.  
 
HOW MANY PEOPLE WILL TAKE PART IN THIS STUDY?  
About 300 children and adolescents will take part in this study  
 
IMPAACT P1093, Version 5.0  Page 114 of 135 12 July 2018    
HOW LONG WILL I/MY CHILD  BE IN THIS STUDY?  
You/your child is enrolling in Stage I of the study, and so will be in the study for at least 48 weeks After 
that time you/your child will enter the long -term safety follow -up phase of the study. During this time, 
you / your child will continue  to take study -provided dolutegravir and will be asked to come to clinic 
every 12 weeks for three more years.  
 
 
WHY WOULD THE DOCTOR TAKE ME / MY CHILD OFF THE STUDY DRUG / THIS STUDY 
EARLY?  
The study doctor may need to take you/your child off the study dr ug early, without your permission, if:  
• Continuing the study drug may be harmful to you / your child  
• You become / your child becomes pregnant while on study  
• If you elect not to attend repeat PK evaluations as part of the study  
 
The study doctor may need to take you/your child off the study early, without your permission, if:  
• You are/ your child is not able to attend the study visits as required by the study  
• You need / your child needs a treatment that you / your child may not take while on the study  
• You a re / your child is not able to take the study drug as required by the study  
• The study is cancelled by the U.S. Food and Drug Administration (FDA), National Institutes of 
Health (NIH), the Office of Human Research Protections (OHRP), other country specific 
governmental agencies, IMPAACT, the drug company supporting this study (GSK), or the site’s 
Institutional Review Board (IRB) or Ethics Committee (EC). An IRB or EC is a committee that 
watches over the safety and rights of research participant s 
If your doct or wants you / your child to stop taking the study drug, you/your child will be asked to return 
to the clinic once more, four weeks after your last dose of dolutegravir, to make sure you are/your child is 
continuing to do well. This visit will include a hi story and physical exam, a blood draw and a review of 
your medical records.  
 
IF MY CHILD HAS TO PERMANENTLY STOP TAKING STUDY -PROVIDED MEDICINE, OR 
ONCE I LEAVE THE STUDY, HOW WOULD THE STUDY MEDICINE BE PROVIDED?  
During the study:  
If you / your child mus t permanently stop taking study -provided dolutegravir before your/your child’s 
study participation is over, the study staff will discuss other options that may be of benefit to you/your 
child.  
 
After the study:  
Once you / your child leaves the study, if yo u/they are gaining benefit from the study -provided drug, this 
drug may continue to be provided until it is available to you in your country, but there is no guarantee . 
Study clinicians will work to ensure that you/your child continue to receive appropriate  care and 
treatment outside of the study.  
 
WHAT ARE THE RISKS OF THE STUDY?  
The drug used in this study may have side effects, some of which are listed below. Please note that 
these lists do not include all the side effects seen with this drug. These lists include the more serious 
 
IMPAACT P1093, Version 5.0  Page 115 of 135 12 July 2018   or common side effects with a known or possible re lationship. It is very important that you tell your 
study doctor of any changes in your/your child’s  medical condition while taking part in the study. At 
any time during the study, if you believe you are/your child is experiencing any of these side effects , 
you have the right to ask questions on possible and /or known risks.  
Possible Risks Associated with Dolutegravir  
The drug used in this study, dolutegravir, has been administered to a total of 6004 participants (4814 
HIV-infected and 1190 healthy) cumulat ive to 16 July 2017 in ongoing and completed ViiV sponsored 
and clinical trials ranging from Phase I to IIIb and the dolutegravir compassionate use program.  The 
following side effects have been seen with dolutegravir:  
 
 
 
Uncommon ( expected in about 1 of every 1000 people taking DTG (0.1%)  
Allergic reaction  (see below)  
Liver toxicity  (see below)  
An inflammatory condition which may develop as the immune system becomes stronger (immune 
reconstitution syndrome or ‘IRIS’ (see below)  
Suicidal thoughts and behaviors  (mainly in patients who have had depression or mental health 
problems before)  (see below)  
 
Most of the side effects listed above have been mild or moderate, and have not generally stopped HIV -
infected patients treate d with dolutegravir  from getting on with their lives as normal.  
In one animal study, gastric erosion ( irritation of the stomach lining) was seen. This finding has not been 
seen in adults in studies to date . However, if you or your child feels heartburn or stomach pain or has 
vomiting, please contact your/your child’s study doctor.  
 
Other side effects that may show up in blood tests:  Very Common ( expected in about 100 of every 1000 people taking DTG (10%))   
Nausea or feeling sick  
Headache  
Diarrhea or loose stools  
 
Common ( expected in about 10 of every 1000 people taking DTG (1%))  
Cold symptoms like runny nose and sore throat; cough; flu  
Dizziness or feeling light headed  
Trouble sleeping; abnormal dreams  
Rash  
Feeling tired  
High temperature  
Pain in the stomach; vomiting  
Changes in kidney, liver and muscle blood tests  
Ocular icterus (yellowing of the whites of the eyes)  
Itching (pruritus)  
Feelings of d eep sadness and unworthiness (depression)  
Flatulence (gas or wind)  
Increase in the level of liver enzymes  
Increase in the level of enzymes produced in the muscles (creatinine phosphokinase)  
Anxiety (fear, worry)  
 
IMPAACT P1093, Version 5.0  Page 116 of 135 12 July 2018   • An increase in bilirubin (a pigment produced from the breakdown of red blood cells) in the blood,   
• An increase in the level of creatinine, a waste product in the blood that gets filtered by the 
kidneys.  
 
Dolutegravir Hypersensitivity Reaction  
Hypersensitivity reactions have also been reported with integrase inhibitors, including dolutegravir, with 
signs and symptoms including general feeling of being sick, skin rash, a high temperature (fever), lack of 
energy (fatigue), swelling sometimes of th e face or mouth (angioedema) causing difficulty in breathing, 
blisters  or peeling skin , mouth ulcers, conjunctivitis (sore eyes), and muscle or joint aches.  If you/your 
child develop (s) any of these signs and symptoms during the study, contact you/your ch ild’s study doctor 
immediately, who may decide to carry out tests on you /your child  liver, kidneys or blood.  
Mental illness  
Some people with HIV infection occasionally have feelings of depression or may have thoughts of 
hurting or killing themselves (committing suicide) . A small number of people being treated with integrase 
inhibitors for HIV infection, including dolutegravir, have had suicidal thoughts and behaviors, 
particularly patients with a prior history of depression or mental health  illness. People with HIV taking 
integrase inhibitors including dolutegravir have also reported depression.  
 
Tell the study doctor if you/your child have a history of mental illness. If you/your child have thoughts of 
hurting or killing yourself or have an y other unusual or distressing thoughts or feelings at any time during 
the study, you/your child should tell the study staff or go to the nearest hospital immediately.  
 
Use of Combination Antiretroviral Drugs  
Immune Reconstitution Syndrome: In some people  with advanced HIV infection, symptoms from other 
infections or certain diseases may occur soon after starting combination anti -HIV treatment but can also 
occur later.  Some of these symptoms may be life threatening.  If you start having new symptoms, or 
notice that existing symptoms are getting worse after starting your antiretroviral therapy, tell your 
healthcare provider right away.  
 
The use of potent antiretroviral drug combinations may be associated with an abnormal placement of 
body fat and wasting.  Some of the body changes include:  
• Increase in fat around the waist and stomach area  
• Increase in fat on the back of the neck  
• Thinning of the face, legs, and arms  
• Breast enlargement  
 
Some patients taking combination anti -HIV therapy may develop a bone diseas e called osteonecrosis 
(death of bone tissue caused by loss of blood supply to the bone).  The length of combination anti -HIV 
therapy, corticosteroid use, drinking alcohol, severe reduction in ability to fight off infection, higher body 
weight, among other s, may be risk factors for developing this disease.  Signs of osteonecrosis are joint 
stiffness, aches and pains (especially of the hip, knee and shoulder) and difficulty in movement.  If 
you/your child notice any of these symptoms, please inform your doct or 
 
Liver Toxicity  
Liver toxicity in the form of abnormal liver enzymes, inflammation of the liver (hepatitis) and liver 
failure have occurred in HIV -infected patients receiving regimens containing dolutegravir . The liver 
toxicity usually occurs in the first few weeks or mon ths of taking anti -HIV medications.   These patients 
were also generally either taking other medications (both HIV treatment and non -HIV treatment) that are 
also known to cause significant liver inflammation and/or allergic reaction, or already had liver pr oblems 
 
IMPAACT P1093, Version 5.0  Page 117 of 135 12 July 2018   (such as hepatitis B or hepatitis C), or drank too much alcohol or had a combination of these.   Cases of 
liver toxicity have also occurred in patients who do not have these risk factors.  
 
If you/your child have  (has)  an unanticipated need for hepatitis C virus (HCV) therapy during the conduct 
of the study, the study doctor will discuss specific HCV treatment options with you. In case you/your 
child experience liver toxicity, the study doctor can decide to stop the adm inistration of the study drug in 
order to assure your/your child’s safety.   
 
Other Risks  
There is the risk of serious and/or life threatening side effects when non -study medications are taken with 
the study drug. For your/your child’s safety, you must tel l your/your child’s HIV care provider and the 
study doctor or nurse about all medications you take/your child takes before the start of this study and 
also before starting any new medications while you are/your child is on the study. In addition, you must 
tell the study doctor or nurse before you enroll/enrolling your child in any other clinical trials while on 
this study.  The use of highly active HIV medications may also be associated with altered fat metabolism 
including increased triglycerides (fatty aci d in the blood) and/or increased cholesterol.  
 
Other side effects besides those listed and side effects from taking these drugs together may occur. If any 
unusual symptoms or changes happen, you should call your/your child’s doctor immediately. It is also 
important that while participating in the study, you do not/your child does not take any other prescription 
drugs or over -the-counter medications without first talking to your/your child’s doctor or study nurse.  
 
With any drug for HIV, there is a risk that  the virus in your body will become resistant, which means that 
the drug will be less effective or not effective against your HIV.  The risk that taking part in this study 
will cause your HIV to develop resistance to the study drug is unknown and will depe nd on how well the 
study drug work s against your virus and whether instructions are followed for taking  the study drug.  
 
Blood Drawing and Heparin Lock Risks:  
Blood drawing may cause some discomfort, bleeding or bruising where the needle enters the body. A  
small blood clot may form where the needle enters the body or there may be swelling in the area. There is 
a small risk of a minor infection at the blood draw site. Lightheadedness and fainting can also occur when 
a needle enters the body.  
 
ARE THERE RISKS RELATED TO PREGNANCY?  
It is not known if the drug or drug combinations in this study harm fetuses.  Tests in pregnant animals do 
not show risk to the mother .  Early results from a large study in Botswana of pregnant women showed a 
possible increased r isk of certain types of serious birth defects involving the brain, and spinal cord in 
babies born to women who received dolutegravir at the time of be coming pregnant. No cases of babies 
born with these types of birth defects have been reported among women who started dolutegravir later in 
pregnancy.   
 
If you are/your child is having sex that could lead to pregnancy, you/your child must agree not to become 
pregnant.  
 
Because of the risk involved, you and your partner, or your child and their partner must use  two methods 
of birth control that you discuss with the study staff. You must continue to use both methods until t wo 
weeks after stopping study drug. Options for birth control methods include these listed below:  
• Birth control drugs that prevent pregnancy given by pills, shots, placed on the skin (e.g. patch) or 
placed under the skin  
 
IMPAACT P1093, Version 5.0  Page 118 of 135 12 July 2018   • Male or female condoms with or without a cream or gel that kills sperm  
• Diaphragm or cervical cap with a cream or gel that kills sperm  
• Intrauterine device (IUD)  
 
Some of these are better than others in preventing pregnancy.  You/your child will work with study staff  
to pick the options best for you.  All birth control methods listed above except condoms do not reduce the 
risk of giving HIV to someone else. HIV -infected individuals should use a birth control method that 
includes condoms to keep from giving HIV to someone else.  
If you think you/your child may be pregnant at any time during the study, tell the study staff right away. 
The study staff will talk to you a bout your/your child’s choices. You/your child will be tested at each 
study visit if it is possible that you/she may be pregnant.  
If you are /your child becomes pregnant while on study, you/she will not be allowed to continue on the 
study drug but will be  asked to remain on study and come in for study visits as planned in case of safety 
concerns and so that the doctors can follow your/her pregnancy until your / your child’s baby is born.  
 
ARE THERE BENEFITS TO TAKING PART IN THIS STUDY?  
If you / your child  take(s) part in this study, the amount of HIV in your / your child’s body may go down 
and your/your child’s immune system may become stronger, but no guarantee can be made. You/your 
child may receive no benefit from being in this study. Information learne d from this study may help 
others who have HIV.  
  
WHAT OTHER CHOICES DO I / DOES MY CHILD HAVE BESIDES THIS STUDY?  
Instead of being in this study you have the choice of:  
• Treatment with prescription drugs available to you/your child  
• Treatment with other exp erimental drugs, if you/your child qualify(ies)  
• No treatment (NOT recommended)  
Please talk to your doctor about these and other choices available to you/your child. Your doctor will 
explain the risks and benefits of these choices.  
 
WHAT ABOUT CONFIDENTIAL ITY?  
(For US Sites Only)  
To help us protect your privacy, we have obtained a Certificate of Confidentiality from the National 
Institutes of Health. With this Certificate, the researchers cannot be forced to disclose information that 
may identify you, even by a court subpoena, in any federal, state, or local civil, criminal, administrative, 
legislative, or other proceedings. The researchers will use the Certificate to resist any demands for 
information that would identify you, except as explained below. The Certificate cannot be used to resist a 
demand for information from personnel of the United States Government that is used for auditing or 
evaluation of federally funded projects or for information that must be disclosed in order to meet the 
requirements of  the federal Food and Drug Administration (FDA).  
 
People who may review your/your child’s records include the U.S. Food and Drug Administration  and 
other U.S., local and international regulatory entities , the Office of Human Research Protections (OHRP), 
the site IRB /EC (insert name of site IRB/EC), the National Institutes of Health, study staff, study 
monitors, drug companies supporting the study, and their designees.  
 
You should understand that a Certificate of Confidentiality does n ot prevent you or a member of your 
family from voluntarily releasing information about you or your participation in this research. If an 
 
IMPAACT P1093, Version 5.0  Page 119 of 135 12 July 2018   insurer, employer, or other person obtains your written consent  to receive research information, then the 
researchers m ay not use the Certificate of Confidentiality to withhold that information.  
 
(For sites outside the U.S.)  
Efforts will be made to keep your personal information confidential. We cannot guarantee absolute 
confidentiality. Your personal information may be di sclosed if required by law. Any publication of this 
study will not use your name of identify you personally.  
Your records may be reviewed by the Ministry of Public Health in your country, the FDA  and other U.S., 
local and international regulatory entities,  the Office of Human Research Protections (OHRP), the NIH, 
(insert name of site) IRB/EC, study staff, study monitors and the drug companies supporting this study.  
 
WHAT ARE THE COSTS TO ME / MY CHILD?  
There are no costs to you/your child for the study drug, study visits or study procedures. However, taking 
part in this study may lead to added costs to you and your insurance company if medical complications 
arise or if your doctor decides extra tests are  needed. In some cases,  it is possible that your insurance 
company will not pay for these costs because [you are/ your child is] taking part in a research study.  
 
WILL I RECEIVE ANY PAYMENT?  
You will receive $XX for each study visit you attend. If you att end all study visits, you may receive up to 
$XX.  
 
WHAT HAPPENS IF I AM / MY CHILD IS INJURED?  
If you are / your child is injured as a result of being in this study, you / your child will be given immediate 
treatment for your/his/her injuries. The cost for this treatment will be charged to you or your insurance 
company. There is no program for compensation either through this institution or the National Institutes 
of Health (NIH). You will not be giving up any of your/your child’s legal rights by signing thi s consent 
form.  
 
WHAT ARE MY / MY CHILD’S RIGHTS AS A RESEARCH PARTICIPANT ? 
Taking part in this study is completely voluntary. You may choose not to take part/not to allow your child 
to take part in this study or leave this study/take your child out of the study at any time. Your decision 
will not have any impact on your participation in other studies conducted by the NIH and will not result in 
any penalty or loss of benefits to which you are otherwise entitled. We will tell you about new 
information fro m this or other studies that may affect your health, welfare or willingness to stay in this 
study. If you want the results of the study, let the study staff know.  
 
(For legal guardians, as applicable)  
If your child reach es the legal age of consent during the study [he/she] will be asked to provide 
independent consent  at their next visit.   
 
WHAT DO I DO IF I HAVE QUESTIONS OR PROBLEMS?  
For questions about this study or a research -related injury, contact:  
• Name of the investigator or other study staff  
• Telepho ne number of above  
For questions about your/your child’s/baby’s rights as a research participant , contact:  
• Name or title of person on the Institutional Review Board (IRB), Ethics Committee (EC) or other 
organization appropriate for the site  
• Telephone number of above   
 
IMPAACT P1093, Version 5.0  Page 120 of 135 12 July 2018   SIGNATURE PAGE   
 
If you have read this consent form (or had it explained to you), all your questions have been answered and 
you agree to take part in this study, please sign your name below.  
 
 
_____________________                              ____________________________________  
Participant ’s Name (print)           Participant ’s Signature and Date    
 
 
____________________________                ____________________________________  
Participant ’s Legal Guardian (print)          Legal Guardian’s Signature and Date    
(As appropriate)  
 
 
________________________                        ____________________________________  
Study Staff Conducting                       Study Staff Signature and Date    
Consen t Discussion (print)  
 
 
________________________                        ____________________________________  
Witn ess’ Name (print)            Witness’s Signature and Date     
(As appropriate)  
 
 
__________________________          _____________________________ _____  
Second Guardian (print)             Second Guardian’s Signature and Date  
(If required)        
 
 
 
IMPAACT P1093, Version 5.0  Page 121 of 135 12 July 2018   Appendix III  
Sample Consent Form f or Participant s Enrolling in S tage II  
 
DIVISION OF AIDS  
INTERNATIONAL MATERNAL PEDIATRIC ADOLESCENT AIDS CLINICAL TRIALS GROUP 
(IMPAACT)  
 
Phase I/II, Multi -Center, Open -Label Pharmacokinetic, Safety, Tolerability and  
Antiviral Activity of dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV -1 
Infected Infants, Children and Adolescents  
 
Participant s Enrolling in STAGE TWO  
P1093  Version 5.0, dated 12 July 2018   
 
SHORT TITLE FOR THE STUDY : Safety and PK of dolutegravir in HIV -1 Infected Children  
 
 
INTRODUCTION  
You are/your child is being asked to take part in this research study because you have /your child has the 
Human Immunodeficiency Virus (HIV), which is the virus that causes AIDS, and because the drugs 
currently available may not keep the amount of HIV in your / your child’s blood low enough or may 
cause side effects too difficult to deal with. This study is sponsored by the National Institutes of Health 
(NIH). The doctor in charge of this study at this site is: (insert name of Principal Investigator). Befo re you 
decide if you want to be/want your child to be a part of this study, we want you to know about the study.  
 
This is a consent form. It gives you information about this study. The study staff will talk with you about 
this information. You are free to  ask questions about this study at any time. If you agree to/agree to allow 
your child to take part in this study, you will be asked to sign this consent form. You will get a copy to 
keep.  
 
WHY IS THIS STUDY BEING DONE?  
This study is being done to study a new antiretroviral HIV medication called dolutegravir. This drug is a 
type of medicine called an integrase inhibitor. Integrase inhibitors work by blocking integrase, a protein 
that HIV needs to enter human cells and make more copies of itself. The study w ill help find the best 
amount or dose of dolutegravir for infants, children and teenagers, when it is taken on its own as well as 
with other antiretroviral medications. This study will also find out the safety of using this medication in 
infants, children and adolescents and if there are any side effects from the medication. Dolutegravir has 
been tested before in adults and children. The study drug (dolutegravir) is approved for use in children 12 
years and older by the FDA [and/or local regulatory authorit ies].  
 
WHAT DO I / DOES MY CHILD HAVE TO DO IF I AM / HE / SHE IS IN THIS STUDY?  
If you decide to (allow your child to) enroll in this study, you / your child will be asked to come to the 
clinic at least 10 times over 48 weeks and then every 12 weeks unti l the end of the study. You / your child 
will be given dolutegravir and you / your child will be asked to take it once or twice a day for the entire 
study, in addition to your / your child’s regular HIV medicines. Dolutegravir is available in three differe nt 
formulations: 1) a film -coated tablet that cannot be crushed or dissolved , 2) a liquid suspension and 3) a 
tablet that can be dissolved in water. You will be given instructions on how to give dolutegravir to your 
child. If your child is between 6 to les s than 12 years of age and was prescribed the liquid or dissolvable 
tablet tablets of dolutegravir he/she may be allowed to switch to the film -coated tablet formulation, at a 
later time . The study staff will let you know when your child can switch, if you request to do so.  
 
 
IMPAACT P1093, Version 5.0  Page 122 of 135 12 July 2018   Although the study will p rovide you/your child with dolutegravir, other antiretrovirals will not be 
provided by the study.  
 
This study will be done in two parts – Stage One and Stage Two. Stage One will enable the doctors to 
find the  right dose of study drug for you/your child and then will keep you on that dose to look for any 
side effects that you/your child might experience. In Stage Two the doctors will know the right dose to 
put you/your child on and will look at any side effects  that you / your child might experience as well as 
how well the drug is controlling your HIV infection. You/your child will be enrolled into Stage One or 
Stage Two, depending on when you enroll /your child enrolls and your age / the age of your child. This  
consent form is for Stage Two.  
 
In this study there are 7 cohorts in Stage II – enrolling infants, children, and adolescents from 4 weeks to 
less than 18 years of age. Participant s who have had their 18th birthday by the entry visit will not be 
enrolled i nto the study.  
 
Screening:  
If you are interes ted in taking part / allowing your child to enroll in this study, we will see if you are / 
your child is eligible for the study:  
 
• We will ask your / your child’s medical history including questions about your / your child’s 
health and what symptoms, medications, and illnesses you have/ your child has had.  
 
• We will do a physical exam including height, weight and vital signs (temperature, blood pressure, 
pulse and respiratory rate). Doses may be modified based on th e results of the weight.  
 
• We will take about 3  teaspoons (1 1mLs) of blood, to check for the following:  
o The amount of HIV in the blood,  
o The amount of cholesterol and triglycerides (types of fat) in the blood,  
o How well your immune system, liver and kidneys are working,  
o Other routine tests .  
 
You will be given the results of these tests. We will also ask you to provide a urine sample for routine 
tests. Girls and women of childbearing age will also be asked to provide a urine or blood sample to test 
for pregnancy. If you are / your child is engaged in sexual activity that could lead to pregnancy, you / 
your child will be asked to take b irth control precautions throughout the study period.  
 
On Study:  
If you are/your child is eligible for this study, you/your child will come to the clinic at least 8 times  in 48 
weeks .  Most of the visits will last about 1 -2 hours. You/your child will come to the clinic for the first 
study visit within 30 days of the screening visit.  
• At each visit, a medical history will be taken and you/your child will have a physical exam. If you 
are/your child is older than 2 years of age, at the enrollment visit and at the week 48 visit, 
you/your child’s stage of sexual development will be determined. For girls/women, this will be 
done by looking at how developed the breasts are. For boys/men, this will be done by measuring 
 
IMPAACT P1093, Version 5.0  Page 123 of 135 12 July 2018   the size of the testes. Girls and women of chil dbearing age will also be asked to provide a urine or 
blood sample to test for pregnancy at each visit.  
• We will draw blood at each visit. Depending upon your/your child’s age, between 1 -5 teaspoons 
(5-17mLs) of blood will be drawn at these visits . You will  be informed of results of routine blood 
tests. Some of the blood drawn will be stored and tested to find out how your/your child’s 
immune system is affected by the study drug. This testing will be done after the study is over, and 
you will not be given th e results of these tests.  
• A palatability assessment will be done at Day 10, Week 4 and Week 24 to assess what you/your 
child thinks about the taste of the study drug . 
• At two visits (week 4 and week 24), blood samples will be drawn two separate times . At week 12, 
you will only have one blood draw. The amount of blood drawn at the different study visits will 
be less than 1 teaspoon ( 0.5-1mL) depending on your /your child’s age.  
• If the amount of HIV virus in your/your child’s blood increases too much while o n this study 
drug, you/your child may be asked to come back to clinic to have your blood drawn to confirm 
the level of HIV in your blood. If the level of HIV virus in your blood is still too high, your study 
doctor may ask you to stop taking the study medi cine and to come back to the clinic for another 
visit. As part of this visit, you/your child will have an interim medical history, physical exam and 
approximately 4 teaspoons of blood (1 4-17mL) will be drawn for testing and storage.  
• If you/your child experiences a severe liver reaction or inflammation while on the study, you/your 
child may be asked to come back to clinic to have less than one teaspoon of blood (2mL) drawn 
to check the level of dolutegravir in the blood. Additional testing as part of routine assessments 
for liver inflammation (e.g. checking for viruses that cause liver inflammation) may be performed 
as well.  
 
Long Term Follow -Up 
After you have been on study drug for approxima tely 48 weeks, you will enter the long term follow -up 
phase of the study. You will be asked to come back into clinic every 12 weeks (every 3 months) for 3 
more years. Most visits will last about 30 minutes.  
• At some visits, a medical history will be taken and you/your child will have a physical exam. You 
will also be asked if you have missed taking any of your medications.  
• We will draw less than 1 teaspoon of blood (3 -4mL) at some visits. You will be informed of 
results of routine blood tests.  
• As bef ore, if the amount of HIV virus in your/your child’s blood increases too much while on this 
study drug, you/your child may be asked to come back to clinic to have your blood drawn to 
confirm the level of HIV in your blood (see above).  
 
You/your child must  continue to take your/his/her anti -HIV medications during the study as prescribed by 
your/your child’s HIV care provider. If your/your child’s HIV care provider changes your/your child’s 
anti-HIV medications during the study, you/your child can still take  the study drug. You/your child will 
be asked questions about taking your/his/her anti -HIV medications and the schedule you take/he/she takes 
them on and if you have/he/she has missed any medications.  
 
 
IMPAACT P1093, Version 5.0  Page 124 of 135 12 July 2018   If you/your child can become pregnant, we will collect  urine or blood to test for pregnancy at each visit. 
We will also ask your child about contraception use.  If you think you/if your child thinks she may be 
pregnant at any time during the study, tell the study staff right away.  
 
Blood and Urine Samples  
Some of your / your child’s blood and urine samples will be shipped out of the country to the US for 
specialized tests. These tests will tell the doctors how much study drug is in your / your child’s blood and 
if the study drug is causing any changes in your kidneys.  
 
[For Participants Receiving Granules for suspension  only]  
  
[If your child is receiving the  (granule)  liquid he/she will need to switch to the dissolvable tablet. The 
study staff will inform you when your child will need to switch . This is because the company will not be 
making the liquid form of dolutegravir any longer. The study staff will provide instr uctions on how to 
dispense the dissolvable tablet and on the day you are scheduled to come to the clinic to begin taking the 
dissolvable tablets you will be asked to not give the (granule) liquid dose to your child . The first dose of 
the dissolvable tablet will be given in the clinic. You will be asked to come back to the clinic about 2 
weeks later and will have a palatability assessment and blood drawn to confirm the level of HIV in your 
child’s blood . If you have been on the study for more than 24 weeks at each of these visits, blood samples 
will be drawn at two separate times . The amount of blood drawn will be less than 1 teaspoon ( 0.5-1mL) 
depending on your /your child’s age. ]  
 
 
WHAT DO I / DOES MY CHILD HAVE TO DO IF I AM / HE / SHE BECOMES INFECTED WITH 
TUBERCULOSIS WHILE ON THIS STUDY?  
If you become/your child becomes exposed to Tuberculosis (TB) while on study and requires anti -TB 
treatment that includes Rifampin you/your child will have to increase the dose of dolutegravir from once a 
day to twice a day while taking Rifampin. After you/your child complete(s) treatment with Rifampin, 
you/your child may go back to taking the dolutegravir once a day, depending on what other medications 
you/your child is taking.  
 
You/your child will also be re quired to return for at least five additional follow -up visits after starting 
Rifampin.  
• At each of these visits, a medical history will be taken and you/your child will have a physical 
exam and we will draw approximately 1 -3 teaspoons of blood to look at the following:  
o The amount of HIV, cholesterol and triglycerides (types of fat) in your blood  
o How well your immune system, liver and kidneys are working, as well as other routine 
tests 
• At each visit you will be asked whether you are taking your medicatio n as instructed.  
• You/your child will be asked to come to the clinic to have blood drawn 8 times over 12 hours 
during one visit, approximately 5 -10 days after you/ your child started taking anti -TB medication. 
For this visit, you/your child will be asked to  fast for 6 hours before your daily dose of study 
medication.  
• The study staff will give you more instructions about this. Depending on your/your child’s age, 
up to 13 mL (a little more than 4 teaspoons) of blood will be drawn at this visit.  
 
IMPAACT P1093, Version 5.0  Page 125 of 135 12 July 2018   • You will have ex tra blood draws at two visits. At weeks 4 and 12, you will have two blood draws 
– blood will be drawn once befor e you take dolutegravir and about 12 hours later.  The amount of 
blood drawn at the different study visits will be less than 1 teaspoon ( 1mL).  
 
OTHER INFORMATION  
The information collected in this study may be used for other IMPAACT -approved HIV -related research.  
 
HOW MANY PEOPLE WILL TAKE PART IN THIS STUDY?  
About 300 children and adolescents will take part in this study  
 
HOW LONG WILL I/MY CHILD  BE IN THIS STUDY?  
By signing this consent form, you are agreeing to / allow your child to participate in Stage II of the study . 
You/your child will stay in the study for at least 48 weeks. After that time After that time you /your child 
will enter the long -term safety follow -up phase of the study. During this time, you / your child will 
continue to take study -provided dolutegravir and will be asked to come to clinic every 12 weeks for three 
more years.  
  
WHY WOULD THE DOCTOR TAKE ME / MY CHILD OFF THE STUDY  DRUG / THIS STUDY 
EARLY?  
 
The study doctor may need to take you/your child off the study drug early, without your permission, if:  
 
• Continuing the study drug may be harmful to you / your child  
• You become / your child becomes pregnant while on study  
The study doctor may need to take you/your child off the study early, without your permission, if:  
• You are/ your child is not able to attend the study visits as required by the study  
• You need / your child needs a treatment that you / your child may not take wh ile on the study  
• You are / your child is not able to take the study drug as required by the study  
• If you elect not to attend repeat PK evaluations as part of the study  
 
The study doctor may need to take you/your child off the study early, without your perm ission, if:  
• The study is cancelled by the U.S. Food and Drug Administration (FDA), National Institutes of 
Health (NIH), the Office of Human Research Protections (OHRP), other country specific 
governmental agencies, IMPAACT, the drug company supporting this  study (GSK), or the site’s 
Institutional Review Board (IRB) or Ethics Committee (EC). An IRB or EC is a committee that 
watches over the safety and rights of research participant s 
 
If your doctor wants you / your child to stop taking the study drug, you/yo ur child will be asked to return 
to the clinic once more, four weeks after your last dose of dolutegravir, to make sure you are/your child is 
continuing to do well. This visit will include a history and physical exam, a blood draw and a review of 
your medi cal records.  
 
 
IMPAACT P1093, Version 5.0  Page 126 of 135 12 July 2018   IF MY CHILD HAS TO PERMANENTLY STOP TAKING STUDY -PROVIDED MEDICINE, OR 
ONCE I LEAVE THE STUDY, HOW WOULD THE STUDY MEDICINE BE PROVIDED?  
During the study:  
If you / your child must permanently stop taking study -provided dolutegravir before yo ur/your child’s 
study participation is over, the study staff will discuss other options that may be of benefit to you/your 
child.  
 
After the study:  
Once you / your child leaves the study, if you/they are gaining benefit from the study -provided drug, this 
drug may continue to be provided until it is available to you in your country, but there is no guarantee . 
Study clinicians will work to ensure that you/your child continue to receive appropriate care and 
treatment outside of the study.  
 
WHAT ARE THE RISKS O F THE STUDY?  
The drug used in this study may have side effects, some of which are listed below. Please note that 
these lists do not include all the side effects seen with this drug. These lists include the more serious 
or common side effects with a known o r possible relationship. It is very important that you tell your 
study doctor of any changes in your/your child’s  medical condition while taking part in the study. At 
any time during the study, if you believe you are/your child is experiencing any of these  side effects, 
you have the right to ask questions on possible and /or known risks.  
Possible Risks Associated with Dolutegravir  
 
DTG has been administered to a total of 6004 participants  (4814 HIV -infected and 1190 healthy) 
cumulative to 16 July 2017 in ongoing and completed ViiV sponsored and clinical trials ranging from 
Phase I to IIIb and the DTG compassionate use program.    
 
The following side effects have been seen with dolutegravir:  
 
Very Common ( expected in about 100 of every 1000 people taking DTG  (10%))  
Nausea or feeling sick (mild to moderate)  
Headache (mild to moderate)  
Diarrhea or loose stools  
 
Common ( expected in about 10 of every 1000 people taking DTG (1%))  
Cold symptoms like runny nose and sore throat; cough; flu  
Dizziness or feeling light headed  
Trouble sleeping; abnormal dreams  
Rash  
Feeling tired  
High temperature  
Pain in the stomach; vomiting  
Changes in kidney, liver and muscle blood tests  
Ocular icterus (yellowing of the whites of the eyes)  
Itching (pruritus)  
Feelings of d eep sadness and unworthiness (depression)  
Flatulence (gas or wind)   
Increase in the level of liver enzymes  
Increase in the level of enzymes produced in the muscles (creatinine phosphokinase)  
Anxiety  (fear, worry)  
 
IMPAACT P1093, Version 5.0  Page 127 of 135 12 July 2018    
Uncommon ( expected in about 1 of every 1000 people taking DTG (0.1%))  
Allergic reaction  (see below)  
Liver toxicity  (see below)  
An inflammatory condition which may develop as the immune system becomes stronger (immune 
reconstitution syndrome or ‘IRIS’ (see below)  
Suicidal thoughts and behaviors  (mainly in patients who have had depression or mental health 
problems before)  (see below)  
 
Most of the side effects listed above have been mild or moderate, and have not generally stopped HIV -
infected patients treated with dolutegravir from getting on with their lives as normal.  
In one animal study, gastric erosion ( irritation of the stomach lin ing) was seen. This finding has not been 
seen in adults in studies to date . However, if you or your child feels heartburn or stomach pain or has 
vomiting, please contact your/your child’s study doctor.  
 
Other side effects that may show up in blood or urine  tests:  
• An increase in bilirubin (a pigment from the breakdown of red blood cells) in the blood .  
• An increase in the level of creatinine, a waste product in the blood that gets filtered by the kidney  
  
Dolutegravir Hypersensitivity Reaction  
Hypersensitivity reactions have also been reported  with integrase inhibitors, including dolutegravir, with 
signs and symptoms including general feeling of being sick, skin rash, a high temperature (fever), lack of 
energy (fatigue), swelling sometimes of th e face or mouth (angioedema) causing difficulty in breathing, 
blisters  or peeling skin , mouth ulcers, conjunctivitis (sore eyes), and muscle or joint aches.  If you/your 
child develop (s) any of these signs and symptoms during the study, contact you/your ch ild’s study doctor 
immediately, who may decide to carry out tests on your /your child’s  liver, kidneys or blood.  
 
Mental illness  
Some people with HIV infection occasionally have feelings of depression or may have thoughts of 
hurting or killing themselves (committing suicide) . A small number of people being treated with integrase 
inhibitors for HIV infection, including dolutegravir, have had suicidal thoughts and behaviors, 
particularly patients with a prior history of depression or mental health  illness. People with HIV and 
taking integrase inhibitors including dolutegravir have also reported depression.  
 
Tell the study doctor if you/your child have a history of mental illness. If you/your child have thoughts of 
hurting or killing yourself or hav e any other unusual or distressing thoughts or feelings at any time during 
the study, you/your child should tell the study staff or go to the nearest hospital immediately.  
 
Use of Combination Antiretroviral Drugs  
 
Immune Reconstitution Syndrome: In some p eople with advanced HIV infection, symptoms from other 
infections or certain diseases may occur soon after starting combination anti -HIV treatment but can also 
occur later.  Some of these symptoms may be life threatening.  If you start having new symptoms,  or 
notice that existing symptoms are getting worse after starting your antiretroviral therapy, tell your 
healthcare provider right away.  
 
The use of potent antiretroviral drug combinations may be associated with an abnormal placement of 
body fat and wasti ng.  Some of the body changes include:  
 
IMPAACT P1093, Version 5.0  Page 128 of 135 12 July 2018   • Increase in fat around the waist and stomach area  
• Increase in fat on the back of the neck  
• Thinning of the face, legs, and arms  
• Breast enlargement  
 
Some patients taking combination anti -HIV therapy may develop a bone disease called osteonecrosis 
(death of bone tissue caused by loss of blood supply to the bone).  The length of combination anti -HIV 
therapy, corticosteroid use, drinking alcohol, severe reduction in ability to fight off infection, higher body 
weight, among others, may be risk factors for developing this disease.  Signs of osteonecrosis are joint 
stiffness, aches and pains (especially of the hip, knee and shoulder) and difficulty in movement.  If 
you/your child notice any of these symptoms, please infor m your doctor . 
 
Liver Toxicity  
Liver toxicity in the form of abnormal liver enzymes, inflammation of the liver (hepatitis) and liver 
failure have occurred in HIV -infected patients receiving regimens containing dolutegravir. The liver 
toxicity usually occur s in the first few weeks or months of taking anti -HIV medications.   These patients 
were also generally either taking other medications (both HIV treatment and non -HIV treatment) that are 
also known to cause significant liver inflammation and/or allergic re action, or already had liver problems 
(such as hepatitis B or hepatitis C), or drank too much alcohol or had a combination of these.   Cases of 
liver toxicity have also occurred in patients who do not have these risk factors.  
 
If you/your child ha s an unant icipated need for hepatitis C virus (HCV) therapy during the conduct of the 
study, the study doctor will discuss specific HCV treatment options with you. In case you/your child 
experience liver toxicity, the study doctor can decide to stop the administrati on of the study drug in order 
to assure your/your child’s safety.   
 
Other Risks  
There is the risk of serious and/or life threatening side effects when non -study medications are taken with 
the study drug. For your/your child’s safety, you must tell your/yo ur child’s HIV care provider and the 
study doctor or nurse about all medications you take/your child takes before the start of this study and 
also before starting any new medications while you are/your child is on the study. In addition, you must 
tell the study doctor or nurse before you enroll/enrolling your child in any other clinical trials while on 
this study.  
 
The use of potent antiretroviral drug combinations may also be associated with altered fat metabolism 
including elevated triglycerides (fatty ac id in the blood) and/or elevated cholesterol.  
 
Other side effects besides those listed and side effects from taking these drugs together may occur. If any 
unusual symptoms or changes happen, you should call your/your child’s doctor immediately. It is also 
important that while participating in the study, you do not/your child does not take any other prescription 
drugs or over -the-counter medications without first talking to your/your child’s doctor or study nurse.  
With any drug for HIV, there is a risk that the virus in your body will become resistant, which means that 
the drug will be less effective or not effective against your HIV.  The risk that taking part in this study 
will cause your HIV to develop resistance to the study drug is unknown and will depen d on how well the 
study dr ug work s against your virus and whether instructions are followed for taking  the study drug.  
 
Blood Drawing and Heparin Lock Risks:  
Blood drawing may cause some discomfort, bleeding or bruising where the needle enters the body. A 
small blood clot may form at the site where the needle enters the body or there may be swelling in the 
 
IMPAACT P1093, Version 5.0  Page 129 of 135 12 July 2018   area. There is a small risk of a minor infection at the  blood draw site. Lightheadedness and fainting can 
also occur.  
 
ARE THERE RISKS RELATED TO PREGNANCY?  
It is not known if the drug or drug combinations in this study harm fetuses. Tests in pregnant animals 
do not show risk. Early results from a large study  in Botswana of pregnant women showed a possible 
increased risk of certain types of serious birth defects involving the brain, and spinal cord in babies 
born to women who received dolutegravir for HIV treatment at the time of becoming pregnant . No 
cases of  babies born with these types of birth defects have been reported among women who started 
dolutegravir later in pregnancy.   
 
If you are/your child is having sex that could lead to pregnancy, you/your child must agree not to become 
pregnant or make a female pregnant.  
 
Because of the risk involved, you and your partner, or your child and their partner, must use two methods 
of birth control that you discuss with the study staff. You must continue to use both methods until two 
weeks after stopping the study drug. Options for birth control methods include these listed below:  
• Birth control drugs that prevent pregnancy given by pills, shots, placed on the skin (e.g. patch) or 
placed under the skin  
• Male or female condoms with or without a cream or gel that kills sperm  
• Diaphragm or cervical cap with a cream or gel that kills sperm  
• Intrauterine device (IUD)  
Some of these a re better than others in preventing pregnancy.  You/your child will work with study staff 
to pick the options best for you.    All birth control methods listed above except condoms do not reduce 
the risk of giving HIV to someone else. HIV -infected individu als should use a birth control method that 
includes condoms to keep from giving HIV to someone else.  
If you think you/your child may be pregnant at any time during the study, tell the study staff right away. 
The study staff will talk to you about your/your  child’s choices. You/your child will be tested at each visit 
during the study if it is possible that you/she may be pregnant. If you are /your child becomes pregnant 
while on study, you/she will not be allowed to continue on the study drug but will be ask ed to remain on 
study and come in for study visits as planned in case of safety concerns and so that the doctors can follow 
your/her pregnancy.  
ARE THERE BENEFITS TO TAKING PART IN THIS STUDY?  
If you / your child take(s) part in this study, the amount of H IV in your / your child’s body may go down 
and your/your child’s immune system may become stronger, but no guarantee can be made. You/your 
child may receive no benefit from being in this study. Information learned from this study may help 
others who have H IV. 
  
WHAT OTHER CHOICES DO I/DOES MY CHILD HAVE BESIDES THIS STUDY?  
Instead of being in this study you have the choice of:  
• Treatment with prescription drugs available to you/your child  
• Treatment with other experimental drugs, if you/your child qualify(ies )  
• No treatment (NOT Recommended)   
 
 
IMPAACT P1093, Version 5.0  Page 130 of 135 12 July 2018   Please talk to your doctor about these and other choices available to you/your child. Your doctor will 
explain the risks and benefits of these choices.  
 
WHAT ABOUT CONFIDENTIALITY?  
(For U.S. sites only)  
To help us protect your privacy, we have obtained a Certificate of Confidentiality from the National 
Institutes of Health. With this Certificate, the researchers cannot be forced to disclose information that 
may identify you, even by a court subpoena, in a ny federal, state, or local civil, criminal, administrative, 
legislative, or other proceedings. The researchers will use the Certificate to resist any demands for 
information that would identify you, except as explained below. The Certificate cannot be use d to resist a 
demand for information from personnel of the United States Government that is used for auditing or 
evaluation of federally funded projects or for information that must be disclosed in order to meet the 
requirements of the federal Food and Dru g Administration (FDA).  
 
People who may review your/your child’s records include the U.S. Food and Drug Administration  and 
other U.S., local, and international regulatory entities , the Office of Human Research Protections 
(OHRP), the site IRB /EC (insert name of site IRB/EC), the National Institutes of Health, study staff, 
study monitors, drug companies supporting the study, and their designees.  
 
You should understand that a Certificate of Confidentiality does not prevent you or a member of your 
family from voluntarily releasing information about you or your participation in this research. If an 
insurer, employer, or other person obtains your written consent to receive research information, then the 
researchers may not use the Certificate of Confide ntiality to withhold that information.  
 
(For sites outside the U.S.)  
Efforts will be made to keep your personal information confidential. We cannot guarantee absolute 
confidentiality. Your personal information may be disclosed if required by law. Any publi cation of this 
study will not use your name of identify you personally.  
 
Your records may be reviewed by the Ministry of Public Health in your country, the FDA  and other US, 
local, and international regulatory entities , the Office of Human Research Protect ions (OHRP), the NIH, 
(insert name of site) IRB/EC, study staff, study monitors and the drug companies supporting this study.  
 
WHAT ARE THE COSTS TO ME / MY CHILD?  
There are no costs to you/your child for the study drug, study visits or study procedures. H owever, taking 
part in this study may lead to added costs to you and your insurance company if medical complications 
arise or if your doctor decides extra tests are needed. In some cases it is possible that your insurance 
company will not pay for these cos ts because you/ your child are taking part in a research study.  
 
WILL I RECEIVE ANY PAYMENT?  
You will receive $XX for each study visit you attend. If you attend all study visits, you may receive up to 
$XX.  
 
WHAT HAPPENS IF I AM / MY CHILD IS INJURED?  
If you are / your child is injured as a result of being in this study, you / your child will be given immediate 
treatment for your/his/her injuries. The cost for this treatment will be charged to you or your insurance 
company. There is no program for compensat ion either through this institution or the National Institutes 
of Health (NIH). You will not be giving up any of your/your child’s legal rights by signing this consent 
form.  
 
WHAT ARE MY / MY CHILD’S RIGHTS AS A RESEARCH PARTICIPANT ? 
 
IMPAACT P1093, Version 5.0  Page 131 of 135 12 July 2018   Taking part in this st udy is completely voluntary. You may choose not to take part/not to allow your child 
to take part in this study or leave this study/take your child out of the study at any time. Your decision 
will not have any impact on your participation in other studies conducted by the NIH and will not result in 
any penalty or loss of benefits to which you are otherwise entitled. We will tell you about new 
information from this or other studies that may affect your health, welfare or willingness to stay in this 
study. If  you want the results of the study, let the study staff know.  
 
(For legal guardians, as applicable)  
If your child reach es the legal age of consent during the study [he/she] will be asked to provide 
independent consent  at their next visit.   
 
WHAT DO I DO IF I HAVE QUESTIONS OR PROBLEMS?  
For questions about this study or a research -related injury, contact:  
• Name of the investigator or other study staff  
• Telephone number of above  
 
For questions about your/your child’s/baby’s rights as a research participant , contact:  
• Name or title of person on the Institutional Review Board (IRB) or other organization appropriate 
for the site  
• Telephone number of above   
 
IMPAACT P1093, Version 5.0  Page 132 of 135 12 July 2018   SIGNATURE PAGE   
 
If you hav e read this consent form (or had it explained to you), all your questions have been answered and 
you agree to take part in this study, please sign your name below.  
 
 
_____________________                              ____________________________________  
Participant ’s Name (print)           Participant ’s Signature and Date    
 
 
____________________________                ____________________________________  
Participant ’s Legal Guardian (print)          Legal Guardian’s Signature and Date    
(As appropriate)  
 
 
________________________                        ____________________________________  
Study Staff Conducting                       Study Staff Signature and Date    
Consent Discussion (print)  
 
 
________________________                        ____________________________________  
Witn ess’ Name (print)            Witness’s Signature and Date     
(As appropriate)  
 
 
__________________________          __________________________________  
Second Guardian (print)             Second Guardian’s Signature and  Date 
(If required)        
 
 
  
 
IMPAACT P1093, Version 5.0  Page 133 of 135 12 July 2018   Appendix IV  
Sample Informed Consent Form for Specimen Storage and Future Use  
 
DIVISION OF AIDS  
INTERNATIONAL MATERNAL PEDIATRIC ADOLESCENT AIDS CLINICAL TRIALS 
GROUP (IMPAACT)  
 
Phase I/II, Multi -Center, Open -Labe l Pharmacokinetic, Safety, Tolerability and  
Antiviral Activity of dolutegravir, a Novel Integrase Inhibitor, in Combination Regimens in HIV -1 
Infected Infants, Children and Adolescents  
 
P1093  Version 5.0, dated 12 July 2018    
 
You have decided to allow your child to join the study named above /You are participating in the study 
named above . As part of the study, you/your child will have blood drawn  and urine collected . After these 
samples are tested for the study, there may be some samples that are left over . We call these extra 
samples . The IMPAACT Network would like to keep these extra samples and use them for other research 
in the future.  
 
This form gives information about use of extra samples . Please read it, or have it read to you, and ask a ny 
questions you may have . After we discuss the information with you, you will record your decisions on use 
of extra samples at the end of the form.  
 
(For legal guardians, as applicable)  
If your child reaches the legal age of consent during the study [he /she] will be asked to provide 
independent consent at their next visit.   
 
1. It is your decision whether or not to allow the extra samples to be used.  
 
You are free to say yes or no, or to change your mind at any time . Your decision will not affect your/you r 
child’s participation in the study . If you say no, all extra samples will be destroyed.  
 
2. If you agree, your child’s  extra samples will be kept in a repository.  
 
A repository is a secure facility that is used to store samples . The IMPAACT Network repository is in the 
United States . There is no limit on how long the samples will be kept [sites may insert time limits or 
additional site -specific requirements here if required by local authorities] . 
 
3. Extra samples could be used  for different types of re search.  
 
Extra samples may be used for research on HIV, the immune system, and other diseases . The research 
may be done in the United States or in other locations.  
 
If you agree, the extra samples could also be used for research that looks at your/ your c hild’s genes .  
 
Any research done with the extra samples must be reviewed and approved by the IMPAACT Network . 
The research must also be approved by an ethics committee . The role of an ethics committee is to review 
the research plan and protect the rights and well -being of the persons whose samples will be used .  
 
4. There is little risk to you/your child.  
 
IMPAACT P1093, Version 5.0  Page 134 of 135 12 July 2018    
When extra samples are used for research, they are labeled with a code number only . To protect your 
child’s privacy, no names are used . However, in formation such as age, gender, HIV status, and other 
health information may be linked to the samples . Information on which study ARVs you/your child 
received and you/your child’s immune system responses to the ARVs may also be linked to the samples.  
 
Ther e may be some risks from tests of you/your child’s genes . If others found out the results of these 
tests, they could treat you badly or unfairly . However, this is almost impossible because the results of 
these tests will not be in you/your child’s study re cords and they will not be given to you.  
 
5. There may be no benefit to you/your child.  
 
The research done with extra samples is not expected to give any information relevant to your child’s 
health . The results will not be given to you and will not be part of your study records.  
 
6. You will not be paid for use of your/ your child’s samples.  
 
There is no cost to you for use of your child’s extra samples . The samples will not be sold and you will 
not be p aid for use of the samples . It is possible that research done with the samples could lead to a new 
discovery or a new product . If this happens, there is no plan to share any money with you or your child.  
 
7. Information from research using extra samples may be reviewed by groups that oversee the 
research.  
 
These groups include :  
 
• The IMPAACT Network  
• The ethics committees that review and approve the research  
• Government and other agencies that pay for the research  
• Government and other agencies that monitor the research  
• Other local, US, and international regulatory entities  
 
The people who do research with the extra samples and the groups listed above are required to make 
efforts to information private and confident ial. 
 
The results of research done with extra samples may be presented publicly or published . However, no 
presentation or publication will use your/ your child’s name or identify your child personally .  
 
8. If you have any questions, concerns, or problems related to your/ your child’s extra samples, use 
these contacts.  
 
• If you have questions about use of your/ your child’s extra samples, contact:  
[sites insert name and telephone number of investigator or other  study staff].  
 
• If you later change your mind about use of your/ your child’s extra samples, contact:  
[sites insert name and telephone number of investigator or other study staff].  
 
• If you have questions about your/ your child’s rights as a research parti cipant, or problems or concerns 
about how your child is being treated in the study, contact:  
 
IMPAACT P1093, Version 5.0  Page 135 of 135 12 July 2018   [sites insert name and telephone number of IRB contact person or other appropriate 
person/organization].  
 
9. Signatures  
 
If you agree to let your/ your child’s extra samples be used, please sign or make your mark below.  
 
__________  I allow my/my child’s extra samples to be used for research on HIV, the immune system, 
and other diseases . I also allow my child’s samples to be used for tests of his or her 
genes .  
 
__________  I allow my/my child’s extra samples to be used for research on HIV, the immune system, 
and other diseases . I do not allow my child’s samples to be used for tests of his or her 
genes .  
 
__________  I do not allow my/my child’s extra sampl es to be used for any research .  
 
 
 
     
Participant ’s Name (print)  
 
             
Parent’s Name (print)    Parent’s Signature     Date  
(Or Legal Guardian)  
 
 
             
Parent’s Name (print)    Parent’s Signature     Date  
(Or Legal Guardian)  
 
 
             
Study Staff Conducting    Study Staff Signature    Date  
Consent Process Name (print)  
 
 
             
Witness Name     Witness Signature    Date  
(As appropriate)  
 
 